CA2554138A1 - Aryl substituted heterocycles, method for production and use thereof as medicaments - Google Patents
Aryl substituted heterocycles, method for production and use thereof as medicaments Download PDFInfo
- Publication number
- CA2554138A1 CA2554138A1 CA002554138A CA2554138A CA2554138A1 CA 2554138 A1 CA2554138 A1 CA 2554138A1 CA 002554138 A CA002554138 A CA 002554138A CA 2554138 A CA2554138 A CA 2554138A CA 2554138 A1 CA2554138 A1 CA 2554138A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- independently
- another
- group
- nitrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000623 heterocyclic group Chemical group 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 125000003118 aryl group Chemical group 0.000 title claims description 21
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 134
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 17
- 208000008589 Obesity Diseases 0.000 claims abstract description 11
- 235000020824 obesity Nutrition 0.000 claims abstract description 11
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 9
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 162
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 129
- 229910052760 oxygen Inorganic materials 0.000 claims description 113
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 106
- 229910052717 sulfur Inorganic materials 0.000 claims description 101
- 125000005842 heteroatom Chemical group 0.000 claims description 91
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 69
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 63
- 229910052799 carbon Inorganic materials 0.000 claims description 63
- 239000001301 oxygen Substances 0.000 claims description 63
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 61
- 239000011593 sulfur Substances 0.000 claims description 61
- 229910052731 fluorine Inorganic materials 0.000 claims description 59
- 229910052801 chlorine Inorganic materials 0.000 claims description 58
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 57
- 125000004043 oxo group Chemical group O=* 0.000 claims description 57
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 56
- -1 O-(C3-C8)-cycloalkyl Chemical group 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 50
- 229910052794 bromium Inorganic materials 0.000 claims description 47
- 239000004480 active ingredient Substances 0.000 claims description 39
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 125000002950 monocyclic group Chemical group 0.000 claims description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 125000002619 bicyclic group Chemical group 0.000 claims description 19
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 19
- 125000004122 cyclic group Chemical group 0.000 claims description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
- 238000011321 prophylaxis Methods 0.000 claims description 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- 230000001539 anorectic effect Effects 0.000 claims description 7
- 150000004866 oxadiazoles Chemical class 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 150000002916 oxazoles Chemical class 0.000 claims description 6
- 150000004867 thiadiazoles Chemical class 0.000 claims description 6
- 150000003557 thiazoles Chemical class 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- 206010061428 decreased appetite Diseases 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 5
- 229930192474 thiophene Natural products 0.000 claims description 5
- 239000013585 weight reducing agent Substances 0.000 claims description 5
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical group C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- 101100073357 Streptomyces halstedii sch2 gene Proteins 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
- 150000002240 furans Chemical class 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 150000003233 pyrroles Chemical class 0.000 claims description 3
- 150000003577 thiophenes Chemical class 0.000 claims description 3
- 150000003852 triazoles Chemical class 0.000 claims description 3
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 2
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical group C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 claims description 2
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical group C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical group C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Chemical group C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 2
- 150000002790 naphthalenes Chemical class 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 235000019256 formaldehyde Nutrition 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract description 7
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 6
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 abstract description 5
- 102000006953 melanin-concentrating hormone receptor activity proteins Human genes 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- 239000000243 solution Substances 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- 239000000460 chlorine Substances 0.000 description 36
- 239000000047 product Substances 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- 239000002904 solvent Substances 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 22
- 150000003254 radicals Chemical class 0.000 description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 229910052938 sodium sulfate Inorganic materials 0.000 description 20
- 235000011152 sodium sulphate Nutrition 0.000 description 20
- 239000000556 agonist Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 14
- 238000002953 preparative HPLC Methods 0.000 description 14
- 229910052792 caesium Inorganic materials 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 6
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- QSKSKBYJAIMSBH-UHFFFAOYSA-N 4-[3-(dimethylamino)pyrrolidin-1-yl]benzohydrazide Chemical compound C1C(N(C)C)CCN1C1=CC=C(C(=O)NN)C=C1 QSKSKBYJAIMSBH-UHFFFAOYSA-N 0.000 description 5
- 229940100389 Sulfonylurea Drugs 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- SPBCGZJDAYRSKO-UHFFFAOYSA-N 1-[4-[5-(aminomethyl)-1,2,4-oxadiazol-3-yl]phenyl]-n,n-dimethylpyrrolidin-3-amine Chemical compound C1C(N(C)C)CCN1C1=CC=C(C=2N=C(CN)ON=2)C=C1 SPBCGZJDAYRSKO-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000003178 anti-diabetic effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 3
- WPLSSHZPPJTIDZ-UHFFFAOYSA-N 4-[3-(dimethylamino)pyrrolidin-1-yl]-n'-hydroxybenzenecarboximidamide Chemical compound C1C(N(C)C)CCN1C1=CC=C(C(=N)NO)C=C1 WPLSSHZPPJTIDZ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 240000008886 Ceratonia siliqua Species 0.000 description 3
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000005275 alkylenearyl group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 229960002354 repaglinide Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical group C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 0 *C(NC(CC1)CN1c(cc1)ncc1-c1nc(-c(cc2)cc(Cl)c2Cl)c[n]1)=O Chemical compound *C(NC(CC1)CN1c(cc1)ncc1-c1nc(-c(cc2)cc(Cl)c2Cl)c[n]1)=O 0.000 description 2
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical class C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 2
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical class C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 2
- FPICIFXADQUFBV-UHFFFAOYSA-N 4-[3-(dimethylamino)pyrrolidin-1-yl]benzoic acid Chemical compound C1C(N(C)C)CCN1C1=CC=C(C(O)=O)C=C1 FPICIFXADQUFBV-UHFFFAOYSA-N 0.000 description 2
- LAUFPZPAKULAGB-UHFFFAOYSA-N 4-butoxybenzoic acid Chemical compound CCCCOC1=CC=C(C(O)=O)C=C1 LAUFPZPAKULAGB-UHFFFAOYSA-N 0.000 description 2
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 2
- BCPGIEPYVGXOOS-UHFFFAOYSA-N 4-phenoxybutanehydrazide Chemical compound NNC(=O)CCCOC1=CC=CC=C1 BCPGIEPYVGXOOS-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 2
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101500028288 Homo sapiens Melanin-concentrating hormone Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- UULIGRNKXHCLQN-UHFFFAOYSA-N N-[[4-[[(4-amino-2-quinazolinyl)amino]methyl]cyclohexyl]methyl]-1-naphthalenesulfonamide Chemical compound C1=CC=C2C(N)=NC(NCC3CCC(CNS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)CC3)=NC2=C1 UULIGRNKXHCLQN-UHFFFAOYSA-N 0.000 description 2
- 102000034570 NR1 subfamily Human genes 0.000 description 2
- 108020001305 NR1 subfamily Proteins 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- 102000005630 Urocortins Human genes 0.000 description 2
- 108010059705 Urocortins Proteins 0.000 description 2
- JBFGSNVBIYJQOS-UHFFFAOYSA-N [3-[4-[3-(dimethylamino)pyrrolidin-1-yl]phenyl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound C1C(N(C)C)CCN1C1=CC=C(C=2N=C(CO)ON=2)C=C1 JBFGSNVBIYJQOS-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- NWXQQMMYARSJNH-UHFFFAOYSA-N ethyl 4-[3-(dimethylamino)pyrrolidin-1-yl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1N1CC(N(C)C)CC1 NWXQQMMYARSJNH-UHFFFAOYSA-N 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229960004346 glimepiride Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229950004994 meglitinide Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- MXTGXUXZUJTGAW-UHFFFAOYSA-N n'-(4-butoxybenzoyl)-4-[3-(dimethylamino)pyrrolidin-1-yl]benzohydrazide Chemical compound C1=CC(OCCCC)=CC=C1C(=O)NNC(=O)C1=CC=C(N2CC(CC2)N(C)C)C=C1 MXTGXUXZUJTGAW-UHFFFAOYSA-N 0.000 description 2
- AVAWMINJNRAQFS-UHFFFAOYSA-N n,n-dimethylpyrrolidin-3-amine Chemical compound CN(C)C1CCNC1 AVAWMINJNRAQFS-UHFFFAOYSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- 239000000777 urocortin Substances 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical group CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- AMNXBQPRODZJQR-DITALETJSA-N (2s)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-n-[(1r)-2-hydroxy-1-phenylethyl]acetamide Chemical compound C1([C@@H](C=2C=CC=C(C=2)CN2C3=CC=CC=C3C3=C(C)C=C(N=C32)C)C(=O)N[C@@H](CO)C=2C=CC=CC=2)CCCC1 AMNXBQPRODZJQR-DITALETJSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- GRZHHTYDZVRPIC-UHFFFAOYSA-N (benzyloxy)acetic acid Chemical compound OC(=O)COCC1=CC=CC=C1 GRZHHTYDZVRPIC-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical class C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- AKMNUCBQGHFICM-UHFFFAOYSA-N 1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea Chemical compound C1=CN=C2C(NC(=O)NC3=CC=C4N=C(OC4=C3)C)=CC=NC2=C1 AKMNUCBQGHFICM-UHFFFAOYSA-N 0.000 description 1
- OMXRTIUYSHDUTH-UHFFFAOYSA-N 1-(3-ethyl-1-benzofuran-7-yl)piperazine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC=C2C(CC)=COC2=C1N1CCNCC1 OMXRTIUYSHDUTH-UHFFFAOYSA-N 0.000 description 1
- KQNBRMUBPRGXSL-UHFFFAOYSA-N 1-(bromomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(CBr)C=C1 KQNBRMUBPRGXSL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PMQMZWQJSSGRLB-UHFFFAOYSA-N 1-[4-[5-(4-butoxyphenyl)-1,3,4-thiadiazol-2-yl]phenyl]-n,n-dimethylpyrrolidin-3-amine Chemical compound C1=CC(OCCCC)=CC=C1C1=NN=C(C=2C=CC(=CC=2)N2CC(CC2)N(C)C)S1 PMQMZWQJSSGRLB-UHFFFAOYSA-N 0.000 description 1
- ROMODKJDEABKGC-UHFFFAOYSA-N 1-[4-[5-[[(4-chlorophenyl)methylamino]methyl]-1,2,4-oxadiazol-3-yl]phenyl]-n,n-dimethylpyrrolidin-3-amine Chemical compound C1C(N(C)C)CCN1C1=CC=C(C=2N=C(CNCC=3C=CC(Cl)=CC=3)ON=2)C=C1 ROMODKJDEABKGC-UHFFFAOYSA-N 0.000 description 1
- BMDGHQROENTAQI-UHFFFAOYSA-N 1-[4-chloro-3-(methylsulfonylmethyl)phenyl]-2-[2-[(2,3-dimethyl-1h-indol-6-yl)oxy]ethylamino]ethanol Chemical compound C=1C=C2C(C)=C(C)NC2=CC=1OCCNCC(O)C1=CC=C(Cl)C(CS(C)(=O)=O)=C1 BMDGHQROENTAQI-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- GUSVHVVOABZHAH-OPZWKQDFSA-N 1aw8p77hkj Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GUSVHVVOABZHAH-OPZWKQDFSA-N 0.000 description 1
- SHWKIHWUFNTMIB-UHFFFAOYSA-N 2-(2-phenoxyethylsulfanyl)acetic acid Chemical compound OC(=O)CSCCOC1=CC=CC=C1 SHWKIHWUFNTMIB-UHFFFAOYSA-N 0.000 description 1
- ALQDFEKVXYMIBQ-UHFFFAOYSA-N 2-(3-aminopyrrolidin-1-yl)benzoic acid Chemical compound C1C(N)CCN1C1=CC=CC=C1C(O)=O ALQDFEKVXYMIBQ-UHFFFAOYSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- FOMOXGLITYUIRE-UHFFFAOYSA-N 2-[(4-chlorophenyl)methoxy]acetic acid Chemical compound OC(=O)COCC1=CC=C(Cl)C=C1 FOMOXGLITYUIRE-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- YCOXJFAUNLRWPU-UHFFFAOYSA-N 2-methyl-n,n-dipropyl-9-(2,4,6-trimethylphenyl)pyrimido[4,5-b]indol-4-amine Chemical compound C12=CC=CC=C2C=2C(N(CCC)CCC)=NC(C)=NC=2N1C1=C(C)C=C(C)C=C1C YCOXJFAUNLRWPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- TWJQZBXURHWBPV-UHFFFAOYSA-N 3-cyclohexyl-1-(4,4-dimethyl-6,7-dihydro-1h-imidazo[4,5-c]pyridin-5-yl)propan-1-one;oxalic acid Chemical compound OC(=O)C(O)=O.C1CC=2NC=NC=2C(C)(C)N1C(=O)CCC1CCCCC1 TWJQZBXURHWBPV-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- BTCHYRRVHVZBRX-UHFFFAOYSA-N 4-[3-(dimethylamino)pyrrolidin-1-yl]-n'-(4-phenoxybenzoyl)benzohydrazide Chemical compound C1C(N(C)C)CCN1C1=CC=C(C(=O)NNC(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)C=C1 BTCHYRRVHVZBRX-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- RYAQFHLUEMJOMF-UHFFFAOYSA-N 4-phenoxybenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1OC1=CC=CC=C1 RYAQFHLUEMJOMF-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102000004146 ATP citrate synthases Human genes 0.000 description 1
- 108090000662 ATP citrate synthases Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229940124802 CB1 antagonist Drugs 0.000 description 1
- PORPMYUTUMAUTE-UHFFFAOYSA-N CCCCNC(CC1)CN1c(cc1)ncc1-c1nc(-c(cc2)cc(Cl)c2Cl)c[nH]1 Chemical compound CCCCNC(CC1)CN1c(cc1)ncc1-c1nc(-c(cc2)cc(Cl)c2Cl)c[nH]1 PORPMYUTUMAUTE-UHFFFAOYSA-N 0.000 description 1
- PAIBHXPKSCLRIZ-UHFFFAOYSA-N CCCCNC(CC1)CN1c(cc1)ncc1-c1nc(-c2ccccc2)c[nH]1 Chemical compound CCCCNC(CC1)CN1c(cc1)ncc1-c1nc(-c2ccccc2)c[nH]1 PAIBHXPKSCLRIZ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102400001370 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 229940122014 Lyase inhibitor Drugs 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229940124757 MC-4 agonist Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 description 1
- 108700036626 Melanin-concentrating hormone receptor 1 Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- JKOXPUSCWTTXLX-UHFFFAOYSA-N NC(CC1)CCN1c(nc1)ccc1-c1nc(-c(cc2)ccc2Cl)c[nH]1 Chemical compound NC(CC1)CCN1c(nc1)ccc1-c1nc(-c(cc2)ccc2Cl)c[nH]1 JKOXPUSCWTTXLX-UHFFFAOYSA-N 0.000 description 1
- MYXUYMWLBZKUBM-UHFFFAOYSA-N NC(CC1)CN1c(cc1)ncc1-c1nc(-c(cc2)cc(Cl)c2Cl)c[nH]1 Chemical compound NC(CC1)CN1c(cc1)ncc1-c1nc(-c(cc2)cc(Cl)c2Cl)c[nH]1 MYXUYMWLBZKUBM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229940123495 Squalene synthetase inhibitor Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 102000008200 Uncoupling Protein 3 Human genes 0.000 description 1
- 108010021098 Uncoupling Protein 3 Proteins 0.000 description 1
- WAHMIDNUZIGEIQ-SNVBAGLBSA-N [(3r)-1-(4-cyanophenyl)pyrrolidin-3-yl]carbamic acid Chemical compound C1[C@H](NC(=O)O)CCN1C1=CC=C(C#N)C=C1 WAHMIDNUZIGEIQ-SNVBAGLBSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940112930 apidra Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 108010014210 axokine Proteins 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- BMWITAUNXBHIPO-OZZZDHQUSA-N benzenesulfonic acid;(2s,4s)-4-fluoro-1-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound OS(=O)(=O)C1=CC=CC=C1.OCC(C)(C)NCC(=O)N1C[C@@H](F)C[C@H]1C#N BMWITAUNXBHIPO-OZZZDHQUSA-N 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- UMPRJGKLMUDRHL-UHFFFAOYSA-N ethyl 4-fluorobenzoate Chemical compound CCOC(=O)C1=CC=C(F)C=C1 UMPRJGKLMUDRHL-UHFFFAOYSA-N 0.000 description 1
- AFRWBGJRWRHQOV-UHFFFAOYSA-N ethyl 5-bromopentanoate Chemical compound CCOC(=O)CCCCBr AFRWBGJRWRHQOV-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 235000014168 granola/muesli bars Nutrition 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 229950005809 implitapide Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 108700039926 insulin glulisine Proteins 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940060975 lantus Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002697 lyase inhibitor Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- AMXILFZUXYTLPL-UHFFFAOYSA-N methyl 4-(3-aminopyrrolidin-1-yl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1N1CC(N)CC1 AMXILFZUXYTLPL-UHFFFAOYSA-N 0.000 description 1
- MSEBQGULDWDIRW-UHFFFAOYSA-N methyl 4-fluorobenzoate Chemical compound COC(=O)C1=CC=C(F)C=C1 MSEBQGULDWDIRW-UHFFFAOYSA-N 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WYVYNNNNHBDRGB-UHFFFAOYSA-N n,n-dimethyl-1-[4-[5-(2-phenoxyethylsulfanylmethyl)-1,3,4-oxadiazol-2-yl]phenyl]pyrrolidin-3-amine Chemical compound C1C(N(C)C)CCN1C1=CC=C(C=2OC(CSCCOC=3C=CC=CC=3)=NN=2)C=C1 WYVYNNNNHBDRGB-UHFFFAOYSA-N 0.000 description 1
- FMBJBGFMENOGPG-UHFFFAOYSA-N n,n-dimethyl-1-[4-[5-(4-phenoxybutyl)-1,3,4-oxadiazol-2-yl]phenyl]pyrrolidin-3-amine Chemical compound C1C(N(C)C)CCN1C1=CC=C(C=2OC(CCCCOC=3C=CC=CC=3)=NN=2)C=C1 FMBJBGFMENOGPG-UHFFFAOYSA-N 0.000 description 1
- LXEDKSZTPGCEPU-UHFFFAOYSA-N n-[2-(3a-benzyl-2-methyl-3-oxo-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]-1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxamide Chemical compound O=C1N(C)N=C2CCN(C(=O)C(NC(=O)C3C(C4=CC=CC=C4CC3)N)C=3C=CC(Cl)=CC=3)CC21CC1=CC=CC=C1 LXEDKSZTPGCEPU-UHFFFAOYSA-N 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- YDCVQGAUCOROHB-UHFFFAOYSA-N oxadiazolidine-4,5-dione Chemical class O=C1NNOC1=O YDCVQGAUCOROHB-UHFFFAOYSA-N 0.000 description 1
- VWMZIGBYZQUQOA-QEEMJVPDSA-N pamaqueside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC(=O)[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VWMZIGBYZQUQOA-QEEMJVPDSA-N 0.000 description 1
- 229950005482 pamaqueside Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical group CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 229960003015 rimonabant Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- ZAOPBCHLHBOUPR-UHFFFAOYSA-N tert-butyl 1-[2-[di(propan-2-yl)amino]ethylcarbamoyl]-6-phenylmethoxy-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C=1C=C2C(C(=O)NCCN(C(C)C)C(C)C)N(C(=O)OC(C)(C)C)CCC2=CC=1OCC1=CC=CC=C1 ZAOPBCHLHBOUPR-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NVXLPTRAYYCTLO-GFCCVEGCSA-N tert-butyl n-[[(3r)-1-[4-[(z)-n'-hydroxycarbamimidoyl]phenyl]pyrrolidin-3-yl]methyl]carbamate Chemical compound C1[C@@H](CNC(=O)OC(C)(C)C)CCN1C1=CC=C(C(=N)NO)C=C1 NVXLPTRAYYCTLO-GFCCVEGCSA-N 0.000 description 1
- DQQJBEAXSOOCPG-UHFFFAOYSA-N tert-butyl n-pyrrolidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNC1 DQQJBEAXSOOCPG-UHFFFAOYSA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 229950004437 tiqueside Drugs 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 torcetrapib Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- VHKIEYIESYMHPT-UHFFFAOYSA-N triethyl(methoxycarbonylsulfamoyl)azanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)S(=O)(=O)NC(=O)OC VHKIEYIESYMHPT-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940124024 weight reducing agent Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
The invention relates to substituted, aryl-substituted heterocycles, the physiologically-acceptable salts and physiologically-functional derivatives thereof, methods for production and use thereof as medicaments. Compounds of formula (I), where the groups have the given meanings, the N-oxides and physiologically-acceptable salts thereof and methods for production thereof are disclosed. The compounds exhibit, for example a weight-reducing effect in mammals and are thus suitable for use in, for example, prevention and treatment of obesity and diabetes. Said compounds are MCH receptor antagonists.
Description
A.S ORIGINALLY FILL'D
Aryl-substituted heterocycles, method for production and thereof as medicaments The invention relates to aryl-substituted heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof.
~ o Compounds similar in their overall structure to the heterocycles described herein and having a pharmacological effect have been described in the prior art. Thus, for example, WO 03/097047 describes aryl-substituted oxadiazoles for the treatment of obesity and diabetes.
Compounds with MCH-antagonistic activity for treatment of obesity are disclosed in the ~ 5 prior art (examples: W02001021577, W02003035624, W02002089729, W02002006245, W02002002744, W02002057233, W02003045313, W02003097047, W02002010146, W02003087044).
The invention was based on the object of providing compounds which bring about a weight 2o reduction in mammals and are suitable for the prevention and treatment of obesity and diabetes.
Surprisingly, a series of compounds which modulate the activity of MCH
receptors has been found. In particular, the compounds are distinguished by MCHIR
antagonism.
25 The invention therefore relates to compounds of the formula I, A-B NR R
R11 ~K~E~X-Het---~~ ~~N ~ 1 2 m in which the meanings are Ri, R2 independently of one another H, (C,-CH)-alkyl, -(CR13R14)o-R12, (C~-Ca)-alkoxy-(C,-C~)-alkyl, (C~-Cs)-alkenyl, (C~-Cs)-alkynyl, CO-(C,-Cg)-alkyl, -CO-(CH~)~ R 12, CO(C(R 15)(R 16)),~N(R17)(R18), CO(C(R 19)(R20))50(R2 I ); or R 1 and R2 form together with the nitrogen S atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 4 additional heteroatorns selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CFA, NO~, CN, (C,-C~)-alkyl, O-(C,-Cs)-alkyl, (C,-C4)-alkoxy-W (C,-Ca)-alkyl, hydroxy-(C,-C4)-alkyl, (Co-C~)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(C~-C6)-alkyl, N(R27)(R28) or SOZCH3;
0 0, I , 2, 3, 4, 5, 6;
~5 q, s independently of one another 0, l, 2, 3, 4;
R 15, R 16, R 17, R 18, R 19, R20, R21, R22, R23, R24, R25, R26, R27, R28 independently of one another H, (C1-C6)-alkyl;
2o R 17 and R 18, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-'S (Cl-C6)-alkyl, oxygen and sulfur;
R12 OH, O-(C,-C6)-alkyl, CN, COO(R29), CON(R30)(R31), N(R32)(R33), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may 30 comprise further substituents such as F, Cl, Br, I, OH, CF3, N02, CN, OCF3, oxo, O-(CI-C6)-alkyl, (C~-C4)-alkoxy-(C,-C4)-alkyl, S-(C~-C6)-alkyl, (C~-C6)-alkyl, (CZ-C6)-alkenyl, (C3-Cg)-cycloalkyl, (C~-C6)-alkynyl, O-(Co-Cg)-alkylene-aryl, (C«-CH)-alkylene-aryl, N(R34)(R35), CO(C,-C6)-alkyl, COO(R36) and S(O)" (R37);
a 0, l, 2;
R34, R35 independently of one another H, (C,-CH)-alkyl;
R34 and R35 m optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur, and optionally be substituted by 1-2 ~oxo groups;
~ 5 R36, R37 H, (C,-CR)-alkyl;
R13, R14 independently of one another H, (C,-Cs)-alkyl, hydroxy-(C~-C4)-alkyl, OH, (C, -C4)-alkoxy-(C, -Ca)-alkyl;
2o R29, R30, R31 independently of one another H, (C~-Cg)-alkyl, (C~-C6)-alkenyl, (Co-Cg)-alkylene-aryl;
R32, R33 independently of one another H, (C~-C6)-alkyl ZS or R32 and R33 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C,-C6)-alkyl, oxygen and 3o sulfur and optionally be substituted by 1-2 oxo groups;
R3 H, (C,-C6)-alkyl;
Aryl-substituted heterocycles, method for production and thereof as medicaments The invention relates to aryl-substituted heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof.
~ o Compounds similar in their overall structure to the heterocycles described herein and having a pharmacological effect have been described in the prior art. Thus, for example, WO 03/097047 describes aryl-substituted oxadiazoles for the treatment of obesity and diabetes.
Compounds with MCH-antagonistic activity for treatment of obesity are disclosed in the ~ 5 prior art (examples: W02001021577, W02003035624, W02002089729, W02002006245, W02002002744, W02002057233, W02003045313, W02003097047, W02002010146, W02003087044).
The invention was based on the object of providing compounds which bring about a weight 2o reduction in mammals and are suitable for the prevention and treatment of obesity and diabetes.
Surprisingly, a series of compounds which modulate the activity of MCH
receptors has been found. In particular, the compounds are distinguished by MCHIR
antagonism.
25 The invention therefore relates to compounds of the formula I, A-B NR R
R11 ~K~E~X-Het---~~ ~~N ~ 1 2 m in which the meanings are Ri, R2 independently of one another H, (C,-CH)-alkyl, -(CR13R14)o-R12, (C~-Ca)-alkoxy-(C,-C~)-alkyl, (C~-Cs)-alkenyl, (C~-Cs)-alkynyl, CO-(C,-Cg)-alkyl, -CO-(CH~)~ R 12, CO(C(R 15)(R 16)),~N(R17)(R18), CO(C(R 19)(R20))50(R2 I ); or R 1 and R2 form together with the nitrogen S atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 4 additional heteroatorns selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CFA, NO~, CN, (C,-C~)-alkyl, O-(C,-Cs)-alkyl, (C,-C4)-alkoxy-W (C,-Ca)-alkyl, hydroxy-(C,-C4)-alkyl, (Co-C~)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(C~-C6)-alkyl, N(R27)(R28) or SOZCH3;
0 0, I , 2, 3, 4, 5, 6;
~5 q, s independently of one another 0, l, 2, 3, 4;
R 15, R 16, R 17, R 18, R 19, R20, R21, R22, R23, R24, R25, R26, R27, R28 independently of one another H, (C1-C6)-alkyl;
2o R 17 and R 18, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-'S (Cl-C6)-alkyl, oxygen and sulfur;
R12 OH, O-(C,-C6)-alkyl, CN, COO(R29), CON(R30)(R31), N(R32)(R33), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may 30 comprise further substituents such as F, Cl, Br, I, OH, CF3, N02, CN, OCF3, oxo, O-(CI-C6)-alkyl, (C~-C4)-alkoxy-(C,-C4)-alkyl, S-(C~-C6)-alkyl, (C~-C6)-alkyl, (CZ-C6)-alkenyl, (C3-Cg)-cycloalkyl, (C~-C6)-alkynyl, O-(Co-Cg)-alkylene-aryl, (C«-CH)-alkylene-aryl, N(R34)(R35), CO(C,-C6)-alkyl, COO(R36) and S(O)" (R37);
a 0, l, 2;
R34, R35 independently of one another H, (C,-CH)-alkyl;
R34 and R35 m optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur, and optionally be substituted by 1-2 ~oxo groups;
~ 5 R36, R37 H, (C,-CR)-alkyl;
R13, R14 independently of one another H, (C,-Cs)-alkyl, hydroxy-(C~-C4)-alkyl, OH, (C, -C4)-alkoxy-(C, -Ca)-alkyl;
2o R29, R30, R31 independently of one another H, (C~-Cg)-alkyl, (C~-C6)-alkenyl, (Co-Cg)-alkylene-aryl;
R32, R33 independently of one another H, (C~-C6)-alkyl ZS or R32 and R33 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C,-C6)-alkyl, oxygen and 3o sulfur and optionally be substituted by 1-2 oxo groups;
R3 H, (C,-C6)-alkyl;
R4, RS independently of one another H, (C,-C~,)-alkyl, OH, O-(C,-C6)-alkyl, O-CO(C,-C~)-alkyl, S-(C,-C6)-alkyl;
R6, R7, R8, R9 independently of one another H, (C,-C~)-alkyl, or R6 and R7, R8 and R9 independently of one another optionally oxo;
I o n, m independently of one another 0, 1, 2;
A, B, D, G independently of one another N, C(R38);
R38 H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-(C,-C6)-alkyl, O-(C,-C4)-Is alkoxy-(C,-C4)-alkyl, S-(C,-C~)-alkyl, (C1-C6)-alkyl, (CZ-C6)-alkenyl, (C3-CR)-cycloalkyl, O-(C3-CA)-cycloalkyl, (C3-Cg)-cycloalkenyl, O-(C3-Cg) cycloalkenyl, (Cz-C6)-alkynyl, (C~-Cg)-alkylene-aryl, O-(Co-C8)-alkylene aryl, S-aryl, N(R39)(R40), S02-CH3, COOH, COO-(C,-C6)-alkyl, CON(R41)(R42), N(R43)CO(R44), N(R45)SOZ(R46), CO(R47), 20 (CR48R49)X-O(R50);
R39, R40, R41, R42, R43, R45 independently of one another H, (C,-Cg)-alkyl;
or 25 R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C~-C6)-alkyl, oxygen and sulfur;
R44, R46, R47 independently of one another H, (C,-Cg)-alkyl, aryl;
S
R4H, R49 independently of one another H, (C,-CH)-alkyl;
R50 H, (C,-C~,)-alkyl;
x I , 2, 3, 4;
Het five-membered aromatic heterocycle X a bond, a group of the formula -(CR51R52)y- in which one or more o (CR51 R52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, C=C;
Y O, S, N(R53), CO, SO, SO2;
~5 RSI, R52 independently of one another H, (C,-C4)-alkyl, where R51 and R52 in the y groups may in each case have the same or different meanings;
y l , 2, 3, 4, 5, 6;
2o R53 H, (C,-Cg)-alkyl;
E 3-14 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, I, OH, CF3, NO~, CN, OCF3, 25 oxo, O-(C,-C6)-alkyl, O-(C1-C4)-alkoxy-(C,-C4)-alkyl, S-(C~-C6)-alkyl, (C1-C6)-alkyl, (CZ-C6)-alkenyl, (C3-Cg)-cycloalkyl, O-(C3-Cg)-cycloalkyl, (C2-C6)-alkynyl, (Co-Cs)-alkylene-aryl, O-(Co-Cg)-alkylene-aryl, S-aryl, N(R54)(R55), SOZ-CH3, COOH, COO-(C,-C6)-alkyl, CON(R56)(R57), N(R58)CO(R59), N(R60)SOZ(R61), CO(R62) and be mono- or bicyclic;
R54, R55, R56, R57, R58, R60 independently of one another H, (C1-Cg)-alkyl;
R54 and R55, R56 and R57 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membercd ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N
(C,-C~)-alkyl, oxygen and sulfur;
R59, R61, R62 independently of one another H, (C,-CA)-alkyl, aryl;
to K a bond, a group of the formula -(CR63R64)Z in which one or more -(CR63R64)- groups may be replaced by Z to result in a chemically reasonable radical, C=C, C=C;
Z O, S, N(R65), CO, SO, S02;
R63, R64 independently of one another H, (C,-Cg)-alkyl, hydroxy, (C,-C6)-alkoxy, where R63 and R64 in the z groups may in each case have the same or different meanings;
2o z 1, 2, 3, 4, 5, 6; preferably 2, 3, 4, 5, 6;
R65 H, (C,-Cg)-alkyl;
Rll H, (C,-Cg)-alkyl, (C,-C4)-alkoxy-(C,-C4)-alkyl, (C~-Cg)-alkenyl, (C3-Cg)-alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O-(C~-C8)-alkyl, (CI-C4)-alkoxy-(C~-C4)-alkyl, (Co-C8)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, hydroxy-(CI-C4)-alkyl, COO(R69), N(R70)CO(C~-C6)-alkyl, N(R71)(R72) or SOZCH3;
R66, R67, R68, R69, R70, R71, R72 independently of one another H, (C,-CH)-alkyl;
or R67 and R68, R71 and R72 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(CI-C~)-alkyl, oxygen and sulfur; or I o the N-oxides thereof and the physiologically tolerated salts thereof.
The invention relates to compounds of the formula I in the form of their racemates, enantiomer-enriched mixtures and pure enantiomers and to their diastereomers and I5 mixtures thereof.
The alkyl, alkenyl and alkynyl radicals in the substituents R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10, R 11, R 12, R 13, R 14, R 15, R 16, R 17, R 18, R 19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, 2o R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77, R78, R79, R80, R81, R82, R83 and R84 may be either straight-chain, branched or optionally halogenated.
25 In a further embodiment, the alkyl, alkenyl and alkynyl radicals in the substituents R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10, R 11, R 12, R 13, R 14, R 15, R 16, R 17, R
18, R 19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62. R63, R64, R65, R66, R67, R68, R69, R70, R71, 30 R72, R73, R74, R75, R76, R77, R78, R79. R80, R81, R82, R83 and R84 may be both straight-chain, branched and/or optionally substituted by substituents such as aryl, heteroaryl, alkoxy or halogen. This also applies if the alkyl, alkenyl and alkynyl radicals are part of another group, for example part of an alkoxy group (such as (C1-C4)-alkoxy-g (C,-C4)-alkyl)). Suitable halogens are fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine and bromine, particularly preferably fluorine.
Examples of alkyl groups are: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl.
Included therein are both the n isomers of these radicals and branched isomers such as isopropyl, isobutyl, isopentyl, sec-butyl, tert-butyl, neopentyl, 3,3-dimethylbutyl etc.
Unless described otherwise, the term alkyl additionally includes alkyl radicals which are unsubstituted or optionally substituted by one or more further radicals, for example 1, 2, 3 or 4 identical or different radicals such as aryl, heteroaryl, alkoxy or halogen. It is moreover possible for the additional substituents to occur in any position of the alkyl radical.
Cycloalkyl means for the purposes of the present application cycloalkyl and cycloalkyl-alkyl(alkyl which is substituted in turn by cycloalkyl, e.g.
cyclopropylmethyl), where ~ 5 cycloalkyl has at least 3 carbon atoms. Examples of cycloalkyl radicals are: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl.
Optional possibilities are also polycyclic ring systems such as decalinyl, norbornanyl, bornanyl or adamantanyl. The cycloalkyl radicals may be unsubstituted or optionally substituted by one or more further radicals as listed above by way of example for the alkyl 2o radicals.
Examples of alkenyl and alkynyl groups are: vinyl, 1-propenyl, 2-propenyl (allyl), 2-butenyl, 2-methyl-2-propenyl, 3-methyl-2-butenyl, ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2-butynyl or 3-butynyl.
Cycloalkenyl means for the purposes of the present application cycloalkenyl radicals and cycloalkenyl-alkyl radicals (alkyl which is substituted by cycloalkenyl), which comprise at least three carbon atoms. Examples of cycloalkenyl are: cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. The alkenyl radicals and cycloalkenyl radicals may have 3o one to three conjugated or unconjugated double bonds (thus also alk-dienyl and alk-trienyl radicals), preferably one double bond in a straight or branched chain. The same applies to the triple bonds in alkynyl radicals. The alkenyl and alkynyl radicals may be unsubstituted or optionally substituted by one or more further radicals as listed above by way of example for the alkyl radicals.
Aryl refers in the present invention to radicals derived from monocyclic or bicyclic aromatic compounds comprising no ring heteroatoms. Where aryl refers to systems which are not monocyclic, the saturated form (perhydroform) or the partially unsaturated form (for example the dihydroform or tetrahydroform) is also possible, where the respective forms are known and stable, for the second ring. The term aryl also includes in the present invention for example bicyclic radicals in which both rings are aromatic and bicyclic radicals in which only one ring is aromatic. Examples of aryl are: phenyl, naphthyl, to indanyl, 1,2-dihydronaphthenyl, 1,4-dihydronaphthenyl, indenyl or 1,2,3,4-tetrahydronaphthyl. Aryl is particularly preferably phenyl or naphthyl. The term "aryl" thus means in particular a phenyl or naphthyl group.
Heteroaryl radicals mean radicals derived from monocyclic or bicyclic aromatic compounds comprising ring heteroatoms, preferably N, O or S. Otherwise, the statements made about aryl radicals apply to heteroaryl radicals.
The aryl and heteroaryl radicals may be unsubstituted or substituted by one or more further radicals. Suitable further radicals are listed by way of example above for the alkyl radicals.
The compounds of the formula I may comprise one or more centers of asymmetry.
The compounds of the formula I may therefore be in the form of their racemates, enantiomer-enriched mixtures, pure enantiomers, diastereomers and diastereomer mixtures.
The present invention includes all these isomeric forms of the compounds of the formula I.
These isomeric forms can be obtained by known methods even if not expressly described m some cases.
Mono-, bi- or spirocyclic rings may be saturated, partially saturated or unsaturated and also bridged.
C=C means a group of the formula R'C=CR" in which R' and R" are independently of one another H, (C,-Cg)-alkyl, preferably H.
l~
In the case where R1 and R2 together with the nitrogen atom to which they are bonded form a ring, this ring may be substituted by one or more of the substituents mentioned.
Pharmaceutically acceptable salts are particularly suitable for medical applications because their solubility in water is higher than the initial or basic compounds. These salts must have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds according to the invention are salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ~ o ethanesulfonic, fumaric, gluconic, glycolic, isethionie, lactic, lactobionic, malefic, malic, methanesulfonic, trifluoromethanesulfonic, succinic, p-toluenesulfonic, tartaric and trifluoroacetic acids. The chloride salt is particularly preferably used for medical purposes.
Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium ~ 5 and calcium salts) and salts of trometamol (2-amino-2-hydroxymethyl-1,3-propanediol), diethanolamine, lysine or ethylenediamine.
Salts with a pharmaceutically unacceptable anion likewise fall within the scope of the invention as useful intermediates for preparing or purifying pharmaceutically acceptable 2o salts and/or for use in nontherapeutic, for example in vitro, applications.
The term "physiologically functional derivative" used herein refers to any physiologically tolerated derivative of a compound according to the invention of the formula I, for example an ester, which is able on administration to a mammal such as, for example, a human to 25 form (directly or indirectly) a compound of the formula I or an active metabolite thereof.
The physiologically functional derivatives also include prodrugs of the compounds according to the invention, as described, for example, in H. Okada et al., Chem. Pharm.
Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound according 3o to the invention. These prodrugs may themselves be active or not.
The compounds according to the invention may also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All polymorphous forms of the compounds according to the invention lie within the scope of the invention and are a further aspect of the invention.
All references hereinafter to "compound(s) of formula (I)" refer to compounds) of the formula (I) as described above, and the salts, solvates and physiologically functional derivatives thereof as described herein.
If radicals or substituents can occur more than once in the compounds of the formula I, they may all independently of one another have the stated meanings and be identical or 0 different.
In a preferred embodiment, the meanings in the compounds of the formula I are R1, R2independently of one another H, (Cl-CA)-alkyl, -(CR13R14)o-R12, (C,-C~)-alkoxy-(C1-C4)-alkyl, (C3-Cs)-alkenyl, (C3-Cs)-alkynyl, CO-(C,-Cg)-alkyl, -CO-(CHZ)o -R12, CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))SO(R21);
~ 5 or R 1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF3, N02, CN, (C1-C6)-alkyl, 2o O-(C,-Cg)-alkyl, (C~-C4)-alkoxy-(C,-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (Co-Cg)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(C,-C6)-alkyl or N(R27)(R28);
R12 OH, O-(C,-C6)-alkyl, CN, COO(R29), CON(R30)(R31), N(R32)(R33), 3-12 25 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, I, OH, CF3, N02, CN, OCF~, oxo, O-(C,-C6)-alkyl, (C1-C4)-alkoxy-(C~-C4)-alkyl, S-(C~-C6)-alkyl, (C,-C6)-alkyl, (C~-C6)-alkenyl, (C3-C~)-cycloalkyl, (C2-C6)-alkynyl, O-(Co-Cg)-3o alkylene-aryl, (Co-C~)-alkylene-aryl, N(R34)(R35), CO(C~-C6)-alkyl and COO(R36);
and R6, R7, R8, R9 independently of one another H, (C,-Cg)-alkyl;
where the further radicals and groups in the compounds of the formula I have the meanings mentioned hereinbefore and preferred meanings mentioned hereinafter.
In a further preferred embodiment, the present invention relates to compounds of the formula I
the meanings are:
io Rl, R2 independently of one another H, (C,-Cs)-alkyl, -(CR13R14)o -R12, (C,-Ca)-alkoxy-(C,-C4)-alkyl, (C3-Cg)-alkenyl, CO-(Cl-C8)-alkyl, -CO-(CH2)o -R12, CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))SO(R21); or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-~ 5 membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C,-C6)-alkyl, O-(C,-C4)-alkyl, (Ci-C4)-alkoxy-(C,-C4)-alkyl, hydroxy-(C~-C4)-alkyl, (Ca-CZ)-alkylene-aryl, 20 oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(C,-C6)-alkyl, N(R27)(R28) or SOZCH3;
preferably independently of one another H, (C1-C~)-alkyl, -(CR13R14)o R12, (C~-C4)-alkoxy-(C,-C4)-alkyl, CO-(C1-Cg)-alkyl, -CO-(CHZ)o R12, CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))SO(R21);
25 or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono- or bicyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C,-C6)-alkyl, O-(C1-C4)-3o alkyl, (C,-C4)-alkoxy-(Ca-C4)-alkyl, (Co-C~)-alkylene-aryl, oxo, CO(R22), hydroxy, N(R27)(R28) or S02CH3;
particularly preferably independently of one another H, (C,-C~)-alkyl, -(CR13R14)o R12, (C,-C4)-alkoxy-(C,-C4)-alkyl, CO-(C1-Cg)-alkyl, -CO-(CH2)~ R12, CO(C(R15)(R16))qN(R17)(R18), or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-or bicyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen and nitrogen, where the heterocyclic ring system may additionally be substituted by F, (Ci-C6)-alkyl, (C~-C4)-alkoxy-(C,-C~)-alkyl, oxo, CO(R22), hydroxy, N(R27)(R28);
0 0, l, 2, 3, 4, 5, 6; preferably 0, l, 2, 3, 4; particularly preferably 0, l, 2, 3;
~o q l, 2, 3; preferably 1 or 2;
s 0, l, 2, 3, 4; preferably 0, l, 2, 3; particularly preferably 0, 1, 2;
~ 5 R 15, R 16, R 17, R 18, R 19, R20, R21, R22, R23, R24, R25, R26, R27, R28 independently of one another H, (C1-C~)-alkyl;
or R 17 and R 18, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to 2o which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur; the ring is preferably pyrrolidine, piperidine, N-methylpiperazine, morpholine;
25 R12 OH, O-(C,-C6)-alkyl, CN, COO(R29), CON(R30)(R31), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, OH, CF3, CN, oxo, O-(C,-C6)-alkyl, (C~-Cd)-alkoxy-(C,-C4)-alkyl, (C,-C6)-alkyl, O-(Co-Cg)-alkylene-aryl, (Co-30 Cg)-alkylene-aryl, N(R34)(R35), CO(C1-C6)-alkyl, COO(R36), S(O)"(R37);
preferably OH, O-(Cl-C6)-alkyl, CN, 3-10 membered mono- or bicyclic ring which may comprise 1-3 heteroatoms from the group of N, O and S, and the 3-10 membered ring may comprise further substituents such as F, Cl, Br, OH, CF3, CN, oxo, O-(C,-C~)-alkyl, (C,-C4)-alkoxy-(Cl-C4)-alkyl, (C,-C~)-alkyl, (Co-Cz)-alkylene-aryl, N(R34)(R35), CO(Cl-C6)-alkyl;
particularly preferably OH, O-(C,-C~)-alkyl, 3-10 membered mono- or bicyclic ring which may comprise 1-2 heteroatoms from the group of N, O
and S, and the 3-10 membered ring may comprise further substituents such as F, OH, oxo, (C,-C~,)-alkyl, CO(C,-C~;)-alkyl;
a 0, 1, 2; preferably 0 or 2; particularly preferably 2;
i o R34, R35 independently of one another H, (C~-Cs)-alkyl;
or R34 and R35 optionally together with the nitrogen atom to which they are bonded a 5-6 i5 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C,-C6)-alkyl, oxygen and sulfur, and optionally be substituted by 1-2 oxo groups;
R36, R37 H, (C,-Cs)-alkyl;
R13, R14 independently of one another H, (C1-Cg)-alkyl, hydroxy-(C~-Cø)-alkyl, OH, (C, -C4)-alkoxy-(C 1-Ca)-alkyl;
R29, R30, R31 independently of one another H, (C1-C~)-alkyl;
R3 H, (Ci-C6)-alkyl; preferably H;
R4, RS independently of one another H, (CI-C6)-alkyl, OH, O-(CI-C6)-alkyl, O-3o CO(CI-C6)-alkyl, S-(Cl-C6)-alkyl; preferably independently of one another H, (C,-C6)-alkyl, OH, O-(C,-C~)-alkyl, O-CO(C~-C6)-alkyl; particularly preferably independently of one another H, OH, O-(C~-C6)-alkyl, very particularly preferably H;
R6, R7, R8, R9 H;
or 5 R6 and R7, R8 and R9 independently of one another optionally oxo;
R6, R7, R8, R9 are preferably H;
n 1 ~o m 1 or 2; preferably l;
A, B, D, G independently of one another N, C(R38);
or ~ 5 the groups A and B or D and G are in each case C(R38) and together form an ortho-phenylene unit so that the overall result is a 1,4-bisubstituted naphthalene system;
preferably A, B, G and D are independently of one another N, C(R38);
particularly preferably D and G are C(R38) and either A or B is N, with the respective other group B or A being C(R38); very particularly preferably B is N, C(R38); and A, D, G C(R38);
especially preferably A, B, D, G are C(R38);
R38 H, F, Cl, Br, CF3, CN, O-(CI-C6)-alkyl, O-(CI-C~)-alkoxy-(Cl-C4)-alkyl, S-(C~-C6)-alkyl, (C1-C6)-alkyl, (Co-Cg)-alkylene-aryl, O-(CQ-Cg)-alkylene-aryl, N(R39)(R40), SOZ-CH3, CON(R41)(R42), N(R43)CO(R44), CO(R47), -(CR48R49)X-O(R50);
preferably H, F, Cl, Br, CF3, CN, O-(C,-C6)-alkyl, (C~-C6)-alkyl, SOZ-CHI, 3o CON(R41)(R42), N(R43)CO(R44), CO(R47), -(CR48R49)X-O(R50);
particularly preferably H, F, Cl, CF3, CN, (C,-Cb)-alkyl, -(CR48R49)X-O(R50);
R39, R40, R41, R42, R43 independently of one another H, (C1-C8)-alkyl;
or R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C,-C~)-alkyl, oxygen and sulfur;
fo R44, R47 independently of one another H, (C,-Cg)-alkyl, aryl; preferably independently of one another H, (C,-CA)-alkyl;
R48, R49 H;
~5 R50 H, (C,-C6)-alkyl;
x 1, 2; preferably l;
20 Het five-membered aromatic heterocycle, preferably i~,~
_~t r~ J' __, i , f- , _ ~~,-W' %,3 ~ !~'. ° ,- ~'x!
~:
~' I
S f: 1 ~J'S--- ~i ~yi,:_...~yJ~
o r ~ ___. , in which A' is O, S, NR73, X' , Y' and Z' are independently of one another CR74 or N, and R73, R74 are independently of one another H, (CI-Cg)-alkyl;
Het is particularly preferably selected from the group consisting of oxadiazoles, thiadiazoles, thiazoles, oxazoles, triazoles, thiophenes, furans and pyrroles; Het is very particularly preferably selected from oxadiazoles, thiadiazoles, thiazoles and oxazoles;
X a bond, a group of the formula -(CR51R52)y- in which one or more -o (CR51R52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, C=C; preferably a bond, CHZ-CHZ, CH2Y, YCH2, (R75)YCH2, CHZ-NCO(R75), CHZCON(R75); C(R76)(R77), C(R78)(R79)O, N(R75), C=C, C-C; particularly preferably a bond, CHZ-CHZ, C(R76)(R77), N(R75), CH2Y, CH2Y(R75), CH2-NCO(R75), ~ 5 CHZCON(R75); C=C; very particularly preferably a bond, CHI-CHz, C(R76)(R77), C=C, (R75)YCH2, CHZ-NCO(R75);
Y O, S, N(R53), CO; preferably O, S, N(R53);
2o R53 H, (C~-Cg)-alkyl;
R75, R76, R77, R78, R79 independently of one another H, (C1-CA)-alkyl;
25 E 3-8 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, O and 5, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO~, CN, OCF~, O-(Cl-C6)-alkyl, O-(C,-C4)-alkoxy-(Cl-C4)-alkyl, S-(CI-C6)-alkyl, (Ct-C6)-alkyl, (CZ-C6)-alkenyl, O-(C3-Cs)-cycloalkyl, (C2-C6)-alkynyl, (Co-Cg)-3o alkylene-aryl, O-(Co-Cg)-alkylene-aryl, S-aryl, N(R54)(R55), S02-CH3, N(R58)CO(R59), N(R60)S02(R61), CO(R62) and be mono- or bicyclic;
preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, C1, Br, OH, CF3, NO~, CN, OCF3, O-(C~-C6)-alkyl, S-(C1-C6)-alkyl, (CI-C6)-alkyl, (C2-C6)-alkenyl, O-(Co-Cg)-alkylene-aryl, S-aryl, N(R54)(R55), SOZ-CH3, N(R58)CO(R59), CO(R62) and be mono- or bicyclic;
s particularly preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-2 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, N02, OCF3, O-(C,-C6)-alkyl, (C,-C6)-alkyl, (C2-C6)-alkenyl, N(R54)(R55), SOZ-CH3, CO(R62), and which is very particularly preferably monocyclic;
o e.g. E is benzene, pyridine, pyrimidine, piperidine, pyrrolidine, cyclopentane, cyclohexane, piperazine, homopiperazine, thiazole, thiophene, furan, pyrrole, pyrazole, 1,2,3,6-tetrahydropyridine, 4,5-dihydroisoxazole, oxazole;
~ 5 R54, R55, R58, R60 independently of one another H, (C,-Cs)-alkyl;
R59, R61, R62 independently of one another H, (Ci-Cg)-alkyl, aryl; preferably 2o independently of one another H, (C1-Cg)-alkyl;
K O, a bond, CHZO, OCHZ, S, SO, SOZ, N(R80), N(R81)CO, CON(R82), (C(R83)(R84))~, CO, C=C, C=C, SCH~, SOzCHz;
preferably O, a bond, CH~O, OCH2, N(R80), N(R81)CO, CON(R82), 25 (C(R83)(R84)),,, CO, C---C, SCH2; particularly preferably O, a bond, CH20, OCH~, CON(R82), (C(R83)(R84))", CO, C=C;
v l, 2, 3, 4; preferably l, 2, 3; particularly preferably 1,2;
3o R80, R81, R82, R83, R84 independently of one another H, (C,-Cg)-alkyl;
R11 H, (C,-Cg)-alkyl, (C,-C4)-alkoxy-(C,-C4)-alkyl, (C3-Cg)-alkenyl, (C3-Cs)-alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O-(Ci-Cs)-alkyl, (C,-C4)-alkoxy-(C,-C4)-alkyl, hydroxy-(C,-C4)-alkyl, (Co-Cs)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, COO(R69), N(R70)CO(C~-C6)-alkyl, N(R71 )(R72) or S02CH3;
preferably (C,-Cg)-alkyl, (C,-C4)-alkoxy-(C~-C4)-alkyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C,-C6)-alkyl, O-(C,-Cs)-alkyl, (C~-CZ)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, N(R70)CO(C~-C6)-alkyl, N(R71)(R72) or SOzCH3;
is particularly preferably (C,-C8)-alkyl, (C1-C4)-alkoxy-(C,-C4)-alkyl, a 3 to 10-membered mono- or bicyclic ring which may include 0 to 2 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C,-C6)-alkyl, O-(C,-Cg)-alkyl, oxo, CO(R66), CON(R67)(R68), N(R70)CO(Ci-C6)-alkyl, 20 or SO~CH3;
R66, R67, R68, R69, R70, R71, R72 independently of one another H, (CI-Cg)-alkyl;
or R67 and R68, R71 and R72 25 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur; or 3o the N-oxides thereof and the physiologically tolerated salts thereof.
In a preferred embodiment of the invention, the radicals R1, R2, R1 l, R38 and groups X, E, K have the following meanings:
Rl, R2 independently of one another H, (C,-CR)-alkyl, -(CR13R14)o R12, (C,-C4)-alkoxy-(C,-C4)-alkyl, or Rl and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring 5 which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (C,-C6)-alkyl, O-(CI-C4)-alkyl, (Ci-C4)-alkoxy-(C,-C4)-alkyl, hydroxy-(C,-C4)-alkyl, (Co-CZ)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, N(R27)(R28) or SO~CH3;
preferably independently of one another H, (C1-C$)-alkyl, -(CR13R14)o-, R12, (Cl-C4)-alkoxy-(C,-C4)-alkyl, or Rl and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 ~ 5 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (C,-C6)-alkyl, O-(C~-C4)-alkyl, (C,-C4)-alkoxy-(C~-C4)-alkyl, hydroxy-(C~-C4)-alkyl, (Co-C2)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy or N(R27)(R28);
2o very particularly preferably independently of one another H, (C,-Cg)-alkyl, or R1 and R2 form together with the nitrogen atom to which they are bonded a 5 to 6-membered monocyclic ring which, apart from the nitrogen atom, may include 0 to 1 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (Cl-C6)-alkyl;
especially preferably independently of one another H, (C1-Cg)-alkyl;
0 0, 1, 2, 3, 4;
3o R22, R23, R24, R27, R28 independently of one another H, (C,-C6)-alkyl;
or R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(Cl-C~)-alkyl, oxygen and sulfur;
R12 OH, O-(C,-C~)-alkyl, CN, 3-12 membered mono-, bi- or spirocyclic ring which may comprise 1 to 3 heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, OH, CF3, CN, oxo, (C1-C6)-alkyl, (C~-CZ)-alkylene-aryl, N(R34)(R35), o COO(R36), CO(C,-C6)-alkyl;
R34, R35 independently of one another H, (C,-C4)-alkyl;
~5 R36 H, (C~-C6)-alkyl;
R13, R14 independently of one another H, (C,-Cs)-alkyl, hydroxy-(C,-C4)-alkyl, OH, (C, -C~)-alkoxy-(C I-C4)-alkyl;
20 R38 H, F, Cl, Br, CFA, CN, (C~-C6)-alkyl;
X a bond, CHZCH~, C(R76)(R77), N(R75), C=C, (R75)YCH2, CHZ-NCO(R75), CHZCON(R75);
25 Y O, S, N(R53), CO
R75, R76, R77 independently of one another H, (CI-Cg)-alkyl;
3o R53 H, (C,-Cg)-alkyl;
E 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, CF3, OH, CN, OCF3, O-(C1-C~)-alkyl, (C,-C6)-alkyl, SOZ-CH3, CO(R65);
R65 H, (C,-Cg)-alkyl;
K O, a bond, CH20, CH2, OCH2, S, SO2, N(R80), N(R81)CO, CON(R82), (C(R83)(R84))", CO, C---C, SCH~, SOZCH2;
preferably O, a bond, CH20, CHZ, OCH2, N(R80), C---C;
io v l, 2, 3;
R80, R81, R82, R83, R84 independently of one another H, (C1-Cg)-alkyl;
~5 R11 (Cl-Cx)-alkyl, (C,-C4)-alkoxy-(C~-C4)-alkyl, a 3 to 10-membered mono-, bi-or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O-(C~-Cs)-alkyl, oxo, CO(R66), hydroxy, N(R70)CO(C1-C6)-alkyl, or SOZCH3;
R66, R70 independently of one another H, (C~-Cg)-alkyl;
the N-oxides thereof and the physiologically tolerated salts thereof.
Particularly preferred compounds of the formula I are those in which A, B, D, G are independently of one another N or C(R38), and the total number of nitrogen atoms in this ring is 0-2, preferably 0 or I , and in the case where the total number of nitrogen atoms is l, particularly preferably A or B are N, and very particularly preferably B is N.
Very particularly preferred compounds of the formula I are those in which n is 1 and m is 1 or 2.
S
Especially preferred compounds of the formula I are those in which A, B, D, G are independently of one another N or C(R38), and the total number of nitrogen atoms in this ring is 0-2, preferably 0 or l, and in the case where m the total number of nitrogen atoms is l, particularly preferably A or B are N, and very particularly preferably B is N.
n is l and IS m is 1 or2.
The radical R38 has the aforementioned meanings.
Especially preferred compounds of the formula I are those in which ~o Het is selected from the group consisting of oxadiazoles, thiadiazoles, thiazoles, oxazoles, triazoles, thiophenes, furans and pyrroles; Het is very particularly preferably selected from oxadiazoles, thiadiazoles, thiazoles and oxazoles.
25 The further radicals may have the aforementioned meanings in the aforementioned preferred embodiments.
In a very particularly preferred embodiment, the present application relates to compounds of the formula IA
. . ~.i _- j~..i'';.1 ,' i-t . _ ~ = ' - -. ,~. - 3~ ~ ~ ,---- ~ ~ I ..
. . a .. ' ' in which the meanings are i.~:
;_ ,r >>
Het ~~,;-..,,_ Or , in which A' is O, S, X' and Y' I o are independently of one another CR74 or N, and R74 are independently of one another H, (C1-Cs)-alkyl;
A, B are CH or CF, where in the case of CF only one of the two groups A or B
is CF and the other group is CH;
Rl, R2 independently of one another H, (C,-Cg)-alkyl, -(CR13R14)o-R12, (C1-C4)-alkoxy-(C,-C4)-alkyl, (C3-Cg)-alkenyl, (C3-Cg)-alkynyl, CO-(Cl-Cg)-alkyl, -CO-(CHZ)o R12, CO(C(R15)(R16))qN(R17)(R18), CO(C(R 19)(R20))50(R21 ); or R 1 and R2 form together with the nitrogen 2o atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C~-C6)-alkyl, O-(C~-Cs)-alkyl, (C~-C4)-alkoxy-(CI-C4)-alkyl, hydroxy-(C~-C4)-alkyl, (Co-C8)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(C1-C6)-alkyl, N(R27)(R28) or SOZCH3;
particularly preferably independently of one another H, (C,-CA)-alkyl, -(CR13R14)~-R12, (C,-C4)-alkoxy-(C,-C4)-alkyl, CO-(Cl-C$)-alkyl, -CO-(CH~)a-R12; or RI and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring 5 which, apart from the nitrogen atom, may include 0 to 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C,-C~)-alkyl, O-(C,-Cg)-alkyl, (C,-C~)-alkoxy-(C~-C4)-alkyl, hydroxy-(C~
C4)-alkyl, (C~-C~)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxyl, o N(R26)CO(C,-C6)-alkyl, N(R27)(R28);
very particularly preferably independently of one another H, (CI-Cg)-alkyl, -(CR13R14)o-R12, (C,-C4)-alkoxy-(C1-C4)-alkyl, -CO-(CHZ)o-R12; or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 7-membered monocyclic ring which, apart from the nitrogen atom, may ~ 5 include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C1-C6)-alkyl, O-(C,-C~)-alkyl, hydroxy-(C,-C4)-alkyl, CO(R22), CON(R23)(R24), hydroxy, N(R26)CO(C,-C6)-alkyl, N(R27)(R28);
2o especially preferably independently of one another H, (C1-Cs)-alkyl, or R1 and R2 form together with the nitrogen atom to which they are bonded a 5 to 6-membered monocyclic ring which, apart from the nitrogen atom, may include 0 to 1 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be z5 substituted by (C,-C6)-alkyl;
further very particularly preferably independently of one another H, (C,-Cg)-alkyl;
0 0, 1, 2, 3, 4, 5, 6; preferably 0, I, 2, 3, 4;
3o q, s independently of one another 0, l, 2, 3, 4;
R 15, R I 6, R 17, R 18, R 19, R20, R21, R22, R23, R24, R25, R26, R27, R28 independently of one another H, (C,-Cf,)-alkyl;
R 17 and R 18, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C ~-C~,)-alkyl, oxygen and sulfur;
R12 OH, O-(C,-C~,)-alkyl, CN, COO(R29), CON(R30)(R31), N(R32)(R33), 3-12 o membercd mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 memhered ring may comprise further substituents such as F, Cl, Br, l, OH, CFA, NO~, CN, OCF3, oxo, O-(C~-C6)-alkyl, (C,-Ca)-alkoxy-(C,-C4)-alkyl, S-(C~-C6)-alkyl, (C,-C6)-alkyl, (C~-C~)-alkenyl, (C3-CA)-cycloalkyl, (CZ-C6)-alkynyl, O-(C~-C~)-~5 alkylene-aryl, (C~-Cs)-alkylene-aryl, N(R34)(R35), CO(Ci-C6)-alkyl, COO(R36) and S(O)"(R37);
particularly preferably OH, O-(C,-C6)-alkyl, CN, CON(R30)(R31), N(R32)(R33), 3-7 membered monocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-7 membered ring 2o may comprise further substituents such as F, Cl, OH, CF3, CN, OCF3, oxo, O-(C,-C6)-alkyl, (C~-C4)-alkoxy-(C~-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (CZ-C6)-alkenyl, (C3-Cg)-cycloalkyl, (CZ-C6)-alkynyl, O-(Co-Cg)-alkylene-aryl, (C~-C8)-alkylene-aryl, N(R34)(R35) and CO(C1-C6)-alkyl;
25 a 0, 1, 2;
R34, R35 independently of one another H, (C,-Cg)-alkyl;
30 R34 and R35 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C~-C~)-alkyl, oxygen and sulfur and optionally be substituted by 1-2 oxo groups;
R36, R37 H, (C,-Cs)-alkyl;
S
R13, R14 independently of one another H, (Cl-Cs)-alkyl, hydroxy-(C,-C4)-alkyl, OH, (C, -C4)-alkoxy-(C ~ -C4)-alkyl;
R29, R30, R31 o independently of one another H, (C~-Cg)-alkyl, (CZ-C6)-alkenyl, (Co-Cg)-alkylene-aryl;
R32, R33 independently of one another H, (C,-C6)-alkyl or ~ 5 R32 and R33 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring, which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C~-C6)-alkyl, oxygen and sulfur and optionally be substituted by 1-2 oxo groups;
X a bond, a group of the formula -(CR51R52)y- in which one or more -(CR51 R52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, C---C; preferably a bond, CHZ-CH2, CH~Y, YCH2, (R75)YCHZ, CHZ-NCO(R75), CHZCON(R75); C(R76)(R77), C(R78)(R79)O, N(R75), C=C, C=C; particularly preferably a bond, CHZ-CH2, C(R76)(R77), N(R75), CHZY, CH2Y(R75), CHZ-NCO(R75), CH2CON(R75); C=C; very particularly preferably a bond, CHZ-CH2, C(R76)(R77), C=C; (R75)YCH~, CH2-NCO(R75);
3o Y O, S, N(R53), CO, SO, SOZ; particularly preferably O, S, N(R53), CO; very particularly preferably O, N (R53);
R51, R52 independently of one another H, (C,-C4)-alkyl, where R51 and R52 in the y groups in each case can have the same or different meanings;
y 1,2,3,4,5,6;
R53 H, (C,-Cs)-alkyl;
E 3-14 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, I, OH, CFA, NOZ, CN, OCF3, oxo, O-(C,-C6)-alkyl, O-(C1-C4)-alkoxy-(C,-C4)-alkyl, S-(C1-C6)-alkyl, (Cl-C6)-alkyl, (C~-C6)-alkenyl, (C3-C~)-cycloalkyl, O-(C3-C8)-cycloalkyl, (CZ-C6)-alkynyl, (Co-C~)-alkylenc-aryl, O-(Co-C8)-alkylene-aryl, S-aryl, N(R54)(R55), S02-CH3, COOH, COO-(C1-C6)-alkyl, CON(R56)(R57), ~5 N(R58)CO(R59), N(R60)SOZ(R61), CO(R62) and be mono- or bicyclic;
preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, OH, CN, CF3, OCF3, O-(Cl-C6)-alkyl, (C,-C6)-alkyl, (Co-Cg)-alkylene-aryl, O-(C3-Cg)-cycloalkyl, 2o N(R54)(R55), SOZ-CHI, CON(R56)(R57), N(R58)CO(R59), N(R60)SOZ(R61), CO(R62) and be mono- or bicyclic; particularly preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, CF3, OCF3, O-(C,-C6)-alkyl, 25 (CI-C6)-alkyl, (Co-CZ)-alkylene-aryl, O-(C3-C6)-cycloalkyl, N(R54)(R55), CON(R56)(R57), N(R58)CO(R59), CO(R62) and be mono- or bicyclic;
R54, R55, K56, R57, R58, R60 independently of one another H, (Ci-C8)-alkyl;
R54 and R55, R56 and R57 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C,-C6)-alkyl, oxygen and sulfur;
R59, R61, R62 independently of one another H, (C,-Cg)-alkyl, aryl;
K a bond, a group of the formula -(CR63R64),-, in which one or more -(CR63R64)- groups may be replaced by Z to result in a chemically reasonable radical, C---C, C=C;
I o preferably O, a bond, CH~O, CH2, OCH2, S, SO2, N(R80), N(R81 )CO, CON(R82), (C(R83)(R84))~, CO, C=C, SCHZ, SOZCH~;
Z O, S, N(R65), CO, SO, SO2;
I5 R63, R64 independently of one another H, (C,-Cg)-alkyl, hydroxy, (C~-C6)-alkoxy, where R63 and R64 in the z groups may in each case have the same or different meanings;
z l, 2, 3, 4, 5, 6, preferably 2, 3, 4, 5, 6;
R65 H, (C~-Cs)-alkyl;
R11 H, (C1-Cg)-alkyl, (C,-C4)-alkoxy-(C,-C4)-alkyl, (C3-C8)-alkenyl, (C3-Cg)-alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O-(C,-Cs)-alkyl, (C1-C4)-alkoxy-(C1-C4) alkyl, (Co-Cg)-alkylene-aryl, oxo, CO(Rb6), CON(R67)(R68), hydroxy, hydroxy-(CI-C4)-alkyl, COO(R69), N(R70)CO(Cl-C6)-alkyl, N(R71)(R72) 3o or SO~CH3;
preferably H, (Ci-Cg)-alkyl, (C,-C4)-alkoxy-(C1-C4)-alkyl, a 5 to 6-membered monocyclic ring which may include 0 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O-(Cz-Cg)-alkyl, (C,-C4)-alkoxy-(C,-C4)-alkyl, CO(R66), CON(R67)(R68), hydroxy, N(R70)CO(C,-C6)-alkyl, N(R71)(R72) or SO~CH3;
5 particularly preferably H, (C,-Cs)-alkyl, (C,-C4)-alkoxy-(C,-C4)-alkyl, a 5 to 6-membered monocyclic ring which may include 0 to 2 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CFA, N02, CN, (C,-C6)-alkyl or O-(C~-Cg)-alkyl;
io R66, R67, R68, R69, R70, R71, R72 independently of one another H, (C,-Cs)-alkyl;
or R67 and R68, R71 and R72 i 5 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0- I further heteroatoms from the group of NH, N-(C,-C6)-alkyl, oxygen and sulfur; or 2o the N-oxides thereof and the physiologically tolerated salts thereof.
The compounds of the invention of the formula I and their precursors can be prepared by processes known to the skilled worker.
z5 The preparation of compounds of the invention of the formula I is described below for the example of the preparation of [1,3,4]-oxadiazoles (Ia), [1,3,4]-thiadiazoles (Ib) and [1,2,4]-oxadiazoles (Ic):
N H
O OR O OR O N~NH
\ NR1 R2 / I H2N-NH2 x H20 /
\ \
(III) (IV) in which R is H, (C,-Cs)-alkyl, and R 1 and R2 have the aforementioned meanings;
O
R11 ~K~E~X~OH ~ ~
(IV) _ X O ~ N\/ -NR1R2 CI PF6 ~K~E~ ~
+~ R11 N-N
~N ~ N~
U
(la) 0 or Burgess' reagent O
H
O O N~N~X~E~K~R11 H
R11 ~K~E~X~OH
(V) TOTU
i N
NR1 R2 Lawesson's reagent N~'NRiR2 x ~K~E~ ~ /
(1b) in which Rl, R2, Rl i and X, E and K have the aforementioned meanings.
. _ ..' ww __- ~ ,, , .. w:,:y.
;../.i... ;= v ~ lIE.;S~i..l ~i ' . .
' ' ~ , ;i ;~v..~f~,i,j-.r .. ; -~~-~~ ,_ S~'y '1a ~ .
~1 -,;~.-:- ~ ;~.' _.. ,, , ,~;,ir n .w.;
in which R1, R2, R1 l and X, E and K have the aforementioned meanings.
s Use This invention further relates to the use of compounds of the formula I and their pharmaceutical compositions as MCH receptor ligands. The MCH receptor ligands of the invention are particularly suitable as modulators of the activity of the MCH1R.
t0 The role of MCH in regulating the energy balance has now been well documented (Qu, D.
et al.; Nature 1996, 380, 243-7; Shimada, M. et al. Nature 1998, 396, 670-4;
Chen, Y. et al.
Endocrinology 2002, 143, 2469-77; Endocrinology 2003, 144, 4831-40; Review: G.
Hervieu, Expert Opin. Ther. Targets 2003, 7, 495-511 ).
There are also indications that MCH antagonists can have a beneficial influence on centrally related disorders such as, for example, depression (Borowsky, B. et al.; Nature Medicine 2002, 8, 825-30; Review: G. Hervieu, Expert Opin. Ther. Targets 2003, 7, 495-511).
Compounds of this type are particularly suitable for the treatment and/or prevention of 1. Obesity 2. Diabetes mellitus, especially type 2 diabetes, including the prevention of the sequelae associated therewith.
Particular aspects in this connection are - hyperglycemia, - improvement in insulin resistance, - improvement in glucose tolerance, - protection of the pancreatic 13 cells ~ 5 - prevention of macro- and microvascular disorders 3. Dyslipidemias and their sequelae such as, for example, atherosclerosis, coronary heart disease, cerebrovascular disorders etc., especially those (but not restricted thereto) which are characterized by one or more of the following factors:
20 - high plasma triglyceride concentrations, high postprandial plasma triglyceride concentrations, - low HDL cholesterol concentration 4. Various other conditions which may be associated with the metabolic syndrome, such 2S as:
- thromboses, hypercoagulable and prothrombotic stages (arterial and venous) - high blood pressure - heart failure such as, for example (but not restricted thereto), following myocardial infarction, hypertensive heart disease or cardiomyopathy 5. Psychiatric indications such as - depression - anxiety states - disturbances of the circadian rhythm - affection disorders - schizophrenia - addictive disorders Formulations The amount of a . compound of formula (I) which is necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound ~ o chosen, the intended use, the mode of administration and the clinical condition of the patient. In general, the daily dose is in the range from 0.001 mg to 100 mg, preferably from 0.3 mg to 100 mg (typically from 0.01 mg to 50 mg, preferably from 3 mg to 50 mg) per day per kilogram of body weight, for example 0.1-10 mg/kg/day, preferably 3-10 mg/kglday. An intravenous dose may be, for example, in the range from 0.001 mg to 1.0 is mgfkg, preferably from 0.3 mg to 1.0 mglkg, which can most suitably be administered as infusion of from 10 ng to 100 ng per kilogram and per minute. Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Single doses may contain, for example, from 1 mg to 10 g of the active ingredient. Single doses may contain, for example, from 1 mg to 10 g of the active 2o ingredient. It is thus possible for ampoules for injections to contain, for example, from 1 mg to 100 mg, and for single-dose formulations which can be administered orally, such as, for example, tablets or capsules, to contain, for example, from 0.05 to 1000 mg, typically from 0.5 to 600 mg, or in a further embodiment from 1.0 to 1000 mg, typically from 10 to 600 mg. In the case of pharmaceutically acceptable salts, the aforementioned 25 weight data are based on the weight of the salt of the underlying free compound. For the prophylaxis or therapy of the abovementioned conditions, the compounds of formula (I) can be used as the compound itself, but they are preferably in the form of a pharmaceutical composition with an acceptable carrier. The carrier must, of course, be acceptable in the sense that it is compatible with the other ingredients of the composition and is not 3o hazardous for the patient's health. The carrier may be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet which may contain from 0.05% to 95% by weight of the active ingredient. Further pharmaceutically active substances may likewise be present, including other compounds of formula (I). The pharmaceutical compositions according to the invention can be produced by one of the known pharmaceutical methods which essentially consist of mixing the ingredients with pharmacologically acceptable carriers and/or excipients.
Pharmaceutical compositions according to the invention are those suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration although the most suitable mode of administration in each individual case depends on the nature and severity of the condition to be treated and on the nature of the compound of formula (I) used in each case.
o Coated formulations and coated slow-release formulations also lie within the scope of the invention. Formulations resistant to acid and gastric fluid are preferred.
Suitable coatings resistant to gastric fluid comprise cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
l5 Suitable pharmaceutical preparations for oral administration may be in the form of separate units such as, for example, capsules, cachets, suckable tablets or tablets, each of which contain a defined amount of the compound of formula (I); as powders or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-2o in-oil emulsion. These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional ingredients) are brought into contact. In general, the compositions are produced by uniform and homogeneous mixing of the active ingredient with a liquid and/or finely divided solid carrier, after which the 25 product is shaped if necessary. Thus, for example, a tablet can be produced by compressing or molding a powder or granules of the compound, where appropriate with one or more additional ingredients. Compressed tablets can be produced by tableting the compound in tree-flowing form, such as, for example, a powder or granules, where appropriate mixed with a binder, lubricant, inert diluent and/or a (plurality of) surface-active/dispersing 30 agents) in a suitable machine. Molded tablets can be produced by molding the compound which is in powder form and is moistened with an inert liquid diluent in a suitable machine.
Pharmaceutical compositions suitable for peroral (sublingual) administration comprise suckable tablets which contain a compound of formula (I) with a flavoring, normally sucrose and gum arabic or tragacanth, and pastilles which comprise the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
Suitable pharmaceutical compositions for parenteral administration comprise preferably sterile aqueous preparations of a compound of formula (I), which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although administration may also take place by subcutaneous, intramuscular 0 or intradermal injection. These preparations can preferably be produced by mixing the compound with water and making the resulting solution sterile and isotonic with blood.
Injectable compositions according to the invention generally contain from 0.1 to 5% by weight of the active compound.
I5 Suitable pharmaceutical compositions for rectal administration are preferably in the form of single-dose suppositories. These can be produced by mixing a compound of formula (I) with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
2o Suitable pharmaceutical compositions for topical application to the skin are preferably in the form of ointment, cream, lotion, paste, spray, aerosol or oil. Carriers which can be used are petrolatum, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances. The active ingredient is generally present in a concentration of from 0.1 to 15% by weight of the composition, for example from 0.5 to 2%.
Transdermal administration is also possible. Suitable pharmaceutical compositions for transdermal uses can be in the form of single plasters which are suitable for long-term close contact with the patient's epidermis. Such plasters suitably contain the active ingredient in an optionally buffered aqueous solution, dissolved and/or dispersed in an adhesive or dispersed in a polymer. A suitable active ingredient concentration is about 1 %
to 35%, preferably about 3% to 15%. As a special possibility, the active ingredient can be released as described, for example, in Pharmaceutical Research, 2(6): 318 ( 1986) by electrotransport or iontophoresis.
The compounds of the formula I are distinguished by beneficial effects on lipid metabolism, and they are particularly suitable for weight reduction and for maintaining a reduced weight after weight reduction has taken place in mammals and as anorectic agents.
The compounds are distinguished by their low toxicity and their few side effects.
The compounds can be employed alone or in combination with other weight-reducing or anorectic active ingredients. Further anorectic active ingredients of this type are mentioned, for example, in the Rote Liste, chapter 01 under weight-reducing agents/appetite suppressants, and may also include active ingredients which increase the energy turnover t o of the organism and thus lead to weight reduction or else those which influence the general metabolism of the organism in such a way that an increased calorie intake does not lead to an enlargement of the fat depots and a normal calorie intake leads to a reduction of the fat depots of the organism. The compounds are suitable for the prophylaxis and, in particular, for the treatment of excessive weight or obesity. The compounds are further suitable for the t 5 prophylaxis and, in particular, for the treatment of type II diabetes, of arteriosclerosis and for normalizing lipid metabolism and for the treatment of high blood pressure.
Combinations with other medicaments 20 In a further aspect of the invention, the compounds of the formula I can be administered in combination with one or more other pharmacologically active substances which have, for example, favorable effects on metabolic disturbances or disorders frequently associated therewith. Examples of such medicaments are 1. medicaments which lower blood glucose, antidiabetics, 25 2. active ingredients for the treatment of dyslipidemias, 3. antiatherosclerotic medicaments, 4. antiobesity agents, 5. antiinflammatory active ingredients 6. active ingredients for the treatment of malignant tumors 30 7. antithrombotic active ingredients 8. active ingredients for the treatment of high blood pressure 9. active ingredients for the treatment of heart failure and 10. active ingredients for the treatment and/or prevention of complications caused by diabetes or associated with diabetes.
They can be combined with the compounds of the invention of the formula I in particular for a synergistic improvement in the effect. Administration of the active ingredient combination can take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation.
~ o Further pharmacologically active substances suitable in particular are:
Antidiabetics All antidiabetics mentioned in the Rote Liste 2001, chapter 12. They may be combined ~ 5 with the compounds of the formula I of the invention in particular for a synergistic improvement of the effect. Administration of the active ingredient combination may take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation. Most of the active ingredients listed below are disclosed in the 2o USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2001.
Suitable antidiabetics include all insulins and insulin derivatives such as, for example, Lantus" or HMR 1964 or Apidra~, and other fast-acting insulins (see, e.g., US
6,221,633), 25 amylin, GLP-1 and GLP-2 derivatives such as described in WO 01/04146 or else such as, for example, those disclosed in WO 98/08871 of Novo Nordisk A/S, and orally effective hypoglycemic active ingredients.
The orally effective hypoglycemic active ingredients include, preferably, sulfonylureas, 30 biguanidines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon receptor antagonists, GLP-1 agonists, DPP-IV inhibitors, potassium channel openers such as, for example, those disclosed in WO 97/26265 and WO
of Novo Nordisk A/S, insulin sensitizers, activators of insulin receptor kinase, inhibitors of GSK3-beta, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and/or glycogenolysis, for example inhibitors of glycogen phosphorylase, modulators of glucose uptake and glucose excretion, compounds which alter lipid metabolism and lead to a change in the lipid composition of the blood, such as antihyperlipidemic active 5 ingredients and antilipidemic active ingredients, e.g. HMGCoA reductase inhibitors, inhibitors of cholesterol transport/of cholesterol uptake, inhibitors of bile acid reabsorption or inhibitors of microsomal triglyceride transfer protein (MTP), compounds which reduce food intake and/or food absorption, PPAR and RXR agonists and active ingredients which act on the ATP-dependent potassium channel of the beta cells.
In one embodiment of the invention, the present compounds are administered in combination with insulin.
In one embodiment of the invention, the compounds of the formula I are administered in ~ 5 combination with substances which influence hepatic glucose production such as, for example, glycogen phosphorylase inhibitors (see: WO 01/94300, WO 02/096864, WO
03/084923, WO 03/084922, WO 03/104188).
In one embodiment, the compounds of the formula I are administered in combination with 20 a sulfonylurea such as, for example, tolbutamide, glibenclamide, glipizide or glimepiride.
In one embodiment, the compounds of the formula I are administered in combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide.
In one embodiment, the compounds of the formula I are administered in combination with a biguanide such as, for example, metformin.
In a further embodiment, the compounds of the formula I are administered in combination 3o with a meglitinide such as, for example, repaglinide.
In one embodiment, the compounds of the formula I are administered in combination with a thiazolidinedione such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy's Research Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]-phenyl]methyl]-2,4-thiazolidinedione.
In one embodiment, the compounds of the formula I are administered in combination with a DPPIV inhibitor as described, for example, in W098/19998, W099/61431, W099/67278, W099/67279, WO01/72290, WO 02/38541, W003/040174, in particular P
93/01 (1-cyclopentyl-3-methyl-1-oxo-2-pentanammonium chloride), P-31/98, LAF237 (1-[2-[3-hydroxyadamant-1-ylamino)acetyl]pyrrolidine-2-(S)-carbonitrile), TS021 ((2S, 4S)-4-fluoro-1-[ [(2-hydroxy-1,1-dimethylethyl)amino] acetyl]pyrrolidine-2-carbonitrile monobenzenesulfonate).
In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPARgamma agonist such as, for example, rosiglitazone, pioglitazone.
In one embodiment, the compounds of the formula I are administered in combination with ~ 5 compounds with an inhibitory effect on SGLT-1 and/or 2, as disclosed directly or indirectly for example in PCTBP03/06841, PCT/EP03/ 13454 and PCT/EP03/ 13455.
In one embodiment, the compounds of the formula I are administered in combination with an a-glucosidase inhibitor such as, for example, miglitol or acarbose.
In one embodiment, the compounds of the formula I are administered in combination with more than one of the aforementioned compounds, e.g. in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.
Lipid modulators In one embodiment of the invention, the compounds of the formula I are administered in combination with an HMGCoA reductase inhibitor such as lovastatin, fluvastatin, 3o pravastatin, simvastatin, ivastatin, itavastatin, atorvastatin, rosuvastatin.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a bile acid absorption inhibitor (see, for example, US
6,245,744, US
6,221,897, US 6,277,831, EP 0 683 773, EP 0 683 774).
In one embodiment of the invention, the compounds of the formula I are administered in combination with a polymeric bile acid adsorbent such as, for example, cholestyramine, colesevelam.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a cholesterol absorption inhibitor as described for example in WO 0250027, or ezetimibe, tiqueside, pamaqueside.
In one embodiment of the invention, the compounds of the formula I are administered in o combination with an LDL receptor inducer (see, for example, US 6,342,512).
In one embodiment, the compounds of the formula I are administered in combination with bulking agents, preferably insoluble bulking agents (see, for example, carob/Caromax~
(Zunft H J; et al., Carob pulp preparation for treatment of hypercholesterolemia, ~ 5 ADVANCES IN THERAPY (2001 Sep-Oct), 18(5), 230-6); Caromax is a carob containing product from Nutrinova, Nutrition Specialties & Food Ingredients GmbH, Industriepark Hoechst, 65926 Frankfurt/Main). Combination with Caromax~ is possible in one preparation or by separate administration of compounds of the formula I
and Caromax~. Caromax° can in this connection also be administered in the form of food 2o products such as, for example, in bakery products or muesli bars.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPARalpha agonist.
25 In one embodiment of the invention, the compounds of the formula I are administered in combination with a fibrate such as, for example, fenofibrate, gemfibrozil, clofibrate, bezafibrate.
In one embodiment of the invention, the compounds of the formula I are administered in 3o combination with nicotinic acid or niacin.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a CETP inhibitor, e.g. CP- 529, 414 (torcetrapib).
35 In one embodiment of the invention, the compounds of the formula I are administered in combination with an ACAT inhibitor.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an MTP inhibitor such as, for example, implitapide.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an antioxidant.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein lipase inhibitor.
to In one embodiment of the invention, the compounds of the formula I are administered in combination with an ATP citrate lyase inhibitor.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a squalene synthetase inhibitor.
~5 In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein(a) antagonist.
Antiobesity agents In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipase inhibitor such as, for example, orlistat.
In one embodiment, the further active ingredient is fenfluramine or dexfenfluramine.
In another embodiment, the further active ingredient is sibutramine.
In another embodiment, the further active ingredient is rimonabant.
In a further embodiment, the compounds of the formula I are administered in combination 3o with CART modulators (see "Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice" Asakawa, A, et al., M.:
Hormone and Metabolic Research (2001), 33(9), 554-558), NPY antagonists, e.g. naphthalene-1-sulfonic acid {4-[(4-aminoquinazolin-2-ylamino)methyl] cyclohexylmethyl}amide;
hydrochloride (CGP 71683A)), MC4 agonists (e.g. 1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid [2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]pyridin-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]amide; (WO 01/91752)), orexin antagonists (e.g. I-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-ylurea; hydrochloride (SB-334867-A)), CB1 antagonists/inverse agonists, H3 antagonists/inverse agonists (e.g. 3-cyclohexyl-l-(4,4-dimethyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)propan-1-one oxalic acid salt (WO 00/63208)); TNF agonists, CRF antagonists (e.g. [2-methyl-9-(2,4,6-trimethylphenyl)-9H-1,3,9-triazafluoren-4-yl]dipropylamine (WO 00/66585)), CRF
BP
antagonists (e.g. urocortin), urocortin agonists, (33 agonists (e.g. 1-(4-chloro-3-methanesulfonylmethylphenyl)-2-[2-(2,3-dimethyl-1 H-indol-6-yloxy)ethylamino]ethanol;
hydrochloride (WO 01/83451 )), MSH (melanocyte-stimulating hormone) agonists, CCK-A
agonists (e.g. { 2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)thiazol-2-o ylcarbamoyl]-5,7-dimethylindol-1-yl}acetic acid trifluoroacetic acid salt (WO 99/15525));
serotonin reuptake inhibitors (e.g. dexfenfluramines), mixed serotoninergic and noradrenergic compounds (e.g. WO 00/71549), 5HT agonists e.g. 1-(3-ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO 01/09111), BR53 agonists, galanin antagonists, ghrelin antagonists, MCH antagonists, mGluRS antagonists, opioid antagonists, growth hormone (e.g. human growth hormone), growth hormone-releasing compounds (6-benzyloxy-1-(2-diisopropylaminoethylcarbamoyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (WO 01/85695)), CNTF, CNTF derivatives (e.g. Axokine), TRH
agonists (see, for example, EP 0 462 884), uncoupling protein 2 or 3 modulators, leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C.; Rozhavskaya-Arena, Marina;
Grasso, Patricia. Leptin agonists as a potential approach to the treatment of obesity.
Drugs of the Future (2001), 26(9), 873-881), DA agonists (e.g. bromocriptine, Doprexin), lipase/amylase inhibitors (e.g. WO 00/40569), PPAR modulators (e.g. WO
00/78312), RXR modulators or TR-~3 agonists.
In one embodiment of the invention, the further active ingredient is leptin.
In one embodiment, the further active ingredient is dexamphetamine, amphetamine, mazindole or phentermine.
In one embodiment, the compounds of the formula I are administered in combination with medicaments having effects on the coronary circulation and the vascular system, such as, for example, ACE inhibitors (e.g.
ramipril), medicaments which act on the angiotensin-renin system, calcium antagonists, beta Mockers etc.
In one embodiment, the compounds of the formula I are administered in combination with medicaments having an antiinflammatory effect.
In one embodiment, the compounds of the formula I are administered in combination with medicaments which are employed for cancer therapy and cancer prevention.
It will be appreciated that every suitable combination of the compounds of the invention 5 with one or more of the aforementioned compounds and optionally one or more other pharmacologically active substances is to be regarded as covered by the scope of protection of the present invention.
In two articles which appeared simultaneously in Nature (Nature 400, 261-264, 1999;
Nature 400, 265-269, 1999), a highly specific receptor for melanine concentrating hormone o (MCH) was described separately by two research groups. MCH assumes important Functions in controlling food intake. Compounds acting on the MCH receptor therefore have an anorectic effect and are suitable for the treatment of obesity.
Testing for an anorectic effect of the compounds of the invention of the formula I was therefore carried out as follows.
Functional measurements to find IC50 values The cloning of the cDNA for the human MCH receptor, preparation of a recombinant HEK293 cell line which expresses the human MCH receptor, and functional measurements 2o with the recombinant cell line took place in analogy to the description by Audinot et al. (J.
Biol. Chem. 276, 13 554-13 562, 2001). A difference from the reference was, however, the use of the plasmid pEAK8 from EDGE Biosystems (USA) to construct the expression vector. The host used for the transfection was a transformed HEK cell line named "PEAK
Stable Cells" (likewise from EDGE Biosystems). The functional measurements of the 25 cellular calcium flux after addition of agonist (MCH) in the presence of ligand of the invention took place with the aid of the FLIPR apparatus from Molecular Devices (USA) using the protocols of the apparatus manufacturer.
Biological activity testing The IC50 values measured for exemplary compounds 33, 96 and 97 under the o aforementioned conditions were of the order of from 0.01 to 10 ~,M.
Genera( explanations a) Mode of drawing the structural formulae Only non-H atoms are depicted for clarity in the structural formulae of the given examples.
Carbon atoms are not written out as "C".
b) Salt forms Many of the compounds of the invention are bases and can form salts with appropriately strong acids. In particular, after purification of the compounds by HPLC
chromatography o using a trifluoroacetic acid-containing mobile phase they may be in the form of hydrotrifluoroacetates. These can be converted into the free bases shown by simple treatment of a solution of the salts for example with sodium carbonate solution.
c) Units of the characterizing data .5 The unit of the stated molecular weights is "g/mol". Peaks observed in the mass spectrum are indicated as integral quotient of the molar molecular ion mass and the charge of the molecular ion (mlz).
Abbreviations Unless indicated otherwise, the abbreviations in the examples below have the following meaning:
NaBH3CN = sodium cyanoborohydride DMF = N,N-dimethylformamide EDC = 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide THF = tetrahydrofuran DMSO = dimethyl sulfoxide HOBt = 1-hydroxybenzotriazole HOAt = 1-hydroxy-7-azabenzotriazole 3o HCl = hydrochloric acid HPLC = high performance liquid chromatography PyBOP = benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate TOTU - O[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium tetratluoroborate eq = equivalents Example 1 ( 1- { 4-[5-(4-Butoxyphenyl )-[ 1,3,4]oxadiazol-2-yl] phenyl } pyrrol idin-3-yl)dimethylamine O N
W O N
v/
N-N
Method A
to A mixture of 4-(3-dimethylaminopyrrolidin-1-yl)benzohydrazide (100 mg), 4-butoxy benzoic acid (78 mg), 2-chloro-1,3-dimethyl-2-imidazolium hexafluorophosphate (112 mg), N,N-diisopropylethylamine (0.14 ml) and dichloromethane (5 ml) was stirred for 12 hours. Volatiles were removed, and the residue was purified by preparative HPLC. The product with the molecular weight of 406.53 (C24H30N402) was obtained in this way;
I5 MS (ESI): 407 (M+H+).
4-(3-Dimethylaminopyrrolidin-1-yl)benzohydrazide A mixture of ethyl 4-(3-dimethylaminopyrrolidin-1-yl)benzoate (2.0 g), hydrazine hydrate (3.8 g) and ethanol (7 ml) was boiled under reflux for 15 hours. After cooling to 5°C, the 2o resulting precipitate was filtered off with suction. The product with the molecular weight of 248.33 (C 13H20N40) was obtained in this way; MS (ESn: 249 (M+H+).
Ethyl 4-(3-dimethylaminopyrrolidin-1-yl)benzoate A mixture of ethyl 4-fluorobenzoate (4.47 g), dimethylpyrrolidin-3-ylamine (3.04 g), 25 potassium carbonate (3.68 g) and dimethyl sulfoxide (20 ml) was heated at 130°C for 7 hours. After cooling, the mixture was diluted with water and extracted with methyl tert butyl ether. The organic phase was washed with water, dried over magnesium sulfate, filtered and concentrated. The product with the molecular weight of 262.35 (C15H22N2O2) was obtained in this way; MS (ESI): 263 (M+H+).
Example 2 Dimethyl-( 1-{ 4-[5-(2-phenoxyethylsulfanylmethyl)-[ 1,3,4]oxadiazol-2-yl]phenyl } -pyrrolidin-3-yl)amine N
o~s o _ NJ
i ~, / N_N
S
4-(3-Dimethylaminopyrrolidin-1-yl)benzohydrazide was reacted with (2-phenoxy-ethylsulfanyl)acetic acid by Method A. The product with the molecular weight of 424.57 (C23H28N402S) was obtained in this way; MS (ESI): 425 (M+H+).
Example 3 Dimethyl-( 1- { 4-[5-(4-phenoxyphenyl) ( 1,3,4]oxadiazol-2-yl]phenyl }
pyrrolidin-3-yl)amine Method B
A mixture of N'-[4-(3-dimethylaminopyrrolidin-1-yl)benzoyl]-4-phenoxybenzohydrazide (178 mg), methoxycarbonylsulfamoyltriethylammonium hydroxide (Burgess' reagent) (96 2o mg) and 5 ml of toluene was stirred at 60°C for 1 h. After the reaction was complete, the reaction mixture was filtered, and the filtrate was washed twice with ethyl acetate. The combined organic phases were subsequently washed with 5% strength sodium carbonate solution and then dried over Chromabond XTR. Volatiles were removed and the residue was purified by preparative HPLC. The product with the molecular weight of 426.21 (C26H26N4O2) was obtained in this way; MS (ESI): 427.21 (M+H+).
N'-[4-(3-Dimethylaminopyrrolidin-1-yl)benzoyl)-4-phenoxybenzohydrazide A mixture of 4-(3-dimethylaminopyrrolidin-1-yl)benzohydrazide (100 mg), 4-phenoxybenzoic acid (77.5 mg), 1-propanephosphonic anhydride 50% in dichloromethane (256 mg), N,N-diisopropylethylamine (0.208 ml) and DMF (3 ml) was stirred at room temperature for 72 h. The reaction mixture was then filtered, washed twice with ethyl acetate and shaken with O.SN NaOH. Volatiles were removed and the residue m was purified by preparative HPLC. The product with the molecular weight of 444.54 was obtained in this way; MS (ESI): 445.24 (M+H+).
4-(3-Dimethylaminopyrrolidin-1-yl)benzohydrazide was prepared as described in method A, with 1 eq of Burgess' reagent being added once again in some cases after heating for 1 h ~5 in the cyclization step, and then heating at 60°C being continued for 1 hour.
Compounds 4-93 in table 1 were synthesized by method B.
Ex Structure ~ ~ v Molecu4ar formula ~ MW MW
', ~ ~~~ ~~
calc. measured C27H28N402 440.22441.24 -~.
~- y ~~y- ~ J .
~
', ~ C26H34N402 434.27435 28 .
_ I, _ . ..
C27H28N402 440.22441.27 ' I ;l r _ ,..
__, ~. .f! /
,"
!J N
~'~~ G26H30N402 430.24431.27 ir'\; ~ r.' , i ~l \
r;~~ , N . r;
',,__ C27H34N402 446.27447 27 I
;,.,;,,N.,', _, y., ~
g '~__, C27H32N402 444.25445.26 o.
II '~~ ~ 1~N-N
C22H26N40 362.21363.22 ~--'u N n.
R6, R7, R8, R9 independently of one another H, (C,-C~)-alkyl, or R6 and R7, R8 and R9 independently of one another optionally oxo;
I o n, m independently of one another 0, 1, 2;
A, B, D, G independently of one another N, C(R38);
R38 H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-(C,-C6)-alkyl, O-(C,-C4)-Is alkoxy-(C,-C4)-alkyl, S-(C,-C~)-alkyl, (C1-C6)-alkyl, (CZ-C6)-alkenyl, (C3-CR)-cycloalkyl, O-(C3-CA)-cycloalkyl, (C3-Cg)-cycloalkenyl, O-(C3-Cg) cycloalkenyl, (Cz-C6)-alkynyl, (C~-Cg)-alkylene-aryl, O-(Co-C8)-alkylene aryl, S-aryl, N(R39)(R40), S02-CH3, COOH, COO-(C,-C6)-alkyl, CON(R41)(R42), N(R43)CO(R44), N(R45)SOZ(R46), CO(R47), 20 (CR48R49)X-O(R50);
R39, R40, R41, R42, R43, R45 independently of one another H, (C,-Cg)-alkyl;
or 25 R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C~-C6)-alkyl, oxygen and sulfur;
R44, R46, R47 independently of one another H, (C,-Cg)-alkyl, aryl;
S
R4H, R49 independently of one another H, (C,-CH)-alkyl;
R50 H, (C,-C~,)-alkyl;
x I , 2, 3, 4;
Het five-membered aromatic heterocycle X a bond, a group of the formula -(CR51R52)y- in which one or more o (CR51 R52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, C=C;
Y O, S, N(R53), CO, SO, SO2;
~5 RSI, R52 independently of one another H, (C,-C4)-alkyl, where R51 and R52 in the y groups may in each case have the same or different meanings;
y l , 2, 3, 4, 5, 6;
2o R53 H, (C,-Cg)-alkyl;
E 3-14 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, I, OH, CF3, NO~, CN, OCF3, 25 oxo, O-(C,-C6)-alkyl, O-(C1-C4)-alkoxy-(C,-C4)-alkyl, S-(C~-C6)-alkyl, (C1-C6)-alkyl, (CZ-C6)-alkenyl, (C3-Cg)-cycloalkyl, O-(C3-Cg)-cycloalkyl, (C2-C6)-alkynyl, (Co-Cs)-alkylene-aryl, O-(Co-Cg)-alkylene-aryl, S-aryl, N(R54)(R55), SOZ-CH3, COOH, COO-(C,-C6)-alkyl, CON(R56)(R57), N(R58)CO(R59), N(R60)SOZ(R61), CO(R62) and be mono- or bicyclic;
R54, R55, R56, R57, R58, R60 independently of one another H, (C1-Cg)-alkyl;
R54 and R55, R56 and R57 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membercd ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N
(C,-C~)-alkyl, oxygen and sulfur;
R59, R61, R62 independently of one another H, (C,-CA)-alkyl, aryl;
to K a bond, a group of the formula -(CR63R64)Z in which one or more -(CR63R64)- groups may be replaced by Z to result in a chemically reasonable radical, C=C, C=C;
Z O, S, N(R65), CO, SO, S02;
R63, R64 independently of one another H, (C,-Cg)-alkyl, hydroxy, (C,-C6)-alkoxy, where R63 and R64 in the z groups may in each case have the same or different meanings;
2o z 1, 2, 3, 4, 5, 6; preferably 2, 3, 4, 5, 6;
R65 H, (C,-Cg)-alkyl;
Rll H, (C,-Cg)-alkyl, (C,-C4)-alkoxy-(C,-C4)-alkyl, (C~-Cg)-alkenyl, (C3-Cg)-alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O-(C~-C8)-alkyl, (CI-C4)-alkoxy-(C~-C4)-alkyl, (Co-C8)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, hydroxy-(CI-C4)-alkyl, COO(R69), N(R70)CO(C~-C6)-alkyl, N(R71)(R72) or SOZCH3;
R66, R67, R68, R69, R70, R71, R72 independently of one another H, (C,-CH)-alkyl;
or R67 and R68, R71 and R72 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(CI-C~)-alkyl, oxygen and sulfur; or I o the N-oxides thereof and the physiologically tolerated salts thereof.
The invention relates to compounds of the formula I in the form of their racemates, enantiomer-enriched mixtures and pure enantiomers and to their diastereomers and I5 mixtures thereof.
The alkyl, alkenyl and alkynyl radicals in the substituents R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10, R 11, R 12, R 13, R 14, R 15, R 16, R 17, R 18, R 19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, 2o R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77, R78, R79, R80, R81, R82, R83 and R84 may be either straight-chain, branched or optionally halogenated.
25 In a further embodiment, the alkyl, alkenyl and alkynyl radicals in the substituents R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10, R 11, R 12, R 13, R 14, R 15, R 16, R 17, R
18, R 19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62. R63, R64, R65, R66, R67, R68, R69, R70, R71, 30 R72, R73, R74, R75, R76, R77, R78, R79. R80, R81, R82, R83 and R84 may be both straight-chain, branched and/or optionally substituted by substituents such as aryl, heteroaryl, alkoxy or halogen. This also applies if the alkyl, alkenyl and alkynyl radicals are part of another group, for example part of an alkoxy group (such as (C1-C4)-alkoxy-g (C,-C4)-alkyl)). Suitable halogens are fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine and bromine, particularly preferably fluorine.
Examples of alkyl groups are: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl.
Included therein are both the n isomers of these radicals and branched isomers such as isopropyl, isobutyl, isopentyl, sec-butyl, tert-butyl, neopentyl, 3,3-dimethylbutyl etc.
Unless described otherwise, the term alkyl additionally includes alkyl radicals which are unsubstituted or optionally substituted by one or more further radicals, for example 1, 2, 3 or 4 identical or different radicals such as aryl, heteroaryl, alkoxy or halogen. It is moreover possible for the additional substituents to occur in any position of the alkyl radical.
Cycloalkyl means for the purposes of the present application cycloalkyl and cycloalkyl-alkyl(alkyl which is substituted in turn by cycloalkyl, e.g.
cyclopropylmethyl), where ~ 5 cycloalkyl has at least 3 carbon atoms. Examples of cycloalkyl radicals are: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl.
Optional possibilities are also polycyclic ring systems such as decalinyl, norbornanyl, bornanyl or adamantanyl. The cycloalkyl radicals may be unsubstituted or optionally substituted by one or more further radicals as listed above by way of example for the alkyl 2o radicals.
Examples of alkenyl and alkynyl groups are: vinyl, 1-propenyl, 2-propenyl (allyl), 2-butenyl, 2-methyl-2-propenyl, 3-methyl-2-butenyl, ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2-butynyl or 3-butynyl.
Cycloalkenyl means for the purposes of the present application cycloalkenyl radicals and cycloalkenyl-alkyl radicals (alkyl which is substituted by cycloalkenyl), which comprise at least three carbon atoms. Examples of cycloalkenyl are: cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. The alkenyl radicals and cycloalkenyl radicals may have 3o one to three conjugated or unconjugated double bonds (thus also alk-dienyl and alk-trienyl radicals), preferably one double bond in a straight or branched chain. The same applies to the triple bonds in alkynyl radicals. The alkenyl and alkynyl radicals may be unsubstituted or optionally substituted by one or more further radicals as listed above by way of example for the alkyl radicals.
Aryl refers in the present invention to radicals derived from monocyclic or bicyclic aromatic compounds comprising no ring heteroatoms. Where aryl refers to systems which are not monocyclic, the saturated form (perhydroform) or the partially unsaturated form (for example the dihydroform or tetrahydroform) is also possible, where the respective forms are known and stable, for the second ring. The term aryl also includes in the present invention for example bicyclic radicals in which both rings are aromatic and bicyclic radicals in which only one ring is aromatic. Examples of aryl are: phenyl, naphthyl, to indanyl, 1,2-dihydronaphthenyl, 1,4-dihydronaphthenyl, indenyl or 1,2,3,4-tetrahydronaphthyl. Aryl is particularly preferably phenyl or naphthyl. The term "aryl" thus means in particular a phenyl or naphthyl group.
Heteroaryl radicals mean radicals derived from monocyclic or bicyclic aromatic compounds comprising ring heteroatoms, preferably N, O or S. Otherwise, the statements made about aryl radicals apply to heteroaryl radicals.
The aryl and heteroaryl radicals may be unsubstituted or substituted by one or more further radicals. Suitable further radicals are listed by way of example above for the alkyl radicals.
The compounds of the formula I may comprise one or more centers of asymmetry.
The compounds of the formula I may therefore be in the form of their racemates, enantiomer-enriched mixtures, pure enantiomers, diastereomers and diastereomer mixtures.
The present invention includes all these isomeric forms of the compounds of the formula I.
These isomeric forms can be obtained by known methods even if not expressly described m some cases.
Mono-, bi- or spirocyclic rings may be saturated, partially saturated or unsaturated and also bridged.
C=C means a group of the formula R'C=CR" in which R' and R" are independently of one another H, (C,-Cg)-alkyl, preferably H.
l~
In the case where R1 and R2 together with the nitrogen atom to which they are bonded form a ring, this ring may be substituted by one or more of the substituents mentioned.
Pharmaceutically acceptable salts are particularly suitable for medical applications because their solubility in water is higher than the initial or basic compounds. These salts must have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds according to the invention are salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ~ o ethanesulfonic, fumaric, gluconic, glycolic, isethionie, lactic, lactobionic, malefic, malic, methanesulfonic, trifluoromethanesulfonic, succinic, p-toluenesulfonic, tartaric and trifluoroacetic acids. The chloride salt is particularly preferably used for medical purposes.
Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium ~ 5 and calcium salts) and salts of trometamol (2-amino-2-hydroxymethyl-1,3-propanediol), diethanolamine, lysine or ethylenediamine.
Salts with a pharmaceutically unacceptable anion likewise fall within the scope of the invention as useful intermediates for preparing or purifying pharmaceutically acceptable 2o salts and/or for use in nontherapeutic, for example in vitro, applications.
The term "physiologically functional derivative" used herein refers to any physiologically tolerated derivative of a compound according to the invention of the formula I, for example an ester, which is able on administration to a mammal such as, for example, a human to 25 form (directly or indirectly) a compound of the formula I or an active metabolite thereof.
The physiologically functional derivatives also include prodrugs of the compounds according to the invention, as described, for example, in H. Okada et al., Chem. Pharm.
Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound according 3o to the invention. These prodrugs may themselves be active or not.
The compounds according to the invention may also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All polymorphous forms of the compounds according to the invention lie within the scope of the invention and are a further aspect of the invention.
All references hereinafter to "compound(s) of formula (I)" refer to compounds) of the formula (I) as described above, and the salts, solvates and physiologically functional derivatives thereof as described herein.
If radicals or substituents can occur more than once in the compounds of the formula I, they may all independently of one another have the stated meanings and be identical or 0 different.
In a preferred embodiment, the meanings in the compounds of the formula I are R1, R2independently of one another H, (Cl-CA)-alkyl, -(CR13R14)o-R12, (C,-C~)-alkoxy-(C1-C4)-alkyl, (C3-Cs)-alkenyl, (C3-Cs)-alkynyl, CO-(C,-Cg)-alkyl, -CO-(CHZ)o -R12, CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))SO(R21);
~ 5 or R 1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF3, N02, CN, (C1-C6)-alkyl, 2o O-(C,-Cg)-alkyl, (C~-C4)-alkoxy-(C,-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (Co-Cg)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(C,-C6)-alkyl or N(R27)(R28);
R12 OH, O-(C,-C6)-alkyl, CN, COO(R29), CON(R30)(R31), N(R32)(R33), 3-12 25 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, I, OH, CF3, N02, CN, OCF~, oxo, O-(C,-C6)-alkyl, (C1-C4)-alkoxy-(C~-C4)-alkyl, S-(C~-C6)-alkyl, (C,-C6)-alkyl, (C~-C6)-alkenyl, (C3-C~)-cycloalkyl, (C2-C6)-alkynyl, O-(Co-Cg)-3o alkylene-aryl, (Co-C~)-alkylene-aryl, N(R34)(R35), CO(C~-C6)-alkyl and COO(R36);
and R6, R7, R8, R9 independently of one another H, (C,-Cg)-alkyl;
where the further radicals and groups in the compounds of the formula I have the meanings mentioned hereinbefore and preferred meanings mentioned hereinafter.
In a further preferred embodiment, the present invention relates to compounds of the formula I
the meanings are:
io Rl, R2 independently of one another H, (C,-Cs)-alkyl, -(CR13R14)o -R12, (C,-Ca)-alkoxy-(C,-C4)-alkyl, (C3-Cg)-alkenyl, CO-(Cl-C8)-alkyl, -CO-(CH2)o -R12, CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))SO(R21); or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-~ 5 membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C,-C6)-alkyl, O-(C,-C4)-alkyl, (Ci-C4)-alkoxy-(C,-C4)-alkyl, hydroxy-(C~-C4)-alkyl, (Ca-CZ)-alkylene-aryl, 20 oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(C,-C6)-alkyl, N(R27)(R28) or SOZCH3;
preferably independently of one another H, (C1-C~)-alkyl, -(CR13R14)o R12, (C~-C4)-alkoxy-(C,-C4)-alkyl, CO-(C1-Cg)-alkyl, -CO-(CHZ)o R12, CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))SO(R21);
25 or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono- or bicyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C,-C6)-alkyl, O-(C1-C4)-3o alkyl, (C,-C4)-alkoxy-(Ca-C4)-alkyl, (Co-C~)-alkylene-aryl, oxo, CO(R22), hydroxy, N(R27)(R28) or S02CH3;
particularly preferably independently of one another H, (C,-C~)-alkyl, -(CR13R14)o R12, (C,-C4)-alkoxy-(C,-C4)-alkyl, CO-(C1-Cg)-alkyl, -CO-(CH2)~ R12, CO(C(R15)(R16))qN(R17)(R18), or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-or bicyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen and nitrogen, where the heterocyclic ring system may additionally be substituted by F, (Ci-C6)-alkyl, (C~-C4)-alkoxy-(C,-C~)-alkyl, oxo, CO(R22), hydroxy, N(R27)(R28);
0 0, l, 2, 3, 4, 5, 6; preferably 0, l, 2, 3, 4; particularly preferably 0, l, 2, 3;
~o q l, 2, 3; preferably 1 or 2;
s 0, l, 2, 3, 4; preferably 0, l, 2, 3; particularly preferably 0, 1, 2;
~ 5 R 15, R 16, R 17, R 18, R 19, R20, R21, R22, R23, R24, R25, R26, R27, R28 independently of one another H, (C1-C~)-alkyl;
or R 17 and R 18, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to 2o which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur; the ring is preferably pyrrolidine, piperidine, N-methylpiperazine, morpholine;
25 R12 OH, O-(C,-C6)-alkyl, CN, COO(R29), CON(R30)(R31), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, OH, CF3, CN, oxo, O-(C,-C6)-alkyl, (C~-Cd)-alkoxy-(C,-C4)-alkyl, (C,-C6)-alkyl, O-(Co-Cg)-alkylene-aryl, (Co-30 Cg)-alkylene-aryl, N(R34)(R35), CO(C1-C6)-alkyl, COO(R36), S(O)"(R37);
preferably OH, O-(Cl-C6)-alkyl, CN, 3-10 membered mono- or bicyclic ring which may comprise 1-3 heteroatoms from the group of N, O and S, and the 3-10 membered ring may comprise further substituents such as F, Cl, Br, OH, CF3, CN, oxo, O-(C,-C~)-alkyl, (C,-C4)-alkoxy-(Cl-C4)-alkyl, (C,-C~)-alkyl, (Co-Cz)-alkylene-aryl, N(R34)(R35), CO(Cl-C6)-alkyl;
particularly preferably OH, O-(C,-C~)-alkyl, 3-10 membered mono- or bicyclic ring which may comprise 1-2 heteroatoms from the group of N, O
and S, and the 3-10 membered ring may comprise further substituents such as F, OH, oxo, (C,-C~,)-alkyl, CO(C,-C~;)-alkyl;
a 0, 1, 2; preferably 0 or 2; particularly preferably 2;
i o R34, R35 independently of one another H, (C~-Cs)-alkyl;
or R34 and R35 optionally together with the nitrogen atom to which they are bonded a 5-6 i5 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C,-C6)-alkyl, oxygen and sulfur, and optionally be substituted by 1-2 oxo groups;
R36, R37 H, (C,-Cs)-alkyl;
R13, R14 independently of one another H, (C1-Cg)-alkyl, hydroxy-(C~-Cø)-alkyl, OH, (C, -C4)-alkoxy-(C 1-Ca)-alkyl;
R29, R30, R31 independently of one another H, (C1-C~)-alkyl;
R3 H, (Ci-C6)-alkyl; preferably H;
R4, RS independently of one another H, (CI-C6)-alkyl, OH, O-(CI-C6)-alkyl, O-3o CO(CI-C6)-alkyl, S-(Cl-C6)-alkyl; preferably independently of one another H, (C,-C6)-alkyl, OH, O-(C,-C~)-alkyl, O-CO(C~-C6)-alkyl; particularly preferably independently of one another H, OH, O-(C~-C6)-alkyl, very particularly preferably H;
R6, R7, R8, R9 H;
or 5 R6 and R7, R8 and R9 independently of one another optionally oxo;
R6, R7, R8, R9 are preferably H;
n 1 ~o m 1 or 2; preferably l;
A, B, D, G independently of one another N, C(R38);
or ~ 5 the groups A and B or D and G are in each case C(R38) and together form an ortho-phenylene unit so that the overall result is a 1,4-bisubstituted naphthalene system;
preferably A, B, G and D are independently of one another N, C(R38);
particularly preferably D and G are C(R38) and either A or B is N, with the respective other group B or A being C(R38); very particularly preferably B is N, C(R38); and A, D, G C(R38);
especially preferably A, B, D, G are C(R38);
R38 H, F, Cl, Br, CF3, CN, O-(CI-C6)-alkyl, O-(CI-C~)-alkoxy-(Cl-C4)-alkyl, S-(C~-C6)-alkyl, (C1-C6)-alkyl, (Co-Cg)-alkylene-aryl, O-(CQ-Cg)-alkylene-aryl, N(R39)(R40), SOZ-CH3, CON(R41)(R42), N(R43)CO(R44), CO(R47), -(CR48R49)X-O(R50);
preferably H, F, Cl, Br, CF3, CN, O-(C,-C6)-alkyl, (C~-C6)-alkyl, SOZ-CHI, 3o CON(R41)(R42), N(R43)CO(R44), CO(R47), -(CR48R49)X-O(R50);
particularly preferably H, F, Cl, CF3, CN, (C,-Cb)-alkyl, -(CR48R49)X-O(R50);
R39, R40, R41, R42, R43 independently of one another H, (C1-C8)-alkyl;
or R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C,-C~)-alkyl, oxygen and sulfur;
fo R44, R47 independently of one another H, (C,-Cg)-alkyl, aryl; preferably independently of one another H, (C,-CA)-alkyl;
R48, R49 H;
~5 R50 H, (C,-C6)-alkyl;
x 1, 2; preferably l;
20 Het five-membered aromatic heterocycle, preferably i~,~
_~t r~ J' __, i , f- , _ ~~,-W' %,3 ~ !~'. ° ,- ~'x!
~:
~' I
S f: 1 ~J'S--- ~i ~yi,:_...~yJ~
o r ~ ___. , in which A' is O, S, NR73, X' , Y' and Z' are independently of one another CR74 or N, and R73, R74 are independently of one another H, (CI-Cg)-alkyl;
Het is particularly preferably selected from the group consisting of oxadiazoles, thiadiazoles, thiazoles, oxazoles, triazoles, thiophenes, furans and pyrroles; Het is very particularly preferably selected from oxadiazoles, thiadiazoles, thiazoles and oxazoles;
X a bond, a group of the formula -(CR51R52)y- in which one or more -o (CR51R52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, C=C; preferably a bond, CHZ-CHZ, CH2Y, YCH2, (R75)YCH2, CHZ-NCO(R75), CHZCON(R75); C(R76)(R77), C(R78)(R79)O, N(R75), C=C, C-C; particularly preferably a bond, CHZ-CHZ, C(R76)(R77), N(R75), CH2Y, CH2Y(R75), CH2-NCO(R75), ~ 5 CHZCON(R75); C=C; very particularly preferably a bond, CHI-CHz, C(R76)(R77), C=C, (R75)YCH2, CHZ-NCO(R75);
Y O, S, N(R53), CO; preferably O, S, N(R53);
2o R53 H, (C~-Cg)-alkyl;
R75, R76, R77, R78, R79 independently of one another H, (C1-CA)-alkyl;
25 E 3-8 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, O and 5, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO~, CN, OCF~, O-(Cl-C6)-alkyl, O-(C,-C4)-alkoxy-(Cl-C4)-alkyl, S-(CI-C6)-alkyl, (Ct-C6)-alkyl, (CZ-C6)-alkenyl, O-(C3-Cs)-cycloalkyl, (C2-C6)-alkynyl, (Co-Cg)-3o alkylene-aryl, O-(Co-Cg)-alkylene-aryl, S-aryl, N(R54)(R55), S02-CH3, N(R58)CO(R59), N(R60)S02(R61), CO(R62) and be mono- or bicyclic;
preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, C1, Br, OH, CF3, NO~, CN, OCF3, O-(C~-C6)-alkyl, S-(C1-C6)-alkyl, (CI-C6)-alkyl, (C2-C6)-alkenyl, O-(Co-Cg)-alkylene-aryl, S-aryl, N(R54)(R55), SOZ-CH3, N(R58)CO(R59), CO(R62) and be mono- or bicyclic;
s particularly preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-2 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, N02, OCF3, O-(C,-C6)-alkyl, (C,-C6)-alkyl, (C2-C6)-alkenyl, N(R54)(R55), SOZ-CH3, CO(R62), and which is very particularly preferably monocyclic;
o e.g. E is benzene, pyridine, pyrimidine, piperidine, pyrrolidine, cyclopentane, cyclohexane, piperazine, homopiperazine, thiazole, thiophene, furan, pyrrole, pyrazole, 1,2,3,6-tetrahydropyridine, 4,5-dihydroisoxazole, oxazole;
~ 5 R54, R55, R58, R60 independently of one another H, (C,-Cs)-alkyl;
R59, R61, R62 independently of one another H, (Ci-Cg)-alkyl, aryl; preferably 2o independently of one another H, (C1-Cg)-alkyl;
K O, a bond, CHZO, OCHZ, S, SO, SOZ, N(R80), N(R81)CO, CON(R82), (C(R83)(R84))~, CO, C=C, C=C, SCH~, SOzCHz;
preferably O, a bond, CH~O, OCH2, N(R80), N(R81)CO, CON(R82), 25 (C(R83)(R84)),,, CO, C---C, SCH2; particularly preferably O, a bond, CH20, OCH~, CON(R82), (C(R83)(R84))", CO, C=C;
v l, 2, 3, 4; preferably l, 2, 3; particularly preferably 1,2;
3o R80, R81, R82, R83, R84 independently of one another H, (C,-Cg)-alkyl;
R11 H, (C,-Cg)-alkyl, (C,-C4)-alkoxy-(C,-C4)-alkyl, (C3-Cg)-alkenyl, (C3-Cs)-alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O-(Ci-Cs)-alkyl, (C,-C4)-alkoxy-(C,-C4)-alkyl, hydroxy-(C,-C4)-alkyl, (Co-Cs)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, COO(R69), N(R70)CO(C~-C6)-alkyl, N(R71 )(R72) or S02CH3;
preferably (C,-Cg)-alkyl, (C,-C4)-alkoxy-(C~-C4)-alkyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C,-C6)-alkyl, O-(C,-Cs)-alkyl, (C~-CZ)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, N(R70)CO(C~-C6)-alkyl, N(R71)(R72) or SOzCH3;
is particularly preferably (C,-C8)-alkyl, (C1-C4)-alkoxy-(C,-C4)-alkyl, a 3 to 10-membered mono- or bicyclic ring which may include 0 to 2 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C,-C6)-alkyl, O-(C,-Cg)-alkyl, oxo, CO(R66), CON(R67)(R68), N(R70)CO(Ci-C6)-alkyl, 20 or SO~CH3;
R66, R67, R68, R69, R70, R71, R72 independently of one another H, (CI-Cg)-alkyl;
or R67 and R68, R71 and R72 25 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur; or 3o the N-oxides thereof and the physiologically tolerated salts thereof.
In a preferred embodiment of the invention, the radicals R1, R2, R1 l, R38 and groups X, E, K have the following meanings:
Rl, R2 independently of one another H, (C,-CR)-alkyl, -(CR13R14)o R12, (C,-C4)-alkoxy-(C,-C4)-alkyl, or Rl and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring 5 which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (C,-C6)-alkyl, O-(CI-C4)-alkyl, (Ci-C4)-alkoxy-(C,-C4)-alkyl, hydroxy-(C,-C4)-alkyl, (Co-CZ)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, N(R27)(R28) or SO~CH3;
preferably independently of one another H, (C1-C$)-alkyl, -(CR13R14)o-, R12, (Cl-C4)-alkoxy-(C,-C4)-alkyl, or Rl and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 ~ 5 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (C,-C6)-alkyl, O-(C~-C4)-alkyl, (C,-C4)-alkoxy-(C~-C4)-alkyl, hydroxy-(C~-C4)-alkyl, (Co-C2)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy or N(R27)(R28);
2o very particularly preferably independently of one another H, (C,-Cg)-alkyl, or R1 and R2 form together with the nitrogen atom to which they are bonded a 5 to 6-membered monocyclic ring which, apart from the nitrogen atom, may include 0 to 1 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (Cl-C6)-alkyl;
especially preferably independently of one another H, (C1-Cg)-alkyl;
0 0, 1, 2, 3, 4;
3o R22, R23, R24, R27, R28 independently of one another H, (C,-C6)-alkyl;
or R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(Cl-C~)-alkyl, oxygen and sulfur;
R12 OH, O-(C,-C~)-alkyl, CN, 3-12 membered mono-, bi- or spirocyclic ring which may comprise 1 to 3 heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, OH, CF3, CN, oxo, (C1-C6)-alkyl, (C~-CZ)-alkylene-aryl, N(R34)(R35), o COO(R36), CO(C,-C6)-alkyl;
R34, R35 independently of one another H, (C,-C4)-alkyl;
~5 R36 H, (C~-C6)-alkyl;
R13, R14 independently of one another H, (C,-Cs)-alkyl, hydroxy-(C,-C4)-alkyl, OH, (C, -C~)-alkoxy-(C I-C4)-alkyl;
20 R38 H, F, Cl, Br, CFA, CN, (C~-C6)-alkyl;
X a bond, CHZCH~, C(R76)(R77), N(R75), C=C, (R75)YCH2, CHZ-NCO(R75), CHZCON(R75);
25 Y O, S, N(R53), CO
R75, R76, R77 independently of one another H, (CI-Cg)-alkyl;
3o R53 H, (C,-Cg)-alkyl;
E 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, CF3, OH, CN, OCF3, O-(C1-C~)-alkyl, (C,-C6)-alkyl, SOZ-CH3, CO(R65);
R65 H, (C,-Cg)-alkyl;
K O, a bond, CH20, CH2, OCH2, S, SO2, N(R80), N(R81)CO, CON(R82), (C(R83)(R84))", CO, C---C, SCH~, SOZCH2;
preferably O, a bond, CH20, CHZ, OCH2, N(R80), C---C;
io v l, 2, 3;
R80, R81, R82, R83, R84 independently of one another H, (C1-Cg)-alkyl;
~5 R11 (Cl-Cx)-alkyl, (C,-C4)-alkoxy-(C~-C4)-alkyl, a 3 to 10-membered mono-, bi-or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O-(C~-Cs)-alkyl, oxo, CO(R66), hydroxy, N(R70)CO(C1-C6)-alkyl, or SOZCH3;
R66, R70 independently of one another H, (C~-Cg)-alkyl;
the N-oxides thereof and the physiologically tolerated salts thereof.
Particularly preferred compounds of the formula I are those in which A, B, D, G are independently of one another N or C(R38), and the total number of nitrogen atoms in this ring is 0-2, preferably 0 or I , and in the case where the total number of nitrogen atoms is l, particularly preferably A or B are N, and very particularly preferably B is N.
Very particularly preferred compounds of the formula I are those in which n is 1 and m is 1 or 2.
S
Especially preferred compounds of the formula I are those in which A, B, D, G are independently of one another N or C(R38), and the total number of nitrogen atoms in this ring is 0-2, preferably 0 or l, and in the case where m the total number of nitrogen atoms is l, particularly preferably A or B are N, and very particularly preferably B is N.
n is l and IS m is 1 or2.
The radical R38 has the aforementioned meanings.
Especially preferred compounds of the formula I are those in which ~o Het is selected from the group consisting of oxadiazoles, thiadiazoles, thiazoles, oxazoles, triazoles, thiophenes, furans and pyrroles; Het is very particularly preferably selected from oxadiazoles, thiadiazoles, thiazoles and oxazoles.
25 The further radicals may have the aforementioned meanings in the aforementioned preferred embodiments.
In a very particularly preferred embodiment, the present application relates to compounds of the formula IA
. . ~.i _- j~..i'';.1 ,' i-t . _ ~ = ' - -. ,~. - 3~ ~ ~ ,---- ~ ~ I ..
. . a .. ' ' in which the meanings are i.~:
;_ ,r >>
Het ~~,;-..,,_ Or , in which A' is O, S, X' and Y' I o are independently of one another CR74 or N, and R74 are independently of one another H, (C1-Cs)-alkyl;
A, B are CH or CF, where in the case of CF only one of the two groups A or B
is CF and the other group is CH;
Rl, R2 independently of one another H, (C,-Cg)-alkyl, -(CR13R14)o-R12, (C1-C4)-alkoxy-(C,-C4)-alkyl, (C3-Cg)-alkenyl, (C3-Cg)-alkynyl, CO-(Cl-Cg)-alkyl, -CO-(CHZ)o R12, CO(C(R15)(R16))qN(R17)(R18), CO(C(R 19)(R20))50(R21 ); or R 1 and R2 form together with the nitrogen 2o atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C~-C6)-alkyl, O-(C~-Cs)-alkyl, (C~-C4)-alkoxy-(CI-C4)-alkyl, hydroxy-(C~-C4)-alkyl, (Co-C8)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(C1-C6)-alkyl, N(R27)(R28) or SOZCH3;
particularly preferably independently of one another H, (C,-CA)-alkyl, -(CR13R14)~-R12, (C,-C4)-alkoxy-(C,-C4)-alkyl, CO-(Cl-C$)-alkyl, -CO-(CH~)a-R12; or RI and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring 5 which, apart from the nitrogen atom, may include 0 to 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C,-C~)-alkyl, O-(C,-Cg)-alkyl, (C,-C~)-alkoxy-(C~-C4)-alkyl, hydroxy-(C~
C4)-alkyl, (C~-C~)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxyl, o N(R26)CO(C,-C6)-alkyl, N(R27)(R28);
very particularly preferably independently of one another H, (CI-Cg)-alkyl, -(CR13R14)o-R12, (C,-C4)-alkoxy-(C1-C4)-alkyl, -CO-(CHZ)o-R12; or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 7-membered monocyclic ring which, apart from the nitrogen atom, may ~ 5 include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C1-C6)-alkyl, O-(C,-C~)-alkyl, hydroxy-(C,-C4)-alkyl, CO(R22), CON(R23)(R24), hydroxy, N(R26)CO(C,-C6)-alkyl, N(R27)(R28);
2o especially preferably independently of one another H, (C1-Cs)-alkyl, or R1 and R2 form together with the nitrogen atom to which they are bonded a 5 to 6-membered monocyclic ring which, apart from the nitrogen atom, may include 0 to 1 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be z5 substituted by (C,-C6)-alkyl;
further very particularly preferably independently of one another H, (C,-Cg)-alkyl;
0 0, 1, 2, 3, 4, 5, 6; preferably 0, I, 2, 3, 4;
3o q, s independently of one another 0, l, 2, 3, 4;
R 15, R I 6, R 17, R 18, R 19, R20, R21, R22, R23, R24, R25, R26, R27, R28 independently of one another H, (C,-Cf,)-alkyl;
R 17 and R 18, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C ~-C~,)-alkyl, oxygen and sulfur;
R12 OH, O-(C,-C~,)-alkyl, CN, COO(R29), CON(R30)(R31), N(R32)(R33), 3-12 o membercd mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 memhered ring may comprise further substituents such as F, Cl, Br, l, OH, CFA, NO~, CN, OCF3, oxo, O-(C~-C6)-alkyl, (C,-Ca)-alkoxy-(C,-C4)-alkyl, S-(C~-C6)-alkyl, (C,-C6)-alkyl, (C~-C~)-alkenyl, (C3-CA)-cycloalkyl, (CZ-C6)-alkynyl, O-(C~-C~)-~5 alkylene-aryl, (C~-Cs)-alkylene-aryl, N(R34)(R35), CO(Ci-C6)-alkyl, COO(R36) and S(O)"(R37);
particularly preferably OH, O-(C,-C6)-alkyl, CN, CON(R30)(R31), N(R32)(R33), 3-7 membered monocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-7 membered ring 2o may comprise further substituents such as F, Cl, OH, CF3, CN, OCF3, oxo, O-(C,-C6)-alkyl, (C~-C4)-alkoxy-(C~-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (CZ-C6)-alkenyl, (C3-Cg)-cycloalkyl, (CZ-C6)-alkynyl, O-(Co-Cg)-alkylene-aryl, (C~-C8)-alkylene-aryl, N(R34)(R35) and CO(C1-C6)-alkyl;
25 a 0, 1, 2;
R34, R35 independently of one another H, (C,-Cg)-alkyl;
30 R34 and R35 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C~-C~)-alkyl, oxygen and sulfur and optionally be substituted by 1-2 oxo groups;
R36, R37 H, (C,-Cs)-alkyl;
S
R13, R14 independently of one another H, (Cl-Cs)-alkyl, hydroxy-(C,-C4)-alkyl, OH, (C, -C4)-alkoxy-(C ~ -C4)-alkyl;
R29, R30, R31 o independently of one another H, (C~-Cg)-alkyl, (CZ-C6)-alkenyl, (Co-Cg)-alkylene-aryl;
R32, R33 independently of one another H, (C,-C6)-alkyl or ~ 5 R32 and R33 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring, which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C~-C6)-alkyl, oxygen and sulfur and optionally be substituted by 1-2 oxo groups;
X a bond, a group of the formula -(CR51R52)y- in which one or more -(CR51 R52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, C---C; preferably a bond, CHZ-CH2, CH~Y, YCH2, (R75)YCHZ, CHZ-NCO(R75), CHZCON(R75); C(R76)(R77), C(R78)(R79)O, N(R75), C=C, C=C; particularly preferably a bond, CHZ-CH2, C(R76)(R77), N(R75), CHZY, CH2Y(R75), CHZ-NCO(R75), CH2CON(R75); C=C; very particularly preferably a bond, CHZ-CH2, C(R76)(R77), C=C; (R75)YCH~, CH2-NCO(R75);
3o Y O, S, N(R53), CO, SO, SOZ; particularly preferably O, S, N(R53), CO; very particularly preferably O, N (R53);
R51, R52 independently of one another H, (C,-C4)-alkyl, where R51 and R52 in the y groups in each case can have the same or different meanings;
y 1,2,3,4,5,6;
R53 H, (C,-Cs)-alkyl;
E 3-14 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, I, OH, CFA, NOZ, CN, OCF3, oxo, O-(C,-C6)-alkyl, O-(C1-C4)-alkoxy-(C,-C4)-alkyl, S-(C1-C6)-alkyl, (Cl-C6)-alkyl, (C~-C6)-alkenyl, (C3-C~)-cycloalkyl, O-(C3-C8)-cycloalkyl, (CZ-C6)-alkynyl, (Co-C~)-alkylenc-aryl, O-(Co-C8)-alkylene-aryl, S-aryl, N(R54)(R55), S02-CH3, COOH, COO-(C1-C6)-alkyl, CON(R56)(R57), ~5 N(R58)CO(R59), N(R60)SOZ(R61), CO(R62) and be mono- or bicyclic;
preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, OH, CN, CF3, OCF3, O-(Cl-C6)-alkyl, (C,-C6)-alkyl, (Co-Cg)-alkylene-aryl, O-(C3-Cg)-cycloalkyl, 2o N(R54)(R55), SOZ-CHI, CON(R56)(R57), N(R58)CO(R59), N(R60)SOZ(R61), CO(R62) and be mono- or bicyclic; particularly preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, CF3, OCF3, O-(C,-C6)-alkyl, 25 (CI-C6)-alkyl, (Co-CZ)-alkylene-aryl, O-(C3-C6)-cycloalkyl, N(R54)(R55), CON(R56)(R57), N(R58)CO(R59), CO(R62) and be mono- or bicyclic;
R54, R55, K56, R57, R58, R60 independently of one another H, (Ci-C8)-alkyl;
R54 and R55, R56 and R57 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C,-C6)-alkyl, oxygen and sulfur;
R59, R61, R62 independently of one another H, (C,-Cg)-alkyl, aryl;
K a bond, a group of the formula -(CR63R64),-, in which one or more -(CR63R64)- groups may be replaced by Z to result in a chemically reasonable radical, C---C, C=C;
I o preferably O, a bond, CH~O, CH2, OCH2, S, SO2, N(R80), N(R81 )CO, CON(R82), (C(R83)(R84))~, CO, C=C, SCHZ, SOZCH~;
Z O, S, N(R65), CO, SO, SO2;
I5 R63, R64 independently of one another H, (C,-Cg)-alkyl, hydroxy, (C~-C6)-alkoxy, where R63 and R64 in the z groups may in each case have the same or different meanings;
z l, 2, 3, 4, 5, 6, preferably 2, 3, 4, 5, 6;
R65 H, (C~-Cs)-alkyl;
R11 H, (C1-Cg)-alkyl, (C,-C4)-alkoxy-(C,-C4)-alkyl, (C3-C8)-alkenyl, (C3-Cg)-alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O-(C,-Cs)-alkyl, (C1-C4)-alkoxy-(C1-C4) alkyl, (Co-Cg)-alkylene-aryl, oxo, CO(Rb6), CON(R67)(R68), hydroxy, hydroxy-(CI-C4)-alkyl, COO(R69), N(R70)CO(Cl-C6)-alkyl, N(R71)(R72) 3o or SO~CH3;
preferably H, (Ci-Cg)-alkyl, (C,-C4)-alkoxy-(C1-C4)-alkyl, a 5 to 6-membered monocyclic ring which may include 0 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O-(Cz-Cg)-alkyl, (C,-C4)-alkoxy-(C,-C4)-alkyl, CO(R66), CON(R67)(R68), hydroxy, N(R70)CO(C,-C6)-alkyl, N(R71)(R72) or SO~CH3;
5 particularly preferably H, (C,-Cs)-alkyl, (C,-C4)-alkoxy-(C,-C4)-alkyl, a 5 to 6-membered monocyclic ring which may include 0 to 2 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CFA, N02, CN, (C,-C6)-alkyl or O-(C~-Cg)-alkyl;
io R66, R67, R68, R69, R70, R71, R72 independently of one another H, (C,-Cs)-alkyl;
or R67 and R68, R71 and R72 i 5 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0- I further heteroatoms from the group of NH, N-(C,-C6)-alkyl, oxygen and sulfur; or 2o the N-oxides thereof and the physiologically tolerated salts thereof.
The compounds of the invention of the formula I and their precursors can be prepared by processes known to the skilled worker.
z5 The preparation of compounds of the invention of the formula I is described below for the example of the preparation of [1,3,4]-oxadiazoles (Ia), [1,3,4]-thiadiazoles (Ib) and [1,2,4]-oxadiazoles (Ic):
N H
O OR O OR O N~NH
\ NR1 R2 / I H2N-NH2 x H20 /
\ \
(III) (IV) in which R is H, (C,-Cs)-alkyl, and R 1 and R2 have the aforementioned meanings;
O
R11 ~K~E~X~OH ~ ~
(IV) _ X O ~ N\/ -NR1R2 CI PF6 ~K~E~ ~
+~ R11 N-N
~N ~ N~
U
(la) 0 or Burgess' reagent O
H
O O N~N~X~E~K~R11 H
R11 ~K~E~X~OH
(V) TOTU
i N
NR1 R2 Lawesson's reagent N~'NRiR2 x ~K~E~ ~ /
(1b) in which Rl, R2, Rl i and X, E and K have the aforementioned meanings.
. _ ..' ww __- ~ ,, , .. w:,:y.
;../.i... ;= v ~ lIE.;S~i..l ~i ' . .
' ' ~ , ;i ;~v..~f~,i,j-.r .. ; -~~-~~ ,_ S~'y '1a ~ .
~1 -,;~.-:- ~ ;~.' _.. ,, , ,~;,ir n .w.;
in which R1, R2, R1 l and X, E and K have the aforementioned meanings.
s Use This invention further relates to the use of compounds of the formula I and their pharmaceutical compositions as MCH receptor ligands. The MCH receptor ligands of the invention are particularly suitable as modulators of the activity of the MCH1R.
t0 The role of MCH in regulating the energy balance has now been well documented (Qu, D.
et al.; Nature 1996, 380, 243-7; Shimada, M. et al. Nature 1998, 396, 670-4;
Chen, Y. et al.
Endocrinology 2002, 143, 2469-77; Endocrinology 2003, 144, 4831-40; Review: G.
Hervieu, Expert Opin. Ther. Targets 2003, 7, 495-511 ).
There are also indications that MCH antagonists can have a beneficial influence on centrally related disorders such as, for example, depression (Borowsky, B. et al.; Nature Medicine 2002, 8, 825-30; Review: G. Hervieu, Expert Opin. Ther. Targets 2003, 7, 495-511).
Compounds of this type are particularly suitable for the treatment and/or prevention of 1. Obesity 2. Diabetes mellitus, especially type 2 diabetes, including the prevention of the sequelae associated therewith.
Particular aspects in this connection are - hyperglycemia, - improvement in insulin resistance, - improvement in glucose tolerance, - protection of the pancreatic 13 cells ~ 5 - prevention of macro- and microvascular disorders 3. Dyslipidemias and their sequelae such as, for example, atherosclerosis, coronary heart disease, cerebrovascular disorders etc., especially those (but not restricted thereto) which are characterized by one or more of the following factors:
20 - high plasma triglyceride concentrations, high postprandial plasma triglyceride concentrations, - low HDL cholesterol concentration 4. Various other conditions which may be associated with the metabolic syndrome, such 2S as:
- thromboses, hypercoagulable and prothrombotic stages (arterial and venous) - high blood pressure - heart failure such as, for example (but not restricted thereto), following myocardial infarction, hypertensive heart disease or cardiomyopathy 5. Psychiatric indications such as - depression - anxiety states - disturbances of the circadian rhythm - affection disorders - schizophrenia - addictive disorders Formulations The amount of a . compound of formula (I) which is necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound ~ o chosen, the intended use, the mode of administration and the clinical condition of the patient. In general, the daily dose is in the range from 0.001 mg to 100 mg, preferably from 0.3 mg to 100 mg (typically from 0.01 mg to 50 mg, preferably from 3 mg to 50 mg) per day per kilogram of body weight, for example 0.1-10 mg/kg/day, preferably 3-10 mg/kglday. An intravenous dose may be, for example, in the range from 0.001 mg to 1.0 is mgfkg, preferably from 0.3 mg to 1.0 mglkg, which can most suitably be administered as infusion of from 10 ng to 100 ng per kilogram and per minute. Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Single doses may contain, for example, from 1 mg to 10 g of the active ingredient. Single doses may contain, for example, from 1 mg to 10 g of the active 2o ingredient. It is thus possible for ampoules for injections to contain, for example, from 1 mg to 100 mg, and for single-dose formulations which can be administered orally, such as, for example, tablets or capsules, to contain, for example, from 0.05 to 1000 mg, typically from 0.5 to 600 mg, or in a further embodiment from 1.0 to 1000 mg, typically from 10 to 600 mg. In the case of pharmaceutically acceptable salts, the aforementioned 25 weight data are based on the weight of the salt of the underlying free compound. For the prophylaxis or therapy of the abovementioned conditions, the compounds of formula (I) can be used as the compound itself, but they are preferably in the form of a pharmaceutical composition with an acceptable carrier. The carrier must, of course, be acceptable in the sense that it is compatible with the other ingredients of the composition and is not 3o hazardous for the patient's health. The carrier may be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet which may contain from 0.05% to 95% by weight of the active ingredient. Further pharmaceutically active substances may likewise be present, including other compounds of formula (I). The pharmaceutical compositions according to the invention can be produced by one of the known pharmaceutical methods which essentially consist of mixing the ingredients with pharmacologically acceptable carriers and/or excipients.
Pharmaceutical compositions according to the invention are those suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration although the most suitable mode of administration in each individual case depends on the nature and severity of the condition to be treated and on the nature of the compound of formula (I) used in each case.
o Coated formulations and coated slow-release formulations also lie within the scope of the invention. Formulations resistant to acid and gastric fluid are preferred.
Suitable coatings resistant to gastric fluid comprise cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
l5 Suitable pharmaceutical preparations for oral administration may be in the form of separate units such as, for example, capsules, cachets, suckable tablets or tablets, each of which contain a defined amount of the compound of formula (I); as powders or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-2o in-oil emulsion. These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional ingredients) are brought into contact. In general, the compositions are produced by uniform and homogeneous mixing of the active ingredient with a liquid and/or finely divided solid carrier, after which the 25 product is shaped if necessary. Thus, for example, a tablet can be produced by compressing or molding a powder or granules of the compound, where appropriate with one or more additional ingredients. Compressed tablets can be produced by tableting the compound in tree-flowing form, such as, for example, a powder or granules, where appropriate mixed with a binder, lubricant, inert diluent and/or a (plurality of) surface-active/dispersing 30 agents) in a suitable machine. Molded tablets can be produced by molding the compound which is in powder form and is moistened with an inert liquid diluent in a suitable machine.
Pharmaceutical compositions suitable for peroral (sublingual) administration comprise suckable tablets which contain a compound of formula (I) with a flavoring, normally sucrose and gum arabic or tragacanth, and pastilles which comprise the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
Suitable pharmaceutical compositions for parenteral administration comprise preferably sterile aqueous preparations of a compound of formula (I), which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although administration may also take place by subcutaneous, intramuscular 0 or intradermal injection. These preparations can preferably be produced by mixing the compound with water and making the resulting solution sterile and isotonic with blood.
Injectable compositions according to the invention generally contain from 0.1 to 5% by weight of the active compound.
I5 Suitable pharmaceutical compositions for rectal administration are preferably in the form of single-dose suppositories. These can be produced by mixing a compound of formula (I) with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
2o Suitable pharmaceutical compositions for topical application to the skin are preferably in the form of ointment, cream, lotion, paste, spray, aerosol or oil. Carriers which can be used are petrolatum, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances. The active ingredient is generally present in a concentration of from 0.1 to 15% by weight of the composition, for example from 0.5 to 2%.
Transdermal administration is also possible. Suitable pharmaceutical compositions for transdermal uses can be in the form of single plasters which are suitable for long-term close contact with the patient's epidermis. Such plasters suitably contain the active ingredient in an optionally buffered aqueous solution, dissolved and/or dispersed in an adhesive or dispersed in a polymer. A suitable active ingredient concentration is about 1 %
to 35%, preferably about 3% to 15%. As a special possibility, the active ingredient can be released as described, for example, in Pharmaceutical Research, 2(6): 318 ( 1986) by electrotransport or iontophoresis.
The compounds of the formula I are distinguished by beneficial effects on lipid metabolism, and they are particularly suitable for weight reduction and for maintaining a reduced weight after weight reduction has taken place in mammals and as anorectic agents.
The compounds are distinguished by their low toxicity and their few side effects.
The compounds can be employed alone or in combination with other weight-reducing or anorectic active ingredients. Further anorectic active ingredients of this type are mentioned, for example, in the Rote Liste, chapter 01 under weight-reducing agents/appetite suppressants, and may also include active ingredients which increase the energy turnover t o of the organism and thus lead to weight reduction or else those which influence the general metabolism of the organism in such a way that an increased calorie intake does not lead to an enlargement of the fat depots and a normal calorie intake leads to a reduction of the fat depots of the organism. The compounds are suitable for the prophylaxis and, in particular, for the treatment of excessive weight or obesity. The compounds are further suitable for the t 5 prophylaxis and, in particular, for the treatment of type II diabetes, of arteriosclerosis and for normalizing lipid metabolism and for the treatment of high blood pressure.
Combinations with other medicaments 20 In a further aspect of the invention, the compounds of the formula I can be administered in combination with one or more other pharmacologically active substances which have, for example, favorable effects on metabolic disturbances or disorders frequently associated therewith. Examples of such medicaments are 1. medicaments which lower blood glucose, antidiabetics, 25 2. active ingredients for the treatment of dyslipidemias, 3. antiatherosclerotic medicaments, 4. antiobesity agents, 5. antiinflammatory active ingredients 6. active ingredients for the treatment of malignant tumors 30 7. antithrombotic active ingredients 8. active ingredients for the treatment of high blood pressure 9. active ingredients for the treatment of heart failure and 10. active ingredients for the treatment and/or prevention of complications caused by diabetes or associated with diabetes.
They can be combined with the compounds of the invention of the formula I in particular for a synergistic improvement in the effect. Administration of the active ingredient combination can take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation.
~ o Further pharmacologically active substances suitable in particular are:
Antidiabetics All antidiabetics mentioned in the Rote Liste 2001, chapter 12. They may be combined ~ 5 with the compounds of the formula I of the invention in particular for a synergistic improvement of the effect. Administration of the active ingredient combination may take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation. Most of the active ingredients listed below are disclosed in the 2o USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2001.
Suitable antidiabetics include all insulins and insulin derivatives such as, for example, Lantus" or HMR 1964 or Apidra~, and other fast-acting insulins (see, e.g., US
6,221,633), 25 amylin, GLP-1 and GLP-2 derivatives such as described in WO 01/04146 or else such as, for example, those disclosed in WO 98/08871 of Novo Nordisk A/S, and orally effective hypoglycemic active ingredients.
The orally effective hypoglycemic active ingredients include, preferably, sulfonylureas, 30 biguanidines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon receptor antagonists, GLP-1 agonists, DPP-IV inhibitors, potassium channel openers such as, for example, those disclosed in WO 97/26265 and WO
of Novo Nordisk A/S, insulin sensitizers, activators of insulin receptor kinase, inhibitors of GSK3-beta, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and/or glycogenolysis, for example inhibitors of glycogen phosphorylase, modulators of glucose uptake and glucose excretion, compounds which alter lipid metabolism and lead to a change in the lipid composition of the blood, such as antihyperlipidemic active 5 ingredients and antilipidemic active ingredients, e.g. HMGCoA reductase inhibitors, inhibitors of cholesterol transport/of cholesterol uptake, inhibitors of bile acid reabsorption or inhibitors of microsomal triglyceride transfer protein (MTP), compounds which reduce food intake and/or food absorption, PPAR and RXR agonists and active ingredients which act on the ATP-dependent potassium channel of the beta cells.
In one embodiment of the invention, the present compounds are administered in combination with insulin.
In one embodiment of the invention, the compounds of the formula I are administered in ~ 5 combination with substances which influence hepatic glucose production such as, for example, glycogen phosphorylase inhibitors (see: WO 01/94300, WO 02/096864, WO
03/084923, WO 03/084922, WO 03/104188).
In one embodiment, the compounds of the formula I are administered in combination with 20 a sulfonylurea such as, for example, tolbutamide, glibenclamide, glipizide or glimepiride.
In one embodiment, the compounds of the formula I are administered in combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide.
In one embodiment, the compounds of the formula I are administered in combination with a biguanide such as, for example, metformin.
In a further embodiment, the compounds of the formula I are administered in combination 3o with a meglitinide such as, for example, repaglinide.
In one embodiment, the compounds of the formula I are administered in combination with a thiazolidinedione such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy's Research Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]-phenyl]methyl]-2,4-thiazolidinedione.
In one embodiment, the compounds of the formula I are administered in combination with a DPPIV inhibitor as described, for example, in W098/19998, W099/61431, W099/67278, W099/67279, WO01/72290, WO 02/38541, W003/040174, in particular P
93/01 (1-cyclopentyl-3-methyl-1-oxo-2-pentanammonium chloride), P-31/98, LAF237 (1-[2-[3-hydroxyadamant-1-ylamino)acetyl]pyrrolidine-2-(S)-carbonitrile), TS021 ((2S, 4S)-4-fluoro-1-[ [(2-hydroxy-1,1-dimethylethyl)amino] acetyl]pyrrolidine-2-carbonitrile monobenzenesulfonate).
In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPARgamma agonist such as, for example, rosiglitazone, pioglitazone.
In one embodiment, the compounds of the formula I are administered in combination with ~ 5 compounds with an inhibitory effect on SGLT-1 and/or 2, as disclosed directly or indirectly for example in PCTBP03/06841, PCT/EP03/ 13454 and PCT/EP03/ 13455.
In one embodiment, the compounds of the formula I are administered in combination with an a-glucosidase inhibitor such as, for example, miglitol or acarbose.
In one embodiment, the compounds of the formula I are administered in combination with more than one of the aforementioned compounds, e.g. in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.
Lipid modulators In one embodiment of the invention, the compounds of the formula I are administered in combination with an HMGCoA reductase inhibitor such as lovastatin, fluvastatin, 3o pravastatin, simvastatin, ivastatin, itavastatin, atorvastatin, rosuvastatin.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a bile acid absorption inhibitor (see, for example, US
6,245,744, US
6,221,897, US 6,277,831, EP 0 683 773, EP 0 683 774).
In one embodiment of the invention, the compounds of the formula I are administered in combination with a polymeric bile acid adsorbent such as, for example, cholestyramine, colesevelam.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a cholesterol absorption inhibitor as described for example in WO 0250027, or ezetimibe, tiqueside, pamaqueside.
In one embodiment of the invention, the compounds of the formula I are administered in o combination with an LDL receptor inducer (see, for example, US 6,342,512).
In one embodiment, the compounds of the formula I are administered in combination with bulking agents, preferably insoluble bulking agents (see, for example, carob/Caromax~
(Zunft H J; et al., Carob pulp preparation for treatment of hypercholesterolemia, ~ 5 ADVANCES IN THERAPY (2001 Sep-Oct), 18(5), 230-6); Caromax is a carob containing product from Nutrinova, Nutrition Specialties & Food Ingredients GmbH, Industriepark Hoechst, 65926 Frankfurt/Main). Combination with Caromax~ is possible in one preparation or by separate administration of compounds of the formula I
and Caromax~. Caromax° can in this connection also be administered in the form of food 2o products such as, for example, in bakery products or muesli bars.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPARalpha agonist.
25 In one embodiment of the invention, the compounds of the formula I are administered in combination with a fibrate such as, for example, fenofibrate, gemfibrozil, clofibrate, bezafibrate.
In one embodiment of the invention, the compounds of the formula I are administered in 3o combination with nicotinic acid or niacin.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a CETP inhibitor, e.g. CP- 529, 414 (torcetrapib).
35 In one embodiment of the invention, the compounds of the formula I are administered in combination with an ACAT inhibitor.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an MTP inhibitor such as, for example, implitapide.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an antioxidant.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein lipase inhibitor.
to In one embodiment of the invention, the compounds of the formula I are administered in combination with an ATP citrate lyase inhibitor.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a squalene synthetase inhibitor.
~5 In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein(a) antagonist.
Antiobesity agents In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipase inhibitor such as, for example, orlistat.
In one embodiment, the further active ingredient is fenfluramine or dexfenfluramine.
In another embodiment, the further active ingredient is sibutramine.
In another embodiment, the further active ingredient is rimonabant.
In a further embodiment, the compounds of the formula I are administered in combination 3o with CART modulators (see "Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice" Asakawa, A, et al., M.:
Hormone and Metabolic Research (2001), 33(9), 554-558), NPY antagonists, e.g. naphthalene-1-sulfonic acid {4-[(4-aminoquinazolin-2-ylamino)methyl] cyclohexylmethyl}amide;
hydrochloride (CGP 71683A)), MC4 agonists (e.g. 1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid [2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]pyridin-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]amide; (WO 01/91752)), orexin antagonists (e.g. I-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-ylurea; hydrochloride (SB-334867-A)), CB1 antagonists/inverse agonists, H3 antagonists/inverse agonists (e.g. 3-cyclohexyl-l-(4,4-dimethyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)propan-1-one oxalic acid salt (WO 00/63208)); TNF agonists, CRF antagonists (e.g. [2-methyl-9-(2,4,6-trimethylphenyl)-9H-1,3,9-triazafluoren-4-yl]dipropylamine (WO 00/66585)), CRF
BP
antagonists (e.g. urocortin), urocortin agonists, (33 agonists (e.g. 1-(4-chloro-3-methanesulfonylmethylphenyl)-2-[2-(2,3-dimethyl-1 H-indol-6-yloxy)ethylamino]ethanol;
hydrochloride (WO 01/83451 )), MSH (melanocyte-stimulating hormone) agonists, CCK-A
agonists (e.g. { 2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)thiazol-2-o ylcarbamoyl]-5,7-dimethylindol-1-yl}acetic acid trifluoroacetic acid salt (WO 99/15525));
serotonin reuptake inhibitors (e.g. dexfenfluramines), mixed serotoninergic and noradrenergic compounds (e.g. WO 00/71549), 5HT agonists e.g. 1-(3-ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO 01/09111), BR53 agonists, galanin antagonists, ghrelin antagonists, MCH antagonists, mGluRS antagonists, opioid antagonists, growth hormone (e.g. human growth hormone), growth hormone-releasing compounds (6-benzyloxy-1-(2-diisopropylaminoethylcarbamoyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (WO 01/85695)), CNTF, CNTF derivatives (e.g. Axokine), TRH
agonists (see, for example, EP 0 462 884), uncoupling protein 2 or 3 modulators, leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C.; Rozhavskaya-Arena, Marina;
Grasso, Patricia. Leptin agonists as a potential approach to the treatment of obesity.
Drugs of the Future (2001), 26(9), 873-881), DA agonists (e.g. bromocriptine, Doprexin), lipase/amylase inhibitors (e.g. WO 00/40569), PPAR modulators (e.g. WO
00/78312), RXR modulators or TR-~3 agonists.
In one embodiment of the invention, the further active ingredient is leptin.
In one embodiment, the further active ingredient is dexamphetamine, amphetamine, mazindole or phentermine.
In one embodiment, the compounds of the formula I are administered in combination with medicaments having effects on the coronary circulation and the vascular system, such as, for example, ACE inhibitors (e.g.
ramipril), medicaments which act on the angiotensin-renin system, calcium antagonists, beta Mockers etc.
In one embodiment, the compounds of the formula I are administered in combination with medicaments having an antiinflammatory effect.
In one embodiment, the compounds of the formula I are administered in combination with medicaments which are employed for cancer therapy and cancer prevention.
It will be appreciated that every suitable combination of the compounds of the invention 5 with one or more of the aforementioned compounds and optionally one or more other pharmacologically active substances is to be regarded as covered by the scope of protection of the present invention.
In two articles which appeared simultaneously in Nature (Nature 400, 261-264, 1999;
Nature 400, 265-269, 1999), a highly specific receptor for melanine concentrating hormone o (MCH) was described separately by two research groups. MCH assumes important Functions in controlling food intake. Compounds acting on the MCH receptor therefore have an anorectic effect and are suitable for the treatment of obesity.
Testing for an anorectic effect of the compounds of the invention of the formula I was therefore carried out as follows.
Functional measurements to find IC50 values The cloning of the cDNA for the human MCH receptor, preparation of a recombinant HEK293 cell line which expresses the human MCH receptor, and functional measurements 2o with the recombinant cell line took place in analogy to the description by Audinot et al. (J.
Biol. Chem. 276, 13 554-13 562, 2001). A difference from the reference was, however, the use of the plasmid pEAK8 from EDGE Biosystems (USA) to construct the expression vector. The host used for the transfection was a transformed HEK cell line named "PEAK
Stable Cells" (likewise from EDGE Biosystems). The functional measurements of the 25 cellular calcium flux after addition of agonist (MCH) in the presence of ligand of the invention took place with the aid of the FLIPR apparatus from Molecular Devices (USA) using the protocols of the apparatus manufacturer.
Biological activity testing The IC50 values measured for exemplary compounds 33, 96 and 97 under the o aforementioned conditions were of the order of from 0.01 to 10 ~,M.
Genera( explanations a) Mode of drawing the structural formulae Only non-H atoms are depicted for clarity in the structural formulae of the given examples.
Carbon atoms are not written out as "C".
b) Salt forms Many of the compounds of the invention are bases and can form salts with appropriately strong acids. In particular, after purification of the compounds by HPLC
chromatography o using a trifluoroacetic acid-containing mobile phase they may be in the form of hydrotrifluoroacetates. These can be converted into the free bases shown by simple treatment of a solution of the salts for example with sodium carbonate solution.
c) Units of the characterizing data .5 The unit of the stated molecular weights is "g/mol". Peaks observed in the mass spectrum are indicated as integral quotient of the molar molecular ion mass and the charge of the molecular ion (mlz).
Abbreviations Unless indicated otherwise, the abbreviations in the examples below have the following meaning:
NaBH3CN = sodium cyanoborohydride DMF = N,N-dimethylformamide EDC = 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide THF = tetrahydrofuran DMSO = dimethyl sulfoxide HOBt = 1-hydroxybenzotriazole HOAt = 1-hydroxy-7-azabenzotriazole 3o HCl = hydrochloric acid HPLC = high performance liquid chromatography PyBOP = benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate TOTU - O[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium tetratluoroborate eq = equivalents Example 1 ( 1- { 4-[5-(4-Butoxyphenyl )-[ 1,3,4]oxadiazol-2-yl] phenyl } pyrrol idin-3-yl)dimethylamine O N
W O N
v/
N-N
Method A
to A mixture of 4-(3-dimethylaminopyrrolidin-1-yl)benzohydrazide (100 mg), 4-butoxy benzoic acid (78 mg), 2-chloro-1,3-dimethyl-2-imidazolium hexafluorophosphate (112 mg), N,N-diisopropylethylamine (0.14 ml) and dichloromethane (5 ml) was stirred for 12 hours. Volatiles were removed, and the residue was purified by preparative HPLC. The product with the molecular weight of 406.53 (C24H30N402) was obtained in this way;
I5 MS (ESI): 407 (M+H+).
4-(3-Dimethylaminopyrrolidin-1-yl)benzohydrazide A mixture of ethyl 4-(3-dimethylaminopyrrolidin-1-yl)benzoate (2.0 g), hydrazine hydrate (3.8 g) and ethanol (7 ml) was boiled under reflux for 15 hours. After cooling to 5°C, the 2o resulting precipitate was filtered off with suction. The product with the molecular weight of 248.33 (C 13H20N40) was obtained in this way; MS (ESn: 249 (M+H+).
Ethyl 4-(3-dimethylaminopyrrolidin-1-yl)benzoate A mixture of ethyl 4-fluorobenzoate (4.47 g), dimethylpyrrolidin-3-ylamine (3.04 g), 25 potassium carbonate (3.68 g) and dimethyl sulfoxide (20 ml) was heated at 130°C for 7 hours. After cooling, the mixture was diluted with water and extracted with methyl tert butyl ether. The organic phase was washed with water, dried over magnesium sulfate, filtered and concentrated. The product with the molecular weight of 262.35 (C15H22N2O2) was obtained in this way; MS (ESI): 263 (M+H+).
Example 2 Dimethyl-( 1-{ 4-[5-(2-phenoxyethylsulfanylmethyl)-[ 1,3,4]oxadiazol-2-yl]phenyl } -pyrrolidin-3-yl)amine N
o~s o _ NJ
i ~, / N_N
S
4-(3-Dimethylaminopyrrolidin-1-yl)benzohydrazide was reacted with (2-phenoxy-ethylsulfanyl)acetic acid by Method A. The product with the molecular weight of 424.57 (C23H28N402S) was obtained in this way; MS (ESI): 425 (M+H+).
Example 3 Dimethyl-( 1- { 4-[5-(4-phenoxyphenyl) ( 1,3,4]oxadiazol-2-yl]phenyl }
pyrrolidin-3-yl)amine Method B
A mixture of N'-[4-(3-dimethylaminopyrrolidin-1-yl)benzoyl]-4-phenoxybenzohydrazide (178 mg), methoxycarbonylsulfamoyltriethylammonium hydroxide (Burgess' reagent) (96 2o mg) and 5 ml of toluene was stirred at 60°C for 1 h. After the reaction was complete, the reaction mixture was filtered, and the filtrate was washed twice with ethyl acetate. The combined organic phases were subsequently washed with 5% strength sodium carbonate solution and then dried over Chromabond XTR. Volatiles were removed and the residue was purified by preparative HPLC. The product with the molecular weight of 426.21 (C26H26N4O2) was obtained in this way; MS (ESI): 427.21 (M+H+).
N'-[4-(3-Dimethylaminopyrrolidin-1-yl)benzoyl)-4-phenoxybenzohydrazide A mixture of 4-(3-dimethylaminopyrrolidin-1-yl)benzohydrazide (100 mg), 4-phenoxybenzoic acid (77.5 mg), 1-propanephosphonic anhydride 50% in dichloromethane (256 mg), N,N-diisopropylethylamine (0.208 ml) and DMF (3 ml) was stirred at room temperature for 72 h. The reaction mixture was then filtered, washed twice with ethyl acetate and shaken with O.SN NaOH. Volatiles were removed and the residue m was purified by preparative HPLC. The product with the molecular weight of 444.54 was obtained in this way; MS (ESI): 445.24 (M+H+).
4-(3-Dimethylaminopyrrolidin-1-yl)benzohydrazide was prepared as described in method A, with 1 eq of Burgess' reagent being added once again in some cases after heating for 1 h ~5 in the cyclization step, and then heating at 60°C being continued for 1 hour.
Compounds 4-93 in table 1 were synthesized by method B.
Ex Structure ~ ~ v Molecu4ar formula ~ MW MW
', ~ ~~~ ~~
calc. measured C27H28N402 440.22441.24 -~.
~- y ~~y- ~ J .
~
', ~ C26H34N402 434.27435 28 .
_ I, _ . ..
C27H28N402 440.22441.27 ' I ;l r _ ,..
__, ~. .f! /
,"
!J N
~'~~ G26H30N402 430.24431.27 ir'\; ~ r.' , i ~l \
r;~~ , N . r;
',,__ C27H34N402 446.27447 27 I
;,.,;,,N.,', _, y., ~
g '~__, C27H32N402 444.25445.26 o.
II '~~ ~ 1~N-N
C22H26N40 362.21363.22 ~--'u N n.
11 C23H26N403 406.20407 22 ~7-- ~
_ , r' I
i ~ C22H23N502 389 390.16 12 ' 19 N_ ,,ri_ o ;;:
~
_ , r' I
i ~ C22H23N502 389 390.16 12 ' 19 N_ ,,ri_ o ;;:
~
13 'y _ C27H28N402 ~ 440.22441.23 i __ _;i 'W . ,:
N-N
N-N
14 N_ C28H30N4C~3 ~ 470.23471.21 I
rd.
~~~ _.
~y '.
I ..Y
,~, i i ~__i' _ "
~
j 'N C28H30N402 454.24455.25 r ;~. : J_ _ y ...
I
1 ;,. _ i 16 ~ ~ , C26H26N402 426.21427 ~_ .
N. ; - I
i' ~ i , , _ _ _ _ ~
_ _ _ 17 ~_ C27H28N402 440.22441.23 O i , I
u_ i1:, _ I
___ ~ -8 C27H28N40 425.231 425.24 " ...I I
19 C27H26N402 438.21439.28 ,, ;
a \ N. ..
_,:
20 C24H23CIN402 434.15436.02 ..
N. :~
~i i ~I' ~ " N N
i 21 C26H32N40 416.26417.36 iV
:.~.. N ,, ,._ , _ ..
.
-, , ., ..
NN
22 ~ C24H30N4O3 422.23424.02 ' i , - '';', ;1 n: _ rJ
23 C27H28N4O2 440.22441.27 _.
'' ;' a J._, ' ;, N-ni ' ~ ~
24 ' G22H26N403 394.20395.21 ~,~-L. : ~. o i '~a u"
.V--N
25 N_ C28H30N4O3 470.23471.25 _. , .. -, ;
26 ';._- C29H29N5O2 479.23480.39 ,\ : _ 27 C22H23F3N4O3 448.17449.22 ;, a , _ ' ~~N -N
rJ- . .
_N, -O~~
c .
. .
_ N_u s' 29 '~,_- C25H25CIN4O3S2 528.11530,08 _ :.. ~ o !
30 C25H25CIN4O2 448.17449.22 I ' _.
' -,'.
-.., ~
i- ,'~. ;., , ,,, r; N
~ 'rJ G25H38N40 ~ 410.31411.32 __ w-n i 32 '~_ C23H28N402 392.22393.24 f '' .
l l N _. ~,j --33 , 24H30N402...._._..__.._.._____.______406.24407 N-_ .
-..~
c, ~~o..=. " ".
__-.__.___ ......-__.- I
34 C23H28N403S 440.19441.20 I
,' _ I
n_ ,.' I :, r.
'e\
J
35 r,; C26H29BrN60 520.16521.16 ', I
_ ~-1. I
rJ j ,v_ ,.: , , ; _.
:;r- -!.., l~r--;u ~
36 ' C25H27N502 429.22430 N .
37 C24H27BrN602 510.14512.13 .; ~ , o. ~' 38 ~ C26H32N403 448 449 rJ _ . .
_ ri.
_ i1 _ ~~~ _ i J' 3g '~,, C25H23F3N402 468.18469.21 I
40 ' I C25H25N5O4 ~ ~ 459.19460.21 N_ -, -=
~' ' ',;
;r ->,y o' i N ;;
41 '.1__ C25H22CIF3N402 502.14503.18 i i ' ~
42 ~ C25H30N4O3 434.23435.24 h, ,_ .\ _.1 _ , .,.;
.t O_ .: -r I
N N
i. y 43 C25H29N50S 447 448.21 N-:, ~-=;;~..N. ,:
' : N._.:w~ O, .:~
:-I
~~
44 'N_ C28H28N60 ' ~ 464.23465.27 ,~ :, _~
~
_-;,~
'N~
~~
~
~' =' _ N
_..';
:
_..
I
-_ 45 ' C32H33N50S 535.24536.25 ~
-' a ;
;N Iu ,.... ' 46 C26H26N40 410.21411.23 N __ N_ ~ i ~.
I
a -N
I ~ C28H30N40 438.24439.27 N
' , ~zT- ~.
o -/ .=
_ ..~
i 48 C29H29N50 463.24464 N__ .
-s?, ri_ , i l V
_. ~' _,. v .._:, n _.~ .:;-49 ~ '~ j C25H30N4O2 418.24419.24 I ~ I
i; ~ I
_., .: ~~; :- 1 ';~_h i _ 50~~ C25H29N502 w_._..._.__......___..__- 431.23432.25 N
i ' '. '-~ ' ' i 51 ~', C24H30N40S 422.21423.23 ,.. I
--< .I_,; i 'i _ _ _ ,iJ_ 4,i a w . i ' ~,..t..._ 52 '~y ,- ; C24H29FN40 408.23409.24 i i ' ' '.
~1, i>-fJ ,y i C22H26N4O2S 410.18411.21 I N j I
. I
I ' i~ V
'I
I
j c I
.
h -h 54 C25H30N40 402.24403.26 ~, 'l ' _, _- _"
_ _.__.__._ 55 ,~J._ C28H30N402 454.24455.25 I .; .. N
I
I J
56 'y C28H29N5O2 467.23468.27 I
I
r~ ' I
57 '~ C23H27CIN40S 442.16~ 443,17 I . N' .
o. , i , ,yy ;;' ~
;. .: , 58 ~~ C26H26N4O3S 474.17475.19 rJ~..
ii s IJ tJ
59 N C28H29N5O2 467.27 468.27 N. ,'' ~ l r ''~
NN
60 'N-- C24H26N60 414.22 415.23 o ,i w..
N_N
;N _N I
61 ~ 'N_ C24H25N5O5 431.18 432,19 v '.
o ;~'r y= --N -r:
62 '~,C27H25N50 435.21 436.23 r;
t .__ N ;, L "
r_._.,, ., ', , ~:, ..
;;.. N
63 "_ C26H24N4O2 ~ 424.19 425,22 <u. ' ;,v:J ',,-,,'° ,>-w -r:~ _v 64 ~,~ G24H23FN40S 434.16 435.19 ,,. o - I
,:' , ._ _,y "' .. ' i N_N
65 '.,_ C25H29FN4O2 436.23 437.26 ,1 , _, v-N
66 ~ '~N' C27H27FN4O 442.22 443.24 N. /
'=:7-J J; , 67 ~ ~~,_ C27H31 FN4O2 ' ' 462.24 464.36 i o a I
68 ;, _ ~ C25H25CIN4O3 - -454.16 465.18 ~CW 1 _. ;_ h, .
__ _____- _ _.
C24H24N403 Y ~ 416.19417.20 N, , :...
,. '-N,.-,_ J: ', ' / _ .. \.
1.
N-R
i N - I C23H23F3N4O2 444.18445.20 _ ;
~~ /; ' N N
~
71 ~~- C23H23N50 385.19386.22 N -.
_I -72 '~'""' C28H29FN40 456.23457.25 'N
._;, ~ ~~ C26H29FN402 448.23449.24 F
=
.
,,:
! f . i .
-.
i i:
74 ~ C22H23F3N40S 448.15449,16 ~' ' ---,: I
-h-N
!
75 '~y- C24H24CIN50S 465.14466.15 -...
-~;
N C25H25CIN4O2 448.17449.20 ;,:
=' 'r N
.
,I , -.
<< , _:f;v:' ~ ,~
. -...-v 77 N_ C24H36N40 396.29397.31 l _..i o -:
78 C29H30N4O2 466.24467.27 i . _ i _ '' . I
_ _ ,...., __ .____.__ _._____. y'-- C25H32N403 436.25 437.27 -Y
v ~,-., .~_ ,.. ,, :
.. . ,, ':;~ ~~
_ 80 ~,v _ C24H25CiN6C --y-_..__.,_..__._.__ 44$.18 449.2] - _ _ N,~:' I
r!_ N:
CI' ~, __81 _____ ._-. N._- C27H25F3N402 494.19 495.22 l ' a r w, i: l N.N i 82 ~l C26H25FN40 428.20 429.23 r.,;,: I
i I
~- I
83 '_ , _..._______..- ,J._ C23H25F3N40 430.20 431.2_0 ~,-~' ,-il __. , rj u- rj , 84 ~- C25H25CIN402S 480.14 481.17 -N
85 ~ ~N-- C25H22BrF3N4C?2 546.09 547,11 N.y i ;. -.. ~N_rJ
1..
Br 86 C24H22C1N504 479.14 480.15 I
J-,v i 'w rJ_ :' LI
87 ~ ,fC27H28N40 424.23 425.24 _ , r, rJ
___ i_ 88 C25H32N402 420.25 421.26 a , 8~ ~JC27H28N40 V- T 424.23 ~ 425.24 rd, ,\f i i w ;_ C23H25F3N402 446.19 447.19 F
F l 1-~. .,-. ~,~-'~1 '~ry C23H25N50S 419.18 420.11 N~,.
.- .O. ~ Y
\-;r__. v't In N-N
C26H28N402 428.22 429.24 ~f I~ ~C.
-_.-._-_-Example 93 Dimethyl-( I -{ 4-[5-(4-phenoxybutyl)[ 1,3,4]oxadiazol-2-yl]phenyl }pyrrolidin-3-yl)amine S
,v,a .... ~i PyBOP (25.2 mg) was added to a mixture of 4-phenoxybutanohydrazide (10 mg), 4-(3-dimethylaminopyrrolidin-1-yl)benzoic acid (12.1 mg), HOAt (6.6 mg), triethylamine (13.5 t o ~ l) and DMF (0.15 ml) at 0°C. The mixture was stirred at 0°C for 10 min and then at room temperature for 3 h. Ethyl acetate and water were then added to the reaction solution. The organic phase was subsequently washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water and dried over sodium sulfate, and the solvent was removed in vacuo.
The residue was then taken up in THF (0.4 ml), and EDC (6.1 mg) and triethylamine (5.5 ~ul) were added, and the mixture was stirred at 50°C for 16 h. Ethyl acetate and water were then added to the reaction solution. The organic phase subsequently washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water and dried over sodium sulfate, and the solvent removed in vacuo. The residue was purified by preparative HPLC. The product with the molecular weight of 406.53 (C24H30N402) was 5 obtained in this way; MS (ESI): 407.15 (M+H+).
4-Phenoxybutanohydrazide A mixture of phenol (100 mg), ethyl 5-bromovalerate (222.2 mg), cesium carbonate (693 mg) and DMF (1.6 ml) was stirred at room temperature for 12 h. Ethyl acetate and water o were then added to the reaction solution, and the aqueous phase was adjusted to pH 6 with 2N HCl solution. The aqueous phase extracted twice more with ethyl acetate.
The combined organic phases were then washed with water and dried over sodium sulfate, and the solvent was removed in vacuo.
The product obtained in this way was taken up in abs. ethanol (0.5 ml), 37.3 ~,1 of ~ 5 hydrazine hydrate were added, and the mixture was heated under rellux for 12 h. Ethyl acetate and water were then added to the reaction solution, and the aqueous phase was neutralized with 2N HCl solution. The aqueous phase was extracted twice with ethyl acetate. The combined organic phases were then washed with water and dried over sodium sulfate, and the solvent was removed in vacuo. The residue was purified by preparative 2o HPLC. The product with the molecular weight of 208.11 (C 11 H 16CIN202) was obtained in this way; MS (ESI): 209.1 (M+H+).
4-(3-Dimethylaminopyrrolidin-1-yl)benzoic acid A 1M sodium cyanoborohydride solution (1.32 ml) was added to a mixture of methyl 4 25 (3-aminopyrrolidin-1-yl)benzoate (300 mg), acetic acid (81 ~,l), formaldehyde (0.113 ml) and THF (3 ml). The reaction was stirred at room temperature for 1 h, then the solvent was removed in vacuo, and the residue was taken up again in ethyl acetate/water.
The organic phase was washed with water and dried over sodium sulfate, and the solvent was removed in vacuo.
3o The product obtained in this way was dissolved in a THF/water mixture ( 1:1 ) (3.1 ml), and potassium hydroxide (66.2 mg) was added. The reaction was heated at 70°C for 4 h. Ethyl acetate and water were then added to the reaction solution, and the aqueous phase was acidified with 2N HCl solution. The aqueous phase was extracted twice with ethyl acetate.
'fhe combined organic phases were then washed with water and dried over sodium sulfate, and the solvent was removed in vacuo. The product with the molecular weight of 234.17 (C ( 3H 18N2O2) was obtained in this way; MS (ESI): 235.10 (M+H+).
Methyl4-(3-aminopyrrolidin-1-yl)benzoate A mixture of 3-(tert-butoxycarbonylamino)pyrrolidine (1 g), methyl 4-fluorobenzoate (0.83 ml), cesium carbonate ( 1.7 g) and DMF ( 10 ml) was heated at 100°C for 12 h. Ethyl acetate and water were then added to the reaction solution. The organic phase was then washed twice with water and dried over sodium sulfate, and the solvent was removed in I o vacuo.
The product obtained in this way was dissolved in methylene chloride ( 12 ml), trilluoroacetic acid (6 ml) was added, and the mixture was stirred at room temperature for 90 min. The solvent was removed in vacuo, and the residue was purified by preparative HPLC. The product with the molecular weight of 220.12 (C12H16N2O2) was obtained in 1S this way; MS (ESI): 221.10 (M+H+).
Example 94 ( 1- { 4-[5-(4-Butoxyphenyl)-[ 1,3,4]thiadiazol-2-yl]phenyl } pyrrolidin-3-yl)dimethylamine p N-, ~ NJ
n ~ v N'N
A mixture of N'-(4-butoxybenzoyl)-4-(3-dimethylaminopyrrolidin-1-yl)benzohydrazide ( 100 mg), Lawesson's reagent ( 191 mg) and toluene (5 ml) was boiled under reflux for 4 hours. Volatiles were removed, and the residue was purified by preparative HPLC. The product with the molecular weight of 422.60 (C24H30N40S) was obtained in this way;
MS (ESI): 423 (M+H+).
N'-(4-Butoxybenzoyl)-4-(3-dimethylaminopyrrolidin-1-yl)benzohydrazide A mixture of 4-butoxybenzoic acid ( 156 mg) and DMF ( 10 ml) was mixed with TOTU
(264 mg) and N,N-diisopropylethylamine (104 mg). After 10 minutes, 4-(3-dimcthylaminopyrrolidin-1-yl)benzohydrazide (200 mg) was added. After one hour, the mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with water, dried over magnesium sulfate, filtered and concentrated.
The product with the molecular weight of 424.55 (C24H32N4O3) was obtained in this way; MS
(ESI):
425 (M+H+).
Example 95 ((R)-3- { 4-[5-(4-Chlorophenoxymethyl) [ 1,2,4]oxadiazol-3-yl]phenyl }
cyclopentyl)-methylamine PyBOP (558 mg), HOAt (146 mg) and triethylamine (0.299 ml) were added to a mixture of tert-butyl {(R)-1-[4-(N-hydroxycarbamimidoyl)phenyl]pyrrolidin-3-yl}methylcarbamate ~ 5 (358.5 mg), (4-chlorophenoxy)acetic acid (200 mg) and 3 ml of DMF at 0°C, and the reaction mixture was stirred at this temperature for 10 min. It was then stirred at room temperature for 2 h and ethyl acetate and water were added to the reaction solution. The organic phase was then washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water, dried over sodium sulfate and filtered, and the 20 solvent was removed in vacuo.
The residue was then taken up in 10 ml of THF, and EDC (160 mg) and triethylamine (0.144 ml) were added, and the mixture was stirred at 50°C for 16 h.
Ethyl acetate and water were then added to the reaction solution. The organic phase was then washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and 25 water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo.
The crude product was taken up in methylene chloride (7.2 ml), and trifluoroacetic acid ( 1.8 ml) was added. The reaction was stirred at room temperature for 5 h and then the solvent was removed in vacuo. The residue was purified by preparative HPLC.
The product with the molecular weight of 384.14 (C20H21C1N402) was obtained in this way;
MS(ESI): 385.26 (M+H+).
(4-Chlorophenoxy)acetic acid A mixture of 4-chlorophenol (500 mg), methyl bromoacetate (0.368 ml), cesium carbonate ( 1.9 g) and 5 ml of acetone was stirred at room temperature for 12 h. Ethyl acetate and water were then added to the reaction solution, and the organic phase was washed twice with water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo.
The crude product was dissolved in a 1:l THF/water mixture (10 ml), and potassium o hydroxide (417 mg) was added. The reaction was stirred at room temperature for 12 h.
Ethyl acetate and water were then added to the reaction solution, and the aqueous phase was adjusted to pH 2 and extracted several times with ethyl acetate. The combined organic phases were washed twice with water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo. The product with the molecular weight of 186.6 ~5 (C8H7C103) was obtained in this way; MS (ESI): 227.0 (M+CH3CN).
{(R)-1-[4-(N-Hydroxycarbamimidoyl)phenyl]pyrrolidin-3-yl}methylcarbamic acid tort-butyl ester Sodium hydride (253.4 mg) was added in portions to a solution of tent-butyl [(R)-1-(4-2o cyanophenyl)pyrrolidin-3-yl]carbamate ( 1.06 g) in 12 ml of DMF at 0°C. After removal of the ice bath, methyl iodide (0.498 ml) was added dropwise to the reaction solution, which was stirred at room temperature for 4 h. Ethyl acetate and water were then added to the reaction solution, and the organic phase was washed twice with water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo.
25 The crude product was dissolved in abs. ethanol (12 ml), and hydroxylamine (0.687 ml) was added. The reaction solution was heated under reflux for 12 h. Ethyl acetate and water were then added to the reaction solution, and the organic phase was washed twice with water and dried over sodium sulfate, and the solvent was removed in vacuo. The residue was purified by preparative HPLC. The product with the molecular weight of 334.42 30 (C17H26N403) was obtained in this way; MS (ESI): 335.20 (M+H+).
[(R)-1-(4-Cyanophenyl)pyrrolidin-3-yl]carbamic acid A mixture of (3R)-(+)-(tort-butoxycarbonylaminopyrrolidine (1.0 g), p-fluorobenzonitrile (650 mg), cesium carbonate ( 1.75 g) and 5 ml of DMF was stirred at 50°C for 12 h. Ethyl acetate and water were then added to the reaction solution, and the organic phase was washed twice with water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo. The residue was purified by preparative HPLC. The product with the molecular weight of 287.36 (C16H21N302) was obtained in this way; M5 (ESI):
288.20 (M+H+).
Example 96 lo ((R)-1-{4-[5-(4-Chlorobenzyloxymethyl)[1,2,4]oxadiazol-3-yl]phenyl}pyrrolidin-3-yl)methylamine ~':l ~..,yr ..., .- .,._S ~. ' ~Y_.~ ~.' //
~~ti~
I5 A solution of (4-chlorobenzyloxy)aeetic acid (70 mg) in thionyl chloride ( 1 ml) was stirred at room temperature for 1 h, and then toluene was added and the solvent was stripped off in vacuo. This procedure was repeated twice more. The acid chloride was then taken up in methylene chloride (1.4 ml), {(R)-1-[4-(N-hydroxycarbamimidoyl)phenyl]pyrrolidin-3-yl } methylcarbamic acid tent-butyl ester ( 116.7 mg), triethylamine (0.05 ml) were added, 20 and the mixture was stirred at room temperature for 12 h. The volatile components were removed in vacuo, and the residue was taken up in ethyl acetatelwater. The organic phase was washed twice with water and dried over sodium sulfate, and the solvent was removed in vacuo. The residue was purified by preparative HPLC. The product with the molecular weight of 398.15 (C21H23C1N402) was obtained in this way; MS (ESI): 399.41 (M+H+).
z5 (4-Chlorobenzyloxy)acetic acid was prepared in analogy to (4-chlorophenoxy)acetic acid using 4-chlorobenzyl bromide as precursor. The product with the molecular weight of 200.62 (C9H9C103) was obtained in this way; MS (ESI): 222.95 (M+Na-H).
3o Example 97 4-Ch Toro-N- { 3-[4-(3-dimethylaminopyrrolidin- I -yl)phenyl] [
1,2,4]oxadiazol-5-ylmethyl } benzamide Method C
TOTU (51.4 mg) and N,N-diisopropylethylamine (0.05 ml) were added to a mixture of { 1-[4-(5-aminomethyl[1,2,4]oxadiazol-3-yl)phenyl]pyrrolidin-3-yl}dimethylamine (75.3 mg), 4-chlorobenzoic acid (23.5 mg) and DMF (0.96 ml), and the solution was stirred at room o temperature for 12 h. The crude product was purified by preparative HPLC
(RP) and then purified again by chromatography on silica gel (dichloromethane/MeOH/AcOH/H20 =
90/10/1/1). The product with the molecular weight of 425.16 (C22H24C1N5O2) was obtained in this way; MS (ESI): 426.17 (M+H).
~5 { 1-[4-(5-Aminomethyl[1,2,4]oxadiazol-3-yl)phenyl]pyrrolidin-3-yl}dimethylamine PyBOP (546.4 mg), HOAt ( 136.1 mg) and triethylamine (0.279 ml) were added to a mixture of 4-(3-dimethylaminopyrrolidin-1-yl)-N-hydroxybenzamidine (248.3 mg), tert-butoxycarbonylaminoacetic acid ( 175.2 mg) and DMF (2.8 ml) at 0°C and the mixture was stirred at this temperature for 10 min. It was subsequently stirred at room temperature for 2 2o h and then ethyl acetate and water were added to the reaction solution. The organic phase then washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water, dried over sodium sulfate and filtered, and the solvent removed in vacuo. The residue was then taken up in 6.2 ml of THF, and EDC ( 105 mg) and triethylamine (0.09 ml) were added, and the mixture was stirred at 50°C for 16 h. Ethyl 25 acetate and water were then added to the reaction solution. The organic phase then washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water and dried over sodium sulfate, and the solvent removed in vacuo.
The crude product was taken up in methylene chloride (9.6 ml), and trifluoroacetic acid (2.3 ml) was added. The reaction was stirred at room temperature for 5 h and then the 3o solvent was removed in vacuo. The residue was purified by preparative HPLC.
The product with the molecular weight of 287.37 (C 15H21 N50) was obtained in this way; MS
(ESI): 288.05 (M+H+).
4-(3-Dimethylaminopyrrolidin-1-yl)-N-hydroxybenzamidine A mixture of 3-(dimethylamino)pyrrolidine (1.l g), p-fluorobenzonitrile (1.2 g), potassium carbonate (2.8 g) and acetonitrile (15 ml) was stirred at 80°C for 12 h. The reaction solution was then filtered, and the precipitate was washed with acetonitrile, the solvent was removed in vacuo, and the residue was taken up again in ethyl acetate. The ethyl acetate phase was washed twice with water and then dried over sodium sulfate, and the solvent ~ o was removed in vacuo.
The product obtained in this way was dissolved in abs. ethanol (48.7 ml), and hydroxylamine ( 1.4 ml) was added to the solution. The reaction mixture was heated under reflux for 12 h. The precipitate obtained after cooling the reaction solution was filtered off and washed with a little ethanol.
~ 5 The product with the molecular weight of 248.33 (C 13H20N40) was obtained in this way;
MS (ESI): 249.15 (M+H+).
Examples 98-110 in table 2 were synthesized by method C.
EX.-....._._-Structure___.-_Molecularformula__ -. ~__ -._ -..M~
__.
.-...M~___._ .__...
i j talc.
measured _ ! ,.. _..._. __..~Y ,?.~ ._.,~' __ _.' J y.r l l ' ~ - _..___._ ' I
_ i _...... . _....,___ ._.. _ _.. , J r .- , , ', . ' .' 'J ,'" .
a y .
~
[
~
JO.
... . ! J PI='::'~' ', ~'~ ';
>:~
i '4.2~
t - , ____-.._, _. _, . . . _ii-__ .
r. _ s ._ :i"~~ -. ..
' . ., ___. i9i - __. , i -_. _._ __ -;__ _ ~
-.-._ , y ' ~ I.-;.; r ~ _ ~ r _..._.._ _ . ___ _ . _ . .. .. - .
.~_~ . y;=? ? i=; ',j ~ '' i L -...._~ _ _ _ ~
r n ,~
..
__...
--~--__.. _~. ~y'a!2i1 ~~V ; ~
__ _ _-_ , ' _-I t~-_~_'_ __ .,____ .-._____-. ~_ ' ~ \~Vr ~'~3vi~~~v~~ ~
i~a~'- ' ~ ''' " ., t .__ _ ~'yrl::=;f,l;>r.,- ,'J' _ ':J
i Y~J
_ _:
i r. y .,_._._i - __~_., -_.._~- ~
~ ~
\I~J~ ~o a X21;-~:,Cl 7 I .
~
i ' ~. _~ I ~.~1~'24~~60z -._._._i _. 392.=0 353.28 ' k i ~~~
ii '~ _" .: ~2sN;5~r;50~ [ .JV~.._J
- ~._~ ~ ~H~.~
i i -_ __.. _ I
f ~f ..- -- ~J: II~~a\yv2 ~
_ ' i - _ _ , .26 _-. 4 _ :2 '~~~
,, I
Example 111 [1-(4-{ 5-[(4-Chlorobenzylamino)methyl][ 1,2,4]oxadiazol-3-yl }phenyl)pyrrolidin-3-yl]-dimethylamine Method D
Polymer-bound sodium cyanoborohydride (5 eq) was added to a mixture of { 1-[4-(5-aminomethyl[1,2,4]oxadiazol-3-yl)phenyl]pyrrolidin-3-yl}dimethylamine (40.1 mg), 4-chlorobenzaldehyde (42.2 mg), acetic acid ( 17.2 ~ l), triethylamine (27.9 ~.l) and THF
( 1 ml), and the reaction mixture was stirred at room temperature for 12 h.
The polymer-bound reagent was filtered off and the solvent was removed in vacuo. The residue was m purified by preparative HPLC. The product with tire molecular weight of 411.18 (C22H26C1N50) was obtained in this way; MS (ESI): 412.23 (M+H+).
Example 112 [1-(4-{ 5-[(4-Methoxybenzylamino)methyl][1,2,4]oxadiazol-3-yl }phenyl)pyrrolidin-3-y]dimethylam.ine :: -~ ._ ~ '~s ~ ~_ - wf ~ '~_"~ f~'i --_ w _~ ~ .. ,,.~
I ' J __ ~,'f~ ' v.
{ 1-[4-(5-aminomethyl[1,2,4]oxadiazol-3-yl)phenyl)pyrrolidin-3-yl}dimethylamine was 2o reacted with p-anisaldehyde by method D. The product with the molecular weight of 407.23 (C23H29N502) was obtained in this way; MS (ESI): 408.30 (M+H+).
Example 113 ( 1-{4-[5-(4-Fluorobenzyloxymethyl)[ 1,2,4]oxadiazol-3-yl]phenyl }pyrrolidin-3-yl)dimethylamine 4-Fluorobenzyl bromide (18.9 mg) and potassium carbonate (27.6 mg) were added to a mixture of {3-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl][1,2,4]oxadiazol-5-yl}methanol (28.8 mg) and DMF (0.3 ml). The reaction mixture was stirred at 60°C
for 3 h, filtered and purified by preparative HPLC. The product with the molecular weight of 396.20 (C22H25FN4O2) was obtained in this way; MS (ES I): 397.27 (M+H+).
{ 3-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl] [ 1,2,4]oxadiazol-5-yl }
methanol PyBOP (546.4 mg), HOAt ( 136.1 mg) and triethylamine (0.139 ml) were added to a 0 mixture of 4-(3-dimethylaminopyrrolidin-1-yl)-N-hydroxybenzamidine (248.3 mg), benzyloxyacetic acid (0.143 ml) and DMF (3.0 ml) at 0°C, and the mixture was stirred at this temperature for 10 min. It was subsequently stirred at room temperature for 1 h, and then ethyl acetate and water were added to the reaction solution. The organic phase was then washed twice each with 10°70 strength citric acid solution, saturated sodium ~ 5 bicarbonate solution and water and dried over sodium sulfate, and the solvent was removed in vacuo.
The residue was then taken up in 3 ml of THF, and EDC ( 170.8 mg) and triethylamine (0.139 ml) were added, and the mixture was stirred at 80°C for 16 h.
Ethyl acetate and water were then added to the reaction solution. The organic phase was then washed twice 20 each with l0alo strength citric acid solution, saturated sodium bicarbonate solution and water and dried over sodium sulfate, and the solvent was removed in vacuo.
The residue was dissolved in methylene chloride (4.4 ml), and the solution was cooled to -78°C. At this temperature, a 1M boron trichloride solution (3 ml) was added. The reaction 25 was allowed to warm to room temperature overnight, and then ethyl acetate and water were added. The product with the molecular weight of 288.2 (C 15H20N4O2) was obtained in this way; MS (EST): 289.2 (M+H+).
7() The following examples could be synthesized analogously:
' ~
,_ .;_-~, _ _.. _.. ._._...~_...__..._..___ _ _;_.. _... i .____..._ _ ....__.._.__.. ._ __........_._.
' .. _ ,_ -, J ~ _:, _ ~ _ , W
_ a .. - _ -. , _ ::
:.._ . :. , . , __. ._.
_ ; r ""
_, ,. . , .- I,. ,, 1_ . ..
,__ ' 1, , _. ; . ' ' ; _.
_ _ ,,; __.,;
:.
-- _, , ,:-- _ .
-. -, _ ;::._ ....
; ,-_ , r , , , , ' l .
~;, ,~; ',, ~~
r II
I7, __ __ h ~
-j , ._ . ~ ,.::,'_._.,' ' 1...' ' ,_; _;. I, _ .
. ', , _ _f;;
~ _ , , . ': , ,,--:
i .-- , lI U ~.~
,: J,....
.. ~ - ,.
v :. ;,.__~- =. :;.. I
g ~'.ay I
'w v.J r I i . f-:, , , , ,. ., , ,, -_,.
. .
I - ,."=~~ '-' r. _.,, ,~., ~3 , _ f.:~._. _ J _-fJ . _ _.
' -i~
YJ
I y.j ~.5'O
/
~
_' I
_ -:.,'. -,.. . . 1~
~ ,-..: _ rn , r1 ., p a f~
- I i, J , II,_.
.- s~ f . - ~'-;,.,_ .- i ~ . , i ; : ~ ~
i-r:: .lei.
...,f , ri,,,-,, w .L....
:r;.
rd.
~~~ _.
~y '.
I ..Y
,~, i i ~__i' _ "
~
j 'N C28H30N402 454.24455.25 r ;~. : J_ _ y ...
I
1 ;,. _ i 16 ~ ~ , C26H26N402 426.21427 ~_ .
N. ; - I
i' ~ i , , _ _ _ _ ~
_ _ _ 17 ~_ C27H28N402 440.22441.23 O i , I
u_ i1:, _ I
___ ~ -8 C27H28N40 425.231 425.24 " ...I I
19 C27H26N402 438.21439.28 ,, ;
a \ N. ..
_,:
20 C24H23CIN402 434.15436.02 ..
N. :~
~i i ~I' ~ " N N
i 21 C26H32N40 416.26417.36 iV
:.~.. N ,, ,._ , _ ..
.
-, , ., ..
NN
22 ~ C24H30N4O3 422.23424.02 ' i , - '';', ;1 n: _ rJ
23 C27H28N4O2 440.22441.27 _.
'' ;' a J._, ' ;, N-ni ' ~ ~
24 ' G22H26N403 394.20395.21 ~,~-L. : ~. o i '~a u"
.V--N
25 N_ C28H30N4O3 470.23471.25 _. , .. -, ;
26 ';._- C29H29N5O2 479.23480.39 ,\ : _ 27 C22H23F3N4O3 448.17449.22 ;, a , _ ' ~~N -N
rJ- . .
_N, -O~~
c .
. .
_ N_u s' 29 '~,_- C25H25CIN4O3S2 528.11530,08 _ :.. ~ o !
30 C25H25CIN4O2 448.17449.22 I ' _.
' -,'.
-.., ~
i- ,'~. ;., , ,,, r; N
~ 'rJ G25H38N40 ~ 410.31411.32 __ w-n i 32 '~_ C23H28N402 392.22393.24 f '' .
l l N _. ~,j --33 , 24H30N402...._._..__.._.._____.______406.24407 N-_ .
-..~
c, ~~o..=. " ".
__-.__.___ ......-__.- I
34 C23H28N403S 440.19441.20 I
,' _ I
n_ ,.' I :, r.
'e\
J
35 r,; C26H29BrN60 520.16521.16 ', I
_ ~-1. I
rJ j ,v_ ,.: , , ; _.
:;r- -!.., l~r--;u ~
36 ' C25H27N502 429.22430 N .
37 C24H27BrN602 510.14512.13 .; ~ , o. ~' 38 ~ C26H32N403 448 449 rJ _ . .
_ ri.
_ i1 _ ~~~ _ i J' 3g '~,, C25H23F3N402 468.18469.21 I
40 ' I C25H25N5O4 ~ ~ 459.19460.21 N_ -, -=
~' ' ',;
;r ->,y o' i N ;;
41 '.1__ C25H22CIF3N402 502.14503.18 i i ' ~
42 ~ C25H30N4O3 434.23435.24 h, ,_ .\ _.1 _ , .,.;
.t O_ .: -r I
N N
i. y 43 C25H29N50S 447 448.21 N-:, ~-=;;~..N. ,:
' : N._.:w~ O, .:~
:-I
~~
44 'N_ C28H28N60 ' ~ 464.23465.27 ,~ :, _~
~
_-;,~
'N~
~~
~
~' =' _ N
_..';
:
_..
I
-_ 45 ' C32H33N50S 535.24536.25 ~
-' a ;
;N Iu ,.... ' 46 C26H26N40 410.21411.23 N __ N_ ~ i ~.
I
a -N
I ~ C28H30N40 438.24439.27 N
' , ~zT- ~.
o -/ .=
_ ..~
i 48 C29H29N50 463.24464 N__ .
-s?, ri_ , i l V
_. ~' _,. v .._:, n _.~ .:;-49 ~ '~ j C25H30N4O2 418.24419.24 I ~ I
i; ~ I
_., .: ~~; :- 1 ';~_h i _ 50~~ C25H29N502 w_._..._.__......___..__- 431.23432.25 N
i ' '. '-~ ' ' i 51 ~', C24H30N40S 422.21423.23 ,.. I
--< .I_,; i 'i _ _ _ ,iJ_ 4,i a w . i ' ~,..t..._ 52 '~y ,- ; C24H29FN40 408.23409.24 i i ' ' '.
~1, i>-fJ ,y i C22H26N4O2S 410.18411.21 I N j I
. I
I ' i~ V
'I
I
j c I
.
h -h 54 C25H30N40 402.24403.26 ~, 'l ' _, _- _"
_ _.__.__._ 55 ,~J._ C28H30N402 454.24455.25 I .; .. N
I
I J
56 'y C28H29N5O2 467.23468.27 I
I
r~ ' I
57 '~ C23H27CIN40S 442.16~ 443,17 I . N' .
o. , i , ,yy ;;' ~
;. .: , 58 ~~ C26H26N4O3S 474.17475.19 rJ~..
ii s IJ tJ
59 N C28H29N5O2 467.27 468.27 N. ,'' ~ l r ''~
NN
60 'N-- C24H26N60 414.22 415.23 o ,i w..
N_N
;N _N I
61 ~ 'N_ C24H25N5O5 431.18 432,19 v '.
o ;~'r y= --N -r:
62 '~,C27H25N50 435.21 436.23 r;
t .__ N ;, L "
r_._.,, ., ', , ~:, ..
;;.. N
63 "_ C26H24N4O2 ~ 424.19 425,22 <u. ' ;,v:J ',,-,,'° ,>-w -r:~ _v 64 ~,~ G24H23FN40S 434.16 435.19 ,,. o - I
,:' , ._ _,y "' .. ' i N_N
65 '.,_ C25H29FN4O2 436.23 437.26 ,1 , _, v-N
66 ~ '~N' C27H27FN4O 442.22 443.24 N. /
'=:7-J J; , 67 ~ ~~,_ C27H31 FN4O2 ' ' 462.24 464.36 i o a I
68 ;, _ ~ C25H25CIN4O3 - -454.16 465.18 ~CW 1 _. ;_ h, .
__ _____- _ _.
C24H24N403 Y ~ 416.19417.20 N, , :...
,. '-N,.-,_ J: ', ' / _ .. \.
1.
N-R
i N - I C23H23F3N4O2 444.18445.20 _ ;
~~ /; ' N N
~
71 ~~- C23H23N50 385.19386.22 N -.
_I -72 '~'""' C28H29FN40 456.23457.25 'N
._;, ~ ~~ C26H29FN402 448.23449.24 F
=
.
,,:
! f . i .
-.
i i:
74 ~ C22H23F3N40S 448.15449,16 ~' ' ---,: I
-h-N
!
75 '~y- C24H24CIN50S 465.14466.15 -...
-~;
N C25H25CIN4O2 448.17449.20 ;,:
=' 'r N
.
,I , -.
<< , _:f;v:' ~ ,~
. -...-v 77 N_ C24H36N40 396.29397.31 l _..i o -:
78 C29H30N4O2 466.24467.27 i . _ i _ '' . I
_ _ ,...., __ .____.__ _._____. y'-- C25H32N403 436.25 437.27 -Y
v ~,-., .~_ ,.. ,, :
.. . ,, ':;~ ~~
_ 80 ~,v _ C24H25CiN6C --y-_..__.,_..__._.__ 44$.18 449.2] - _ _ N,~:' I
r!_ N:
CI' ~, __81 _____ ._-. N._- C27H25F3N402 494.19 495.22 l ' a r w, i: l N.N i 82 ~l C26H25FN40 428.20 429.23 r.,;,: I
i I
~- I
83 '_ , _..._______..- ,J._ C23H25F3N40 430.20 431.2_0 ~,-~' ,-il __. , rj u- rj , 84 ~- C25H25CIN402S 480.14 481.17 -N
85 ~ ~N-- C25H22BrF3N4C?2 546.09 547,11 N.y i ;. -.. ~N_rJ
1..
Br 86 C24H22C1N504 479.14 480.15 I
J-,v i 'w rJ_ :' LI
87 ~ ,fC27H28N40 424.23 425.24 _ , r, rJ
___ i_ 88 C25H32N402 420.25 421.26 a , 8~ ~JC27H28N40 V- T 424.23 ~ 425.24 rd, ,\f i i w ;_ C23H25F3N402 446.19 447.19 F
F l 1-~. .,-. ~,~-'~1 '~ry C23H25N50S 419.18 420.11 N~,.
.- .O. ~ Y
\-;r__. v't In N-N
C26H28N402 428.22 429.24 ~f I~ ~C.
-_.-._-_-Example 93 Dimethyl-( I -{ 4-[5-(4-phenoxybutyl)[ 1,3,4]oxadiazol-2-yl]phenyl }pyrrolidin-3-yl)amine S
,v,a .... ~i PyBOP (25.2 mg) was added to a mixture of 4-phenoxybutanohydrazide (10 mg), 4-(3-dimethylaminopyrrolidin-1-yl)benzoic acid (12.1 mg), HOAt (6.6 mg), triethylamine (13.5 t o ~ l) and DMF (0.15 ml) at 0°C. The mixture was stirred at 0°C for 10 min and then at room temperature for 3 h. Ethyl acetate and water were then added to the reaction solution. The organic phase was subsequently washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water and dried over sodium sulfate, and the solvent was removed in vacuo.
The residue was then taken up in THF (0.4 ml), and EDC (6.1 mg) and triethylamine (5.5 ~ul) were added, and the mixture was stirred at 50°C for 16 h. Ethyl acetate and water were then added to the reaction solution. The organic phase subsequently washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water and dried over sodium sulfate, and the solvent removed in vacuo. The residue was purified by preparative HPLC. The product with the molecular weight of 406.53 (C24H30N402) was 5 obtained in this way; MS (ESI): 407.15 (M+H+).
4-Phenoxybutanohydrazide A mixture of phenol (100 mg), ethyl 5-bromovalerate (222.2 mg), cesium carbonate (693 mg) and DMF (1.6 ml) was stirred at room temperature for 12 h. Ethyl acetate and water o were then added to the reaction solution, and the aqueous phase was adjusted to pH 6 with 2N HCl solution. The aqueous phase extracted twice more with ethyl acetate.
The combined organic phases were then washed with water and dried over sodium sulfate, and the solvent was removed in vacuo.
The product obtained in this way was taken up in abs. ethanol (0.5 ml), 37.3 ~,1 of ~ 5 hydrazine hydrate were added, and the mixture was heated under rellux for 12 h. Ethyl acetate and water were then added to the reaction solution, and the aqueous phase was neutralized with 2N HCl solution. The aqueous phase was extracted twice with ethyl acetate. The combined organic phases were then washed with water and dried over sodium sulfate, and the solvent was removed in vacuo. The residue was purified by preparative 2o HPLC. The product with the molecular weight of 208.11 (C 11 H 16CIN202) was obtained in this way; MS (ESI): 209.1 (M+H+).
4-(3-Dimethylaminopyrrolidin-1-yl)benzoic acid A 1M sodium cyanoborohydride solution (1.32 ml) was added to a mixture of methyl 4 25 (3-aminopyrrolidin-1-yl)benzoate (300 mg), acetic acid (81 ~,l), formaldehyde (0.113 ml) and THF (3 ml). The reaction was stirred at room temperature for 1 h, then the solvent was removed in vacuo, and the residue was taken up again in ethyl acetate/water.
The organic phase was washed with water and dried over sodium sulfate, and the solvent was removed in vacuo.
3o The product obtained in this way was dissolved in a THF/water mixture ( 1:1 ) (3.1 ml), and potassium hydroxide (66.2 mg) was added. The reaction was heated at 70°C for 4 h. Ethyl acetate and water were then added to the reaction solution, and the aqueous phase was acidified with 2N HCl solution. The aqueous phase was extracted twice with ethyl acetate.
'fhe combined organic phases were then washed with water and dried over sodium sulfate, and the solvent was removed in vacuo. The product with the molecular weight of 234.17 (C ( 3H 18N2O2) was obtained in this way; MS (ESI): 235.10 (M+H+).
Methyl4-(3-aminopyrrolidin-1-yl)benzoate A mixture of 3-(tert-butoxycarbonylamino)pyrrolidine (1 g), methyl 4-fluorobenzoate (0.83 ml), cesium carbonate ( 1.7 g) and DMF ( 10 ml) was heated at 100°C for 12 h. Ethyl acetate and water were then added to the reaction solution. The organic phase was then washed twice with water and dried over sodium sulfate, and the solvent was removed in I o vacuo.
The product obtained in this way was dissolved in methylene chloride ( 12 ml), trilluoroacetic acid (6 ml) was added, and the mixture was stirred at room temperature for 90 min. The solvent was removed in vacuo, and the residue was purified by preparative HPLC. The product with the molecular weight of 220.12 (C12H16N2O2) was obtained in 1S this way; MS (ESI): 221.10 (M+H+).
Example 94 ( 1- { 4-[5-(4-Butoxyphenyl)-[ 1,3,4]thiadiazol-2-yl]phenyl } pyrrolidin-3-yl)dimethylamine p N-, ~ NJ
n ~ v N'N
A mixture of N'-(4-butoxybenzoyl)-4-(3-dimethylaminopyrrolidin-1-yl)benzohydrazide ( 100 mg), Lawesson's reagent ( 191 mg) and toluene (5 ml) was boiled under reflux for 4 hours. Volatiles were removed, and the residue was purified by preparative HPLC. The product with the molecular weight of 422.60 (C24H30N40S) was obtained in this way;
MS (ESI): 423 (M+H+).
N'-(4-Butoxybenzoyl)-4-(3-dimethylaminopyrrolidin-1-yl)benzohydrazide A mixture of 4-butoxybenzoic acid ( 156 mg) and DMF ( 10 ml) was mixed with TOTU
(264 mg) and N,N-diisopropylethylamine (104 mg). After 10 minutes, 4-(3-dimcthylaminopyrrolidin-1-yl)benzohydrazide (200 mg) was added. After one hour, the mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with water, dried over magnesium sulfate, filtered and concentrated.
The product with the molecular weight of 424.55 (C24H32N4O3) was obtained in this way; MS
(ESI):
425 (M+H+).
Example 95 ((R)-3- { 4-[5-(4-Chlorophenoxymethyl) [ 1,2,4]oxadiazol-3-yl]phenyl }
cyclopentyl)-methylamine PyBOP (558 mg), HOAt (146 mg) and triethylamine (0.299 ml) were added to a mixture of tert-butyl {(R)-1-[4-(N-hydroxycarbamimidoyl)phenyl]pyrrolidin-3-yl}methylcarbamate ~ 5 (358.5 mg), (4-chlorophenoxy)acetic acid (200 mg) and 3 ml of DMF at 0°C, and the reaction mixture was stirred at this temperature for 10 min. It was then stirred at room temperature for 2 h and ethyl acetate and water were added to the reaction solution. The organic phase was then washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water, dried over sodium sulfate and filtered, and the 20 solvent was removed in vacuo.
The residue was then taken up in 10 ml of THF, and EDC (160 mg) and triethylamine (0.144 ml) were added, and the mixture was stirred at 50°C for 16 h.
Ethyl acetate and water were then added to the reaction solution. The organic phase was then washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and 25 water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo.
The crude product was taken up in methylene chloride (7.2 ml), and trifluoroacetic acid ( 1.8 ml) was added. The reaction was stirred at room temperature for 5 h and then the solvent was removed in vacuo. The residue was purified by preparative HPLC.
The product with the molecular weight of 384.14 (C20H21C1N402) was obtained in this way;
MS(ESI): 385.26 (M+H+).
(4-Chlorophenoxy)acetic acid A mixture of 4-chlorophenol (500 mg), methyl bromoacetate (0.368 ml), cesium carbonate ( 1.9 g) and 5 ml of acetone was stirred at room temperature for 12 h. Ethyl acetate and water were then added to the reaction solution, and the organic phase was washed twice with water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo.
The crude product was dissolved in a 1:l THF/water mixture (10 ml), and potassium o hydroxide (417 mg) was added. The reaction was stirred at room temperature for 12 h.
Ethyl acetate and water were then added to the reaction solution, and the aqueous phase was adjusted to pH 2 and extracted several times with ethyl acetate. The combined organic phases were washed twice with water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo. The product with the molecular weight of 186.6 ~5 (C8H7C103) was obtained in this way; MS (ESI): 227.0 (M+CH3CN).
{(R)-1-[4-(N-Hydroxycarbamimidoyl)phenyl]pyrrolidin-3-yl}methylcarbamic acid tort-butyl ester Sodium hydride (253.4 mg) was added in portions to a solution of tent-butyl [(R)-1-(4-2o cyanophenyl)pyrrolidin-3-yl]carbamate ( 1.06 g) in 12 ml of DMF at 0°C. After removal of the ice bath, methyl iodide (0.498 ml) was added dropwise to the reaction solution, which was stirred at room temperature for 4 h. Ethyl acetate and water were then added to the reaction solution, and the organic phase was washed twice with water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo.
25 The crude product was dissolved in abs. ethanol (12 ml), and hydroxylamine (0.687 ml) was added. The reaction solution was heated under reflux for 12 h. Ethyl acetate and water were then added to the reaction solution, and the organic phase was washed twice with water and dried over sodium sulfate, and the solvent was removed in vacuo. The residue was purified by preparative HPLC. The product with the molecular weight of 334.42 30 (C17H26N403) was obtained in this way; MS (ESI): 335.20 (M+H+).
[(R)-1-(4-Cyanophenyl)pyrrolidin-3-yl]carbamic acid A mixture of (3R)-(+)-(tort-butoxycarbonylaminopyrrolidine (1.0 g), p-fluorobenzonitrile (650 mg), cesium carbonate ( 1.75 g) and 5 ml of DMF was stirred at 50°C for 12 h. Ethyl acetate and water were then added to the reaction solution, and the organic phase was washed twice with water, dried over sodium sulfate and filtered, and the solvent was removed in vacuo. The residue was purified by preparative HPLC. The product with the molecular weight of 287.36 (C16H21N302) was obtained in this way; M5 (ESI):
288.20 (M+H+).
Example 96 lo ((R)-1-{4-[5-(4-Chlorobenzyloxymethyl)[1,2,4]oxadiazol-3-yl]phenyl}pyrrolidin-3-yl)methylamine ~':l ~..,yr ..., .- .,._S ~. ' ~Y_.~ ~.' //
~~ti~
I5 A solution of (4-chlorobenzyloxy)aeetic acid (70 mg) in thionyl chloride ( 1 ml) was stirred at room temperature for 1 h, and then toluene was added and the solvent was stripped off in vacuo. This procedure was repeated twice more. The acid chloride was then taken up in methylene chloride (1.4 ml), {(R)-1-[4-(N-hydroxycarbamimidoyl)phenyl]pyrrolidin-3-yl } methylcarbamic acid tent-butyl ester ( 116.7 mg), triethylamine (0.05 ml) were added, 20 and the mixture was stirred at room temperature for 12 h. The volatile components were removed in vacuo, and the residue was taken up in ethyl acetatelwater. The organic phase was washed twice with water and dried over sodium sulfate, and the solvent was removed in vacuo. The residue was purified by preparative HPLC. The product with the molecular weight of 398.15 (C21H23C1N402) was obtained in this way; MS (ESI): 399.41 (M+H+).
z5 (4-Chlorobenzyloxy)acetic acid was prepared in analogy to (4-chlorophenoxy)acetic acid using 4-chlorobenzyl bromide as precursor. The product with the molecular weight of 200.62 (C9H9C103) was obtained in this way; MS (ESI): 222.95 (M+Na-H).
3o Example 97 4-Ch Toro-N- { 3-[4-(3-dimethylaminopyrrolidin- I -yl)phenyl] [
1,2,4]oxadiazol-5-ylmethyl } benzamide Method C
TOTU (51.4 mg) and N,N-diisopropylethylamine (0.05 ml) were added to a mixture of { 1-[4-(5-aminomethyl[1,2,4]oxadiazol-3-yl)phenyl]pyrrolidin-3-yl}dimethylamine (75.3 mg), 4-chlorobenzoic acid (23.5 mg) and DMF (0.96 ml), and the solution was stirred at room o temperature for 12 h. The crude product was purified by preparative HPLC
(RP) and then purified again by chromatography on silica gel (dichloromethane/MeOH/AcOH/H20 =
90/10/1/1). The product with the molecular weight of 425.16 (C22H24C1N5O2) was obtained in this way; MS (ESI): 426.17 (M+H).
~5 { 1-[4-(5-Aminomethyl[1,2,4]oxadiazol-3-yl)phenyl]pyrrolidin-3-yl}dimethylamine PyBOP (546.4 mg), HOAt ( 136.1 mg) and triethylamine (0.279 ml) were added to a mixture of 4-(3-dimethylaminopyrrolidin-1-yl)-N-hydroxybenzamidine (248.3 mg), tert-butoxycarbonylaminoacetic acid ( 175.2 mg) and DMF (2.8 ml) at 0°C and the mixture was stirred at this temperature for 10 min. It was subsequently stirred at room temperature for 2 2o h and then ethyl acetate and water were added to the reaction solution. The organic phase then washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water, dried over sodium sulfate and filtered, and the solvent removed in vacuo. The residue was then taken up in 6.2 ml of THF, and EDC ( 105 mg) and triethylamine (0.09 ml) were added, and the mixture was stirred at 50°C for 16 h. Ethyl 25 acetate and water were then added to the reaction solution. The organic phase then washed twice each with 10% strength citric acid solution, saturated sodium bicarbonate solution and water and dried over sodium sulfate, and the solvent removed in vacuo.
The crude product was taken up in methylene chloride (9.6 ml), and trifluoroacetic acid (2.3 ml) was added. The reaction was stirred at room temperature for 5 h and then the 3o solvent was removed in vacuo. The residue was purified by preparative HPLC.
The product with the molecular weight of 287.37 (C 15H21 N50) was obtained in this way; MS
(ESI): 288.05 (M+H+).
4-(3-Dimethylaminopyrrolidin-1-yl)-N-hydroxybenzamidine A mixture of 3-(dimethylamino)pyrrolidine (1.l g), p-fluorobenzonitrile (1.2 g), potassium carbonate (2.8 g) and acetonitrile (15 ml) was stirred at 80°C for 12 h. The reaction solution was then filtered, and the precipitate was washed with acetonitrile, the solvent was removed in vacuo, and the residue was taken up again in ethyl acetate. The ethyl acetate phase was washed twice with water and then dried over sodium sulfate, and the solvent ~ o was removed in vacuo.
The product obtained in this way was dissolved in abs. ethanol (48.7 ml), and hydroxylamine ( 1.4 ml) was added to the solution. The reaction mixture was heated under reflux for 12 h. The precipitate obtained after cooling the reaction solution was filtered off and washed with a little ethanol.
~ 5 The product with the molecular weight of 248.33 (C 13H20N40) was obtained in this way;
MS (ESI): 249.15 (M+H+).
Examples 98-110 in table 2 were synthesized by method C.
EX.-....._._-Structure___.-_Molecularformula__ -. ~__ -._ -..M~
__.
.-...M~___._ .__...
i j talc.
measured _ ! ,.. _..._. __..~Y ,?.~ ._.,~' __ _.' J y.r l l ' ~ - _..___._ ' I
_ i _...... . _....,___ ._.. _ _.. , J r .- , , ', . ' .' 'J ,'" .
a y .
~
[
~
JO.
... . ! J PI='::'~' ', ~'~ ';
>:~
i '4.2~
t - , ____-.._, _. _, . . . _ii-__ .
r. _ s ._ :i"~~ -. ..
' . ., ___. i9i - __. , i -_. _._ __ -;__ _ ~
-.-._ , y ' ~ I.-;.; r ~ _ ~ r _..._.._ _ . ___ _ . _ . .. .. - .
.~_~ . y;=? ? i=; ',j ~ '' i L -...._~ _ _ _ ~
r n ,~
..
__...
--~--__.. _~. ~y'a!2i1 ~~V ; ~
__ _ _-_ , ' _-I t~-_~_'_ __ .,____ .-._____-. ~_ ' ~ \~Vr ~'~3vi~~~v~~ ~
i~a~'- ' ~ ''' " ., t .__ _ ~'yrl::=;f,l;>r.,- ,'J' _ ':J
i Y~J
_ _:
i r. y .,_._._i - __~_., -_.._~- ~
~ ~
\I~J~ ~o a X21;-~:,Cl 7 I .
~
i ' ~. _~ I ~.~1~'24~~60z -._._._i _. 392.=0 353.28 ' k i ~~~
ii '~ _" .: ~2sN;5~r;50~ [ .JV~.._J
- ~._~ ~ ~H~.~
i i -_ __.. _ I
f ~f ..- -- ~J: II~~a\yv2 ~
_ ' i - _ _ , .26 _-. 4 _ :2 '~~~
,, I
Example 111 [1-(4-{ 5-[(4-Chlorobenzylamino)methyl][ 1,2,4]oxadiazol-3-yl }phenyl)pyrrolidin-3-yl]-dimethylamine Method D
Polymer-bound sodium cyanoborohydride (5 eq) was added to a mixture of { 1-[4-(5-aminomethyl[1,2,4]oxadiazol-3-yl)phenyl]pyrrolidin-3-yl}dimethylamine (40.1 mg), 4-chlorobenzaldehyde (42.2 mg), acetic acid ( 17.2 ~ l), triethylamine (27.9 ~.l) and THF
( 1 ml), and the reaction mixture was stirred at room temperature for 12 h.
The polymer-bound reagent was filtered off and the solvent was removed in vacuo. The residue was m purified by preparative HPLC. The product with tire molecular weight of 411.18 (C22H26C1N50) was obtained in this way; MS (ESI): 412.23 (M+H+).
Example 112 [1-(4-{ 5-[(4-Methoxybenzylamino)methyl][1,2,4]oxadiazol-3-yl }phenyl)pyrrolidin-3-y]dimethylam.ine :: -~ ._ ~ '~s ~ ~_ - wf ~ '~_"~ f~'i --_ w _~ ~ .. ,,.~
I ' J __ ~,'f~ ' v.
{ 1-[4-(5-aminomethyl[1,2,4]oxadiazol-3-yl)phenyl)pyrrolidin-3-yl}dimethylamine was 2o reacted with p-anisaldehyde by method D. The product with the molecular weight of 407.23 (C23H29N502) was obtained in this way; MS (ESI): 408.30 (M+H+).
Example 113 ( 1-{4-[5-(4-Fluorobenzyloxymethyl)[ 1,2,4]oxadiazol-3-yl]phenyl }pyrrolidin-3-yl)dimethylamine 4-Fluorobenzyl bromide (18.9 mg) and potassium carbonate (27.6 mg) were added to a mixture of {3-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl][1,2,4]oxadiazol-5-yl}methanol (28.8 mg) and DMF (0.3 ml). The reaction mixture was stirred at 60°C
for 3 h, filtered and purified by preparative HPLC. The product with the molecular weight of 396.20 (C22H25FN4O2) was obtained in this way; MS (ES I): 397.27 (M+H+).
{ 3-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl] [ 1,2,4]oxadiazol-5-yl }
methanol PyBOP (546.4 mg), HOAt ( 136.1 mg) and triethylamine (0.139 ml) were added to a 0 mixture of 4-(3-dimethylaminopyrrolidin-1-yl)-N-hydroxybenzamidine (248.3 mg), benzyloxyacetic acid (0.143 ml) and DMF (3.0 ml) at 0°C, and the mixture was stirred at this temperature for 10 min. It was subsequently stirred at room temperature for 1 h, and then ethyl acetate and water were added to the reaction solution. The organic phase was then washed twice each with 10°70 strength citric acid solution, saturated sodium ~ 5 bicarbonate solution and water and dried over sodium sulfate, and the solvent was removed in vacuo.
The residue was then taken up in 3 ml of THF, and EDC ( 170.8 mg) and triethylamine (0.139 ml) were added, and the mixture was stirred at 80°C for 16 h.
Ethyl acetate and water were then added to the reaction solution. The organic phase was then washed twice 20 each with l0alo strength citric acid solution, saturated sodium bicarbonate solution and water and dried over sodium sulfate, and the solvent was removed in vacuo.
The residue was dissolved in methylene chloride (4.4 ml), and the solution was cooled to -78°C. At this temperature, a 1M boron trichloride solution (3 ml) was added. The reaction 25 was allowed to warm to room temperature overnight, and then ethyl acetate and water were added. The product with the molecular weight of 288.2 (C 15H20N4O2) was obtained in this way; MS (EST): 289.2 (M+H+).
7() The following examples could be synthesized analogously:
' ~
,_ .;_-~, _ _.. _.. ._._...~_...__..._..___ _ _;_.. _... i .____..._ _ ....__.._.__.. ._ __........_._.
' .. _ ,_ -, J ~ _:, _ ~ _ , W
_ a .. - _ -. , _ ::
:.._ . :. , . , __. ._.
_ ; r ""
_, ,. . , .- I,. ,, 1_ . ..
,__ ' 1, , _. ; . ' ' ; _.
_ _ ,,; __.,;
:.
-- _, , ,:-- _ .
-. -, _ ;::._ ....
; ,-_ , r , , , , ' l .
~;, ,~; ',, ~~
r II
I7, __ __ h ~
-j , ._ . ~ ,.::,'_._.,' ' 1...' ' ,_; _;. I, _ .
. ', , _ _f;;
~ _ , , . ': , ,,--:
i .-- , lI U ~.~
,: J,....
.. ~ - ,.
v :. ;,.__~- =. :;.. I
g ~'.ay I
'w v.J r I i . f-:, , , , ,. ., , ,, -_,.
. .
I - ,."=~~ '-' r. _.,, ,~., ~3 , _ f.:~._. _ J _-fJ . _ _.
' -i~
YJ
I y.j ~.5'O
/
~
_' I
_ -:.,'. -,.. . . 1~
~ ,-..: _ rn , r1 ., p a f~
- I i, J , II,_.
.- s~ f . - ~'-;,.,_ .- i ~ . , i ; : ~ ~
i-r:: .lei.
...,f , ri,,,-,, w .L....
:r;.
Claims (17)
1. A compound of the formula I, in which the meanings are R1,R2 independently of one another H, (C1-C8)-alkyl, -(CR13R14)o-R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, CO-(C1-C8)-alkyl, -CO-(CH2)o-R12, CO(C(R15)(R16))q N(R17)(R18), CO(C(R19)(R20))s O(R21); or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O-(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(C1-C6)-alkyl, N(R27)(R28) or SO2CH3;
o 0, 1, 2, 3, 4, 5, 6;
q, s independently of one another 0, 1, 2, 3, 4;
R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28 independently of one another H, (C1-C6)-alkyl;
R17 and R18, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R12 OH, O-(C1-C6)-alkyl, CN, COO(R29), CON(R30)(R31), N(R32)(R33), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, (C2-C6)-alkynyl, O-(C0-C8)-alkylene-aryl, (C0-C8)-alkylene-aryl, N(R34)(R35), CO(C1-C6)-alkyl, COO(R36) and S(O)u (R37);
u 0, 1, 2;
R34, R35 independently of one another H, (C1-C8)-alkyl;
R34 and R35 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur, and optionally be substituted by 1-2 oxo groups;
R36, R37 H, (C1-C8)-alkyl;
R13, R14 independently of one another H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl;
R29, R30, R31 independently of one another H, (C1-C8)-alkyl, (C2-C6)-alkenly, (C0-C8)-alkylene-aryl;
R32, R33 independently of one another H, (C1-C6)-alkyl or R32 and R33 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur and optionally be substituted by 1-2 oxo groups;
R3 H, (C1-C6)-alkyl;
R4, R5 independently of one another H, (C1-C6)-alkyl, OH, O-(C1-C6)-alkyl, O-CO(C1-C6)-alkyl, S-(C1-C6)-alkyl;
R6, R7, R8, R9 independently of one another H, (C1-C8)-alkyl, or R6 and R7, R8 and R9 independently of one another optionally oxo;
n, m independently of one another 0, 1, 2;
A, B, D, G independently of one another N, C(R38);
R38 H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-alkyl, O-(C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O-(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O-(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O-(C0-C8)-alkylene-aryl, S-aryl, N(R39)(R40), SO2-CH3, COOH, COO-(C1-C6)-alkyl, CON(R41)(R42), N(R43)CO(R44), N(R45)SO2(R46), CO(R47), -(CR48R49)x-O(R50);
R39, R40, R41, R42, R43, R45 independently of one another H, (C1-C8)-alkyl;
or R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R44, R46, R47 independently of one another H, (C1-C8)-alkyl, aryl;
R48, R49 independently of one another H, (C1-C8)-alkyl;
R50 H, (C1-C6)-alkyl;
x 1, 2, 3, 4;
Het five-membered aromatic heterocycle X a bond, a group of the formula -(CR51R52)y- in which one or more -(CR51R52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, C.ident.C,;
Y O, S, N(R53), CO, SO, SO2;
R51, R52 independently of one another H, (C1-C4)-alkyl, where R51 and R52 in the y groups may in each case have the same or different meanings;
y 1,2,3,4,5,6;
R53 H, (C1-C8)-alkyl;
E 3-14 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-(C1-C6)-alkyl, O-(C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O-(C3-C8)-cycloalkyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O-(C0-C8)-alkylene-aryl, S-aryl, N(R54)(R55), SO2-CH3, COOH, COO-(C1-C6)-alkyl, CON(R56)(R57), N(R58)CO(R59), N(R60)SO2(R61), CO(R62) and be mono- or bicyclic;
R54, R55, R56, R57, R58, R60 independently of one another H, (C1-C8)-alkyl;
R54 and R55, R56 and R57 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R59, R61, R62 independently of one another H, (C1-C8)-alkyl, aryl;
K a bond, a group of the formula -(CR63R64)z- in which one or more -(CR63R64)- groups may be replaced by Z to result in a chemically reasonable radical, C.ident.C, C=C;
Z O, S, N(R65), CO, SO, SO2;
R63, R64 independently of one another H, (C1-C8)-alkyl, hydroxy, (C1-C6)-alkoxy, where R63 and R64 in the z groups may in each case have the same or different meanings;
z 1,2,3,4,5,6;
R65 H, (C1-C8)-alkyl;
R11 H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O-(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, hydroxy-(C1-C4)-alkyl, COO(R69), N(R70)CO(C1-C6)-alkyl, N(R71)(R72) or SO2CH3;
R66, R67, R68, R69, R70, R71, R72 independently of one another H, (C1-C8)-alkyl;
or R67 and R68, R71 and R72 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C5)-alkyl, oxygen and sulfur; or the N-oxides thereof and the physiologically tolerated salts thereof;
wherein compounds of the following formulae are excluded:
o 0, 1, 2, 3, 4, 5, 6;
q, s independently of one another 0, 1, 2, 3, 4;
R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28 independently of one another H, (C1-C6)-alkyl;
R17 and R18, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R12 OH, O-(C1-C6)-alkyl, CN, COO(R29), CON(R30)(R31), N(R32)(R33), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, (C2-C6)-alkynyl, O-(C0-C8)-alkylene-aryl, (C0-C8)-alkylene-aryl, N(R34)(R35), CO(C1-C6)-alkyl, COO(R36) and S(O)u (R37);
u 0, 1, 2;
R34, R35 independently of one another H, (C1-C8)-alkyl;
R34 and R35 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur, and optionally be substituted by 1-2 oxo groups;
R36, R37 H, (C1-C8)-alkyl;
R13, R14 independently of one another H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl;
R29, R30, R31 independently of one another H, (C1-C8)-alkyl, (C2-C6)-alkenly, (C0-C8)-alkylene-aryl;
R32, R33 independently of one another H, (C1-C6)-alkyl or R32 and R33 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur and optionally be substituted by 1-2 oxo groups;
R3 H, (C1-C6)-alkyl;
R4, R5 independently of one another H, (C1-C6)-alkyl, OH, O-(C1-C6)-alkyl, O-CO(C1-C6)-alkyl, S-(C1-C6)-alkyl;
R6, R7, R8, R9 independently of one another H, (C1-C8)-alkyl, or R6 and R7, R8 and R9 independently of one another optionally oxo;
n, m independently of one another 0, 1, 2;
A, B, D, G independently of one another N, C(R38);
R38 H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-alkyl, O-(C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O-(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O-(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O-(C0-C8)-alkylene-aryl, S-aryl, N(R39)(R40), SO2-CH3, COOH, COO-(C1-C6)-alkyl, CON(R41)(R42), N(R43)CO(R44), N(R45)SO2(R46), CO(R47), -(CR48R49)x-O(R50);
R39, R40, R41, R42, R43, R45 independently of one another H, (C1-C8)-alkyl;
or R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R44, R46, R47 independently of one another H, (C1-C8)-alkyl, aryl;
R48, R49 independently of one another H, (C1-C8)-alkyl;
R50 H, (C1-C6)-alkyl;
x 1, 2, 3, 4;
Het five-membered aromatic heterocycle X a bond, a group of the formula -(CR51R52)y- in which one or more -(CR51R52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, C.ident.C,;
Y O, S, N(R53), CO, SO, SO2;
R51, R52 independently of one another H, (C1-C4)-alkyl, where R51 and R52 in the y groups may in each case have the same or different meanings;
y 1,2,3,4,5,6;
R53 H, (C1-C8)-alkyl;
E 3-14 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-(C1-C6)-alkyl, O-(C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O-(C3-C8)-cycloalkyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O-(C0-C8)-alkylene-aryl, S-aryl, N(R54)(R55), SO2-CH3, COOH, COO-(C1-C6)-alkyl, CON(R56)(R57), N(R58)CO(R59), N(R60)SO2(R61), CO(R62) and be mono- or bicyclic;
R54, R55, R56, R57, R58, R60 independently of one another H, (C1-C8)-alkyl;
R54 and R55, R56 and R57 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R59, R61, R62 independently of one another H, (C1-C8)-alkyl, aryl;
K a bond, a group of the formula -(CR63R64)z- in which one or more -(CR63R64)- groups may be replaced by Z to result in a chemically reasonable radical, C.ident.C, C=C;
Z O, S, N(R65), CO, SO, SO2;
R63, R64 independently of one another H, (C1-C8)-alkyl, hydroxy, (C1-C6)-alkoxy, where R63 and R64 in the z groups may in each case have the same or different meanings;
z 1,2,3,4,5,6;
R65 H, (C1-C8)-alkyl;
R11 H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O-(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, hydroxy-(C1-C4)-alkyl, COO(R69), N(R70)CO(C1-C6)-alkyl, N(R71)(R72) or SO2CH3;
R66, R67, R68, R69, R70, R71, R72 independently of one another H, (C1-C8)-alkyl;
or R67 and R68, R71 and R72 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C5)-alkyl, oxygen and sulfur; or the N-oxides thereof and the physiologically tolerated salts thereof;
wherein compounds of the following formulae are excluded:
2. A compound of the formula I as claimed in claim 1, in which the meanings are R1, R2 independently of one another H, (C1-C8)-alkyl, -(CR13R14)o-R 12, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, CO-(C1-C8)-alkyl, -CO-(CH2)o-R12, CO(C(R15)(R16))q N(R17)(R18), CO(C(R19)(R20))SO(R21);
or R 1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O-(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(C1-C6)-alkyl or N(R27)(R28).
R12 OH, O-(C1-C6)-alkyl, CN, COO(R29), CON(R30)(R31), N(R32)(R33), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, (C2-C6)-alkynyl, O-(C0-C8)-alkylene-aryl, (C0-C8)-alkylene-aryl, N(R34)(R35), CO(C1-C6)-alkyl and COO(R36);
and R6, R7, R8, R9 independently of one another H, (C1-C8)-alkyl;
where the further radicals and groups in the compound of the formula I have the meanings stated in claim 1;
wherein compounds of the following formulae are excluded:
or R 1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O-(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(C1-C6)-alkyl or N(R27)(R28).
R12 OH, O-(C1-C6)-alkyl, CN, COO(R29), CON(R30)(R31), N(R32)(R33), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, (C2-C6)-alkynyl, O-(C0-C8)-alkylene-aryl, (C0-C8)-alkylene-aryl, N(R34)(R35), CO(C1-C6)-alkyl and COO(R36);
and R6, R7, R8, R9 independently of one another H, (C1-C8)-alkyl;
where the further radicals and groups in the compound of the formula I have the meanings stated in claim 1;
wherein compounds of the following formulae are excluded:
3. A compound of the formula I as claimed in claim 1, in which the meanings are R1, R2 independently of one another H, (C1-C8)-alkyl, -(CR13R14)o -R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, CO-(C1-C8)-alkyl, -CO-(CH2)o -R12, CO(C(R15)(R16))q N(R17)(R18), CO(C(R19)(R20))s O(R21); or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C1-C6)-alkyl, O-(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, COO(R25), N(R26)CO(C1-C6)-alkyl, N(R27)(R28) or SO2CH3;
o 0, 1, 2, 3, 4, 5, 6;
q 1,2,3;
s 0, 1,2,3,4;
R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28 independently of one another H, (C1-C6)-alkyl;
or R17 and R18, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R12 OH, O-(C1-C6)-alkyl, CN, COO(R29), CON(R30)(R31), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, OH, CF3, CN, oxo, O-(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, O-(C0-C8)-alkylene-aryl, (C0-C8)-alkylene-aryl, N(R34)(R35), CO(C1-C6)-alkyl, COO(R36), S(O)u(R37);
u 0, 1, 2;
R34, R35 independently of one another H, (C1-C8)-alkyl;
or R34 and R35 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur, and optionally be substituted by 1-2 oxo groups;
R36, R37 H, (C1-C8)-alkyl;
R13, R14 independently of one another H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl;
R29, R30, R31 independently of one another H, (C1-C8)-alkyl;
R3 H, (C1-C6)-alkyl;
R4, R5 independently of one another H, (C1-C6)-alkyl, OH, O-(C1-C6)-alkyl, O-CO(C1-C6)-alkyl, S-(C1-C6)-alkyl;
R6, R7, R8, R9 H;
or R6 and R7, R8 and R9 independently of one another optionally oxo;
n 1 m 1 or 2;
A, B, D, G
independently of one another N, C(R38);
or the groups A and B or D and G are in each case C(R38) and together form an ortho-phenylene unit so that the overall result is a 1,4-bisubstituted naphthalene system;
R38 H, F, Cl, Br, CF3, CN, O-(C1-C6)-alkyl, O-(C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C0-C8)-alkylene-aryl, O-(C0-C8)-alkylene-aryl, N(R39)(R40), SO2-CH3, CON(R41)(R42), N(R43)CO(R44), CO(R47), -(CR48R49)x-O(R50);
R39, R40, R41, R42, R43 independently of one another H, (C1-C8)-alkyl;
or R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R44, R47 independently of one another H, (C1-C8)-alkyl, aryl;
R48, R49 H;
R50 H, (C1-C6)-alkyl;
x 1, 2;
Het five-membered aromatic heterocycle, preferably in which A' is O, S, NR73, X', Y' and Z' are independently of one another CR74 or N, and R73, R74 are independently of one another H, (C1-CA)-alkyl;
X a bond, a group of the formula -(CR51 R52)y-, in which one or more -(CR51R52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, C.ident.C;
R51, R52 independently of one another H, (C1-C4)-alkyl, where R51 and R52 in the y groups may in each case have the same or different meanings;
Y O, S, N(R53), CO;
R53 H, (C1-C8)-alkyl;
E 3-8 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-alkyl, O-(C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, O-(C3-C8)-cycloalkyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O-(C0-C8)-alkylene-aryl, S-aryl, N(R54)(R55), SO2-CH3, N(R58)CO(R59), N(R60)SO2(R61), CO(R62) and be mono- or bicyclic;
R54, R55, R58, R60 independently of one another H, (C1-C8)-alkyl;
R59, R61, R62 independently of one another H, (C1-C8)-alkyl, aryl;
K O, a bond, CH2O, OCH2, S, SO, SO2, N(R80), N(R81)CO, CON(R82), (C(R83)(R84))v, CO, C=C, C.ident.C, SCH2, SO2CH2;
v 1, 2, 3, 4;
R80, R81, R82, R83, R84 independently of one another H, (C1-C8)-alkyl;
R11 H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O-(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, COO(R69), N(R70)CO(C1-C6)-alkyl, N(R71)(R72) or SO2CH3;
R66, R67, R68, R69, R70, R71, R72 independently of one another H, (C1-C8)-alkyl;
or R67 and R68, R71 and R72 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur; or the N-oxides thereof and the physiologically tolerated salts thereof;
wherein compounds of the following formulae are excluded:
o 0, 1, 2, 3, 4, 5, 6;
q 1,2,3;
s 0, 1,2,3,4;
R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28 independently of one another H, (C1-C6)-alkyl;
or R17 and R18, R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R12 OH, O-(C1-C6)-alkyl, CN, COO(R29), CON(R30)(R31), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, OH, CF3, CN, oxo, O-(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, O-(C0-C8)-alkylene-aryl, (C0-C8)-alkylene-aryl, N(R34)(R35), CO(C1-C6)-alkyl, COO(R36), S(O)u(R37);
u 0, 1, 2;
R34, R35 independently of one another H, (C1-C8)-alkyl;
or R34 and R35 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur, and optionally be substituted by 1-2 oxo groups;
R36, R37 H, (C1-C8)-alkyl;
R13, R14 independently of one another H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl;
R29, R30, R31 independently of one another H, (C1-C8)-alkyl;
R3 H, (C1-C6)-alkyl;
R4, R5 independently of one another H, (C1-C6)-alkyl, OH, O-(C1-C6)-alkyl, O-CO(C1-C6)-alkyl, S-(C1-C6)-alkyl;
R6, R7, R8, R9 H;
or R6 and R7, R8 and R9 independently of one another optionally oxo;
n 1 m 1 or 2;
A, B, D, G
independently of one another N, C(R38);
or the groups A and B or D and G are in each case C(R38) and together form an ortho-phenylene unit so that the overall result is a 1,4-bisubstituted naphthalene system;
R38 H, F, Cl, Br, CF3, CN, O-(C1-C6)-alkyl, O-(C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C0-C8)-alkylene-aryl, O-(C0-C8)-alkylene-aryl, N(R39)(R40), SO2-CH3, CON(R41)(R42), N(R43)CO(R44), CO(R47), -(CR48R49)x-O(R50);
R39, R40, R41, R42, R43 independently of one another H, (C1-C8)-alkyl;
or R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R44, R47 independently of one another H, (C1-C8)-alkyl, aryl;
R48, R49 H;
R50 H, (C1-C6)-alkyl;
x 1, 2;
Het five-membered aromatic heterocycle, preferably in which A' is O, S, NR73, X', Y' and Z' are independently of one another CR74 or N, and R73, R74 are independently of one another H, (C1-CA)-alkyl;
X a bond, a group of the formula -(CR51 R52)y-, in which one or more -(CR51R52)- groups may be replaced by Y to result in a chemically reasonable radical, C=C, C.ident.C;
R51, R52 independently of one another H, (C1-C4)-alkyl, where R51 and R52 in the y groups may in each case have the same or different meanings;
Y O, S, N(R53), CO;
R53 H, (C1-C8)-alkyl;
E 3-8 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-alkyl, O-(C1-C4)-alkoxy-(C1-C4)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, O-(C3-C8)-cycloalkyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O-(C0-C8)-alkylene-aryl, S-aryl, N(R54)(R55), SO2-CH3, N(R58)CO(R59), N(R60)SO2(R61), CO(R62) and be mono- or bicyclic;
R54, R55, R58, R60 independently of one another H, (C1-C8)-alkyl;
R59, R61, R62 independently of one another H, (C1-C8)-alkyl, aryl;
K O, a bond, CH2O, OCH2, S, SO, SO2, N(R80), N(R81)CO, CON(R82), (C(R83)(R84))v, CO, C=C, C.ident.C, SCH2, SO2CH2;
v 1, 2, 3, 4;
R80, R81, R82, R83, R84 independently of one another H, (C1-C8)-alkyl;
R11 H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O-(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, COO(R69), N(R70)CO(C1-C6)-alkyl, N(R71)(R72) or SO2CH3;
R66, R67, R68, R69, R70, R71, R72 independently of one another H, (C1-C8)-alkyl;
or R67 and R68, R71 and R72 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur; or the N-oxides thereof and the physiologically tolerated salts thereof;
wherein compounds of the following formulae are excluded:
4. A compound of the formula I as claimed in claim 1 or 3, in which the meanings are:
R1, R2 independently of one another H, (C1-C8)-alkyl, -(CR13R14)o -R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, CO-(C1-C8)-alkyl, -CO-(CH2)o -R12, CO(C(R15)(R16))q N(R17)(R18), CO(C(R19)(R20))s O(R21); or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-or bicyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C1-C6)-alkyl, O-(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R22), hydroxy, N(R27)(R28) or SO2CH3;
preferably independently of one another H, (C1-C8)-alkyl, (CR13R14)o -R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, CO-(C1-C8)-alkyl, -CO-(CH2)o -R12, CO(C(R15)(R16))g N(R17)(R18), or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono- or bicyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen and nitrogen, where the heterocyclic ring system may additionally be substituted by F, (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, oxo, CO(R22), hydroxy, N(R27)(R28);
0, 1, 2, 3, 4; preferably 0, 1, 2, 3;
q 1 or 2;
s 0, 1, 2, 3; preferably 0, 1, 2;
R15, R16, R17, R18, R19, R20, R21, R22, R27, R28 independently of one another H, (C1-C6)-alkyl;
or R17 and R18, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring selected from pyrrolidine, piperidine, N-methylpiperazine and morpholine;
R12 OH, O-(C1-C6)-alkyl, CN, 3-10 membered mono- or bicyclic ring which may comprise 1-3 heteroatoms from the group of N, O and S, and the 3-10 membered ring may comprise further substituents such as F, Cl, Br, OH, CF3, CN, oxo, O-(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, (C0-C2)-alkylene-aryl, N(R34)(R35), CO(C1-C6)-alkyl;
preferably OH, O-(C1-C6)-alkyl, 3-10 membered mono- or bicyclic ring which may comprise 1-2 heteroatoms from the group of N, O
and S, and the 3-10 membered ring may comprise further substituents such as F, OH, oxo, (C1-C6)-alkyl, CO(C1-C6)-alkyl;
u 0 or 2; preferably 2;
R34, R35 independently of one another H, (C1-C8)-alkyl;
or R34 and R35 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur, and optionally be substituted by 1-2 oxo groups;
R36, R37 H,(C1-C8)-alkyl;
R13, R14 independently of one another H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl;
R3 H;
R4, R5 independently of one another H,(C1-C6)-alkyl, OH, O-(C1-C6)-alkyl, O-CO(C1-C6)-alkyl; preferably independently of one another H, OH, O-(C1-C6)-alkyl, very particularly preferably H;
R6, R7, R8, R9 H;
n 1 m 1;
A, B, D, G
C(R38);
R38 H, F, Cl, Br, CF3, CN, O-(C1-C6)-alkyl, (C1-C6)-alkyl, SO2-CH3, CON(R41)(R42), N(R43)CO(R44), CO(R47), -(CR48R49)x-O(R50);
particularly preferably H, F, Cl, CF3, CN, (C1-C6)-alkyl, -(CR48R49)x-O(R50);
R41, R42, R43 independently of one another H, (C1-C8)-alkyl;
or R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R47 H,(C1-C8)-alkyl;
R48, R49 H;
R50 H,(C1-C6)-alkyl;
x 1;
Het heteroaromatic group selected from the group consisting of oxadiazoles, thiadiazoles, thiazoles, oxazoles, triazoles, thiophenes, furans and pyrroles; Het is very particularly preferably selected from oxadiazoles, thiadiazoles, thiazoles and oxazoles;
X a bond, CH2-CH2, CH2Y, YCH2, (R75)YCH2, CH2-NCO(R75), CH2CON(R75); C(R76)(R77), C(R78)(R79)O, N(R75), C=C, C.ident.C;
preferably a bond, CH2-CH2, C(R76)(R77), N(R75), CH2Y, CH2Y(R75), CH2-NCO(R75), CH2-CON(R75); C=C; particularly preferably a bond, CH2-CH2, C(R76)(R77), C=C, (R75)YCH2, CH2-NCO(R75);
Y O, S, N(R53);
R53 H, (C1-C8)-alkyl;
R75, R76, R77, R78, R79 independently of one another H, (C1-C8)-alkyl;
E 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, O-(C0-C8)-alkylene-aryl, S-aryl, N(R54)(R55), SO2-CH3, N(R58)CO(R59), CO(R62) and be mono- or bicyclic;
preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-2 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, OCF3, O-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, N(R54)(R55), SO2-CH3, CO(R62), and which is particularly preferably monocyclic;
e.g. E is benzene, pyridine, pyrimidine, piperidine, pyrrolidine, cyclopentane, cyclohexane, piperazine, homopiperazine, thiazole, thiophene, furan, pyrrole, pyrazole, 1,2,3,6-tetrahydropyridine, 4,5-dihydroisoxazole, oxazole;
R54, R55, R58 independently of one another H, (C1-C8)-alkyl;
R59, R62 independently of one another H, (C1-C8)-alkyl;
K O, a bond, CH2O, OCH2, N(R80), N(R81)CO, CON(R82), (C(R83)(R84))v, CO, C.ident.C, SCH2; preferably O, a bond, CH2O, OCH2, CON(R82), (C(R83)(R84))v, CO, C.ident.C;
v 1, 2, 3; preferably 1,2;
R80, R81, R83, R84 independently of one another H, (C1-C8)-alkyl;
R11 (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O-(C1-C8)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, N(R70)CO(C1-C6)-alkyl, N(R71)(R72) or SO2CH3;
preferably (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, a 3 to 10-membered mono- or bicyclic ring which may include 0 to 2 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O-(C1-C8)-alkyl, oxo, CO(R66), CON(R67)(R68), N(R70)CO(C1-C6)-alkyl, or SO2CH3;
R66, R67, R68, R70, R71, R72 independently of one another H, (C1-C8)-alkyl;
or R67 and R68, R71 and R72 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur; or the N-oxides thereof and the physiologically tolerated salts thereof.
R1, R2 independently of one another H, (C1-C8)-alkyl, -(CR13R14)o -R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, CO-(C1-C8)-alkyl, -CO-(CH2)o -R12, CO(C(R15)(R16))q N(R17)(R18), CO(C(R19)(R20))s O(R21); or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-or bicyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C1-C6)-alkyl, O-(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R22), hydroxy, N(R27)(R28) or SO2CH3;
preferably independently of one another H, (C1-C8)-alkyl, (CR13R14)o -R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, CO-(C1-C8)-alkyl, -CO-(CH2)o -R12, CO(C(R15)(R16))g N(R17)(R18), or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono- or bicyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen and nitrogen, where the heterocyclic ring system may additionally be substituted by F, (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, oxo, CO(R22), hydroxy, N(R27)(R28);
0, 1, 2, 3, 4; preferably 0, 1, 2, 3;
q 1 or 2;
s 0, 1, 2, 3; preferably 0, 1, 2;
R15, R16, R17, R18, R19, R20, R21, R22, R27, R28 independently of one another H, (C1-C6)-alkyl;
or R17 and R18, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring selected from pyrrolidine, piperidine, N-methylpiperazine and morpholine;
R12 OH, O-(C1-C6)-alkyl, CN, 3-10 membered mono- or bicyclic ring which may comprise 1-3 heteroatoms from the group of N, O and S, and the 3-10 membered ring may comprise further substituents such as F, Cl, Br, OH, CF3, CN, oxo, O-(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, (C0-C2)-alkylene-aryl, N(R34)(R35), CO(C1-C6)-alkyl;
preferably OH, O-(C1-C6)-alkyl, 3-10 membered mono- or bicyclic ring which may comprise 1-2 heteroatoms from the group of N, O
and S, and the 3-10 membered ring may comprise further substituents such as F, OH, oxo, (C1-C6)-alkyl, CO(C1-C6)-alkyl;
u 0 or 2; preferably 2;
R34, R35 independently of one another H, (C1-C8)-alkyl;
or R34 and R35 optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur, and optionally be substituted by 1-2 oxo groups;
R36, R37 H,(C1-C8)-alkyl;
R13, R14 independently of one another H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl;
R3 H;
R4, R5 independently of one another H,(C1-C6)-alkyl, OH, O-(C1-C6)-alkyl, O-CO(C1-C6)-alkyl; preferably independently of one another H, OH, O-(C1-C6)-alkyl, very particularly preferably H;
R6, R7, R8, R9 H;
n 1 m 1;
A, B, D, G
C(R38);
R38 H, F, Cl, Br, CF3, CN, O-(C1-C6)-alkyl, (C1-C6)-alkyl, SO2-CH3, CON(R41)(R42), N(R43)CO(R44), CO(R47), -(CR48R49)x-O(R50);
particularly preferably H, F, Cl, CF3, CN, (C1-C6)-alkyl, -(CR48R49)x-O(R50);
R41, R42, R43 independently of one another H, (C1-C8)-alkyl;
or R39 and R40, R41 and R42 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R47 H,(C1-C8)-alkyl;
R48, R49 H;
R50 H,(C1-C6)-alkyl;
x 1;
Het heteroaromatic group selected from the group consisting of oxadiazoles, thiadiazoles, thiazoles, oxazoles, triazoles, thiophenes, furans and pyrroles; Het is very particularly preferably selected from oxadiazoles, thiadiazoles, thiazoles and oxazoles;
X a bond, CH2-CH2, CH2Y, YCH2, (R75)YCH2, CH2-NCO(R75), CH2CON(R75); C(R76)(R77), C(R78)(R79)O, N(R75), C=C, C.ident.C;
preferably a bond, CH2-CH2, C(R76)(R77), N(R75), CH2Y, CH2Y(R75), CH2-NCO(R75), CH2-CON(R75); C=C; particularly preferably a bond, CH2-CH2, C(R76)(R77), C=C, (R75)YCH2, CH2-NCO(R75);
Y O, S, N(R53);
R53 H, (C1-C8)-alkyl;
R75, R76, R77, R78, R79 independently of one another H, (C1-C8)-alkyl;
E 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, CN, OCF3, O-(C1-C6)-alkyl, S-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, O-(C0-C8)-alkylene-aryl, S-aryl, N(R54)(R55), SO2-CH3, N(R58)CO(R59), CO(R62) and be mono- or bicyclic;
preferably 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-2 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, OCF3, O-(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, N(R54)(R55), SO2-CH3, CO(R62), and which is particularly preferably monocyclic;
e.g. E is benzene, pyridine, pyrimidine, piperidine, pyrrolidine, cyclopentane, cyclohexane, piperazine, homopiperazine, thiazole, thiophene, furan, pyrrole, pyrazole, 1,2,3,6-tetrahydropyridine, 4,5-dihydroisoxazole, oxazole;
R54, R55, R58 independently of one another H, (C1-C8)-alkyl;
R59, R62 independently of one another H, (C1-C8)-alkyl;
K O, a bond, CH2O, OCH2, N(R80), N(R81)CO, CON(R82), (C(R83)(R84))v, CO, C.ident.C, SCH2; preferably O, a bond, CH2O, OCH2, CON(R82), (C(R83)(R84))v, CO, C.ident.C;
v 1, 2, 3; preferably 1,2;
R80, R81, R83, R84 independently of one another H, (C1-C8)-alkyl;
R11 (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O-(C1-C8)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R66), CON(R67)(R68), hydroxy, N(R70)CO(C1-C6)-alkyl, N(R71)(R72) or SO2CH3;
preferably (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, a 3 to 10-membered mono- or bicyclic ring which may include 0 to 2 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O-(C1-C8)-alkyl, oxo, CO(R66), CON(R67)(R68), N(R70)CO(C1-C6)-alkyl, or SO2CH3;
R66, R67, R68, R70, R71, R72 independently of one another H, (C1-C8)-alkyl;
or R67 and R68, R71 and R72 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur; or the N-oxides thereof and the physiologically tolerated salts thereof.
5. A compound of the formula I as claimed in any of claims 1 or 2 to 4, in which radicals R1, R2, R11, R38 and the groups X, E and K have the following meanings:
R1, R2 independently of one another H, (C1-C8)-alkyl, -(CR13R14)o -R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (C1-C6)-alkyl, O-(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, N(R27)(R28) or SO2CH3;
preferably independently of one another H, (C1-C8)-alkyl, -(CR13R14)o-, R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (C1-C6)-alkyl, O-(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy or N(R27)(R28); very particularly preferably independently of one another H, (C1-C8)-alkyl, or R1 and R2 form together with the nitrogen atom to which they are bonded a 5 to 6-membered monocyclic ring which, apart from the nitrogen atom, may include 0 to 1 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (C1-C6)-alkyl;
especially preferably independently of one another H, (C1-C8)-alkyl;
0 0, 1, 2, 3, 4;
R22, R23, R24, R27, R28 independently of one another H, (C1-C6)-alkyl;
or R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R12 OH, O-(C1-C6)-alkyl, CN 3-12 membered mono-, bi- or spirocyclic ring which may comprise 1 to 3 heteroatoms from the group of N, O
and S, and the 3-12 membered ring may comprise further substituents such as F, OH, CF3, CN, oxo, (C,-C6)-alkyl, (C0-C2)-alkylene-aryl, N(R34)(R35), COO(R36), CO(C1-C6)-alkyl;
R34, R35 independently of one another H, (C1-C4)-alkyl;
R36 H, (C1-C6)-alkyl, (C0-C2)-alkylene-aryl;
R13, R14 independently of one another H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl;
R38 H, F, Cl, Br, CF3, CN, (C1-C6)-alkyl;
X a bond, CH2CH2, C(R76)(R77), N(R75), C=C, (R75)YCH2, CH2-NCO(R75), CH2CON(R75);
Y O, S, N(R53), CO
R75, R76, R77 independently of one another H, (C1-CH)-alkyl;
R53 H, (C1-C8)-alkyl;
E 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, CF3, OH, CN, OCF3, O-(C1-C6)-alkyl, (C1-C6)-alkyl, SO2-CH3, CO(R65);
R65 H,(C1-C8)-alkyl;
K O, a bond, CH2O, CH2, OCH2, S, SO2, N(R80), N(R81)CO, CON(R82), (C(R83)(R84))v, CO, C.ident.C, SCH2, SO2CH2; preferably O, a bond, CH2O, CH2, OCH2, N(R80), C.ident.C;
v 1,2,3;
R80, R81, R82, R83, R84 independently of one another H, (C1-C8)-alkyl;
R11 (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O-(C1-C8)-alkyl, oxo, CO(R66), hydroxy, N(R70)CO(C1-C6)-alkyl, or SO2CH3;
R66, R70 independently of one another H, (C1-C8)-alkyl;
the N-oxides thereof and the physiologically tolerated salts thereof.
R1, R2 independently of one another H, (C1-C8)-alkyl, -(CR13R14)o -R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (C1-C6)-alkyl, O-(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy, N(R27)(R28) or SO2CH3;
preferably independently of one another H, (C1-C8)-alkyl, -(CR13R14)o-, R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (C1-C6)-alkyl, O-(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R22), CON(R23)(R24), hydroxy or N(R27)(R28); very particularly preferably independently of one another H, (C1-C8)-alkyl, or R1 and R2 form together with the nitrogen atom to which they are bonded a 5 to 6-membered monocyclic ring which, apart from the nitrogen atom, may include 0 to 1 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by (C1-C6)-alkyl;
especially preferably independently of one another H, (C1-C8)-alkyl;
0 0, 1, 2, 3, 4;
R22, R23, R24, R27, R28 independently of one another H, (C1-C6)-alkyl;
or R23 and R24, R27 and R28 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatoms from the group of NH, N-(C1-C6)-alkyl, oxygen and sulfur;
R12 OH, O-(C1-C6)-alkyl, CN 3-12 membered mono-, bi- or spirocyclic ring which may comprise 1 to 3 heteroatoms from the group of N, O
and S, and the 3-12 membered ring may comprise further substituents such as F, OH, CF3, CN, oxo, (C,-C6)-alkyl, (C0-C2)-alkylene-aryl, N(R34)(R35), COO(R36), CO(C1-C6)-alkyl;
R34, R35 independently of one another H, (C1-C4)-alkyl;
R36 H, (C1-C6)-alkyl, (C0-C2)-alkylene-aryl;
R13, R14 independently of one another H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl;
R38 H, F, Cl, Br, CF3, CN, (C1-C6)-alkyl;
X a bond, CH2CH2, C(R76)(R77), N(R75), C=C, (R75)YCH2, CH2-NCO(R75), CH2CON(R75);
Y O, S, N(R53), CO
R75, R76, R77 independently of one another H, (C1-CH)-alkyl;
R53 H, (C1-C8)-alkyl;
E 5-7 membered bivalent carbo- or heterocyclic ring structure having 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, CF3, OH, CN, OCF3, O-(C1-C6)-alkyl, (C1-C6)-alkyl, SO2-CH3, CO(R65);
R65 H,(C1-C8)-alkyl;
K O, a bond, CH2O, CH2, OCH2, S, SO2, N(R80), N(R81)CO, CON(R82), (C(R83)(R84))v, CO, C.ident.C, SCH2, SO2CH2; preferably O, a bond, CH2O, CH2, OCH2, N(R80), C.ident.C;
v 1,2,3;
R80, R81, R82, R83, R84 independently of one another H, (C1-C8)-alkyl;
R11 (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O-(C1-C8)-alkyl, oxo, CO(R66), hydroxy, N(R70)CO(C1-C6)-alkyl, or SO2CH3;
R66, R70 independently of one another H, (C1-C8)-alkyl;
the N-oxides thereof and the physiologically tolerated salts thereof.
6. A compound of the formula I as claimed in any of claims 1 to 5, in which A, B, D, G are independently of one another N or C(R38), and the total number of nitrogen atoms in this ring is 0-2, preferably 0 or 1, and for the case where the total number of nitrogen atoms is 1, particularly preferably A or B are N and very particularly preferably B is N;
wherein compounds of the following formulae are excluded:
wherein compounds of the following formulae are excluded:
7. A compound of the formula I as claimed in any of claims 1 to 6, in which n is 1 and m is 1 or 2;
wherein compounds of the following formulae are excluded:
wherein compounds of the following formulae are excluded:
8. A medicament comprising one or more of the compounds as claimed in any of claims 1 to 7.
9. A medicament comprising one or more of the compounds as claimed in any of claims 1 to 7 and one or more anorectic active ingredients.
10. A compound of the formula I as claimed in any of claims 1 to 7 for use as medicament for the prophylaxis or treatment of obesity.
11. A compound of the formula I as claimed in any of claims 1 to 7 for use as medicament for the prophylaxis or treatment of type II diabetes.
12. A compound of the formula I as claimed in any of claims 1 to 7 in combination with at least one further anorectic active ingredient for use as medicament for the prophylaxis or treatment of obesity.
13. A compound of the formula I as claimed in any of claims 1 to 7 in combination with at least one further anorectic active ingredient for use as medicament for the prophylaxis or treatment of type II diabetes.
14. A process for producing a medicament comprising one or more of the compounds of the formula I as claimed in any of claims 1 to 7, which comprises mixing the active ingredient with a pharmaceutically suitable carrier, and converting this mixture into a form suitable for administration.
15. The use of the compounds of the formula I as claimed in any of claims 1 to 7 for producing a medicament for weight reduction in mammals.
16. The use of the compounds of the formula I as claimed in any of claims 1 to 7 for producing a medicament for the prophylaxis or treatment of obesity.
17. The use of the compounds of the formula I as claimed in any of claims 1 to 7 for producing a medicament for the prophylaxis or treatment of type II diabetes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004003812.0 | 2004-01-25 | ||
DE102004003812A DE102004003812A1 (en) | 2004-01-25 | 2004-01-25 | Aryl-substituted heterocycles, methods of their preparation and their use as pharmaceuticals |
PCT/EP2005/000699 WO2005070925A1 (en) | 2004-01-25 | 2005-01-25 | Aryl substituted heterocycles, method for production and use thereof as medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2554138A1 true CA2554138A1 (en) | 2005-08-04 |
Family
ID=34745116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002554138A Abandoned CA2554138A1 (en) | 2004-01-25 | 2005-01-25 | Aryl substituted heterocycles, method for production and use thereof as medicaments |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1711494B1 (en) |
JP (1) | JP2007518770A (en) |
KR (1) | KR20060127917A (en) |
CN (1) | CN1934105A (en) |
AR (1) | AR047454A1 (en) |
AT (1) | ATE470666T1 (en) |
AU (1) | AU2005206307A1 (en) |
BR (1) | BRPI0507100A (en) |
CA (1) | CA2554138A1 (en) |
DE (2) | DE102004003812A1 (en) |
DK (1) | DK1711494T3 (en) |
ES (1) | ES2346889T3 (en) |
IL (1) | IL176916A0 (en) |
PE (1) | PE20050768A1 (en) |
PT (1) | PT1711494E (en) |
TW (1) | TW200536850A (en) |
WO (1) | WO2005070925A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9791067B2 (en) | 2014-07-31 | 2017-10-17 | Steffes Corporation | Flare tip valve dampening |
US10618056B2 (en) | 2007-09-11 | 2020-04-14 | X-Zell Inc. | Systems and methods for high gradient magnetic separation of biological material |
US11226271B2 (en) | 2016-03-07 | 2022-01-18 | X-Zell Biotech Pte Ltd | Systems and methods for identifying rare cells |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1966164B1 (en) | 2005-12-21 | 2013-03-06 | Janssen Pharmaceutica N.V. | Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases |
EP2061767B1 (en) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
WO2008143649A2 (en) * | 2006-12-04 | 2008-11-27 | Dr. Reddy's Laboratories Limited | Novel oxazolidinone compounds as antiinfective agents |
MX2009005908A (en) | 2006-12-05 | 2009-06-16 | Janssen Pharmaceutica Nv | Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases. |
NZ577111A (en) | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
DE102008057343A1 (en) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | New phenyl or pyridyl ring containing compounds are hypoxia-inducible factor regulation pathway modulators, useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis and diabetic retinopathy |
DE102008057364A1 (en) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | New pyridyl or phenyl ring containing compounds are hypoxia-inducible factor regulation pathway modulators, useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis and diabetic retinopathy |
DE102008057344A1 (en) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Aminoalkyl-substituted aryl compounds and their use |
DE102009041242A1 (en) | 2009-09-11 | 2011-12-15 | Bayer Schering Pharma Aktiengesellschaft | New heterocyclically substituted aryl compounds are hypoxia-inducible factor inhibitors useful to treat and/or prevent e.g. cancer or tumor diseases, ischemic cardiovascular diseases, heart attack, arrhythmia, stroke, and psoriasis |
DE102009041241A1 (en) | 2009-09-11 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft, 13353 | New heteroaromatic compounds are hypoxia-inducible factor inhibitors useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis, diabetic retinopathy, rheumatoid arthritis and polycythemia |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
DK2470552T3 (en) | 2009-08-26 | 2014-02-17 | Sanofi Sa | NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE |
CN103619171B (en) | 2010-11-03 | 2015-11-25 | 陶氏益农公司 | Insect-killing composition and relative method |
WO2012120051A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120058A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120056A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120053A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120057A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120050A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
CN104010505B (en) | 2011-10-26 | 2017-03-15 | 陶氏益农公司 | Pesticidal combination and relative method |
US9282739B2 (en) | 2012-04-27 | 2016-03-15 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
US9708288B2 (en) | 2012-04-27 | 2017-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
NZ700595A (en) | 2012-04-27 | 2016-04-29 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
MX2016004940A (en) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds. |
CA2925914A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
CN105636446B (en) | 2013-10-17 | 2018-07-13 | 美国陶氏益农公司 | The method for preparing Pesticidal compound |
KR20160074540A (en) | 2013-10-17 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | Processes for the preparation of pesticidal compounds |
JP2016539092A (en) | 2013-10-17 | 2016-12-15 | ダウ アグロサイエンシィズ エルエルシー | Method for producing pest control compound |
MX2016004945A (en) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds. |
CN105636440A (en) | 2013-10-17 | 2016-06-01 | 美国陶氏益农公司 | Processes for the preparation of pesticidal compounds |
CA2926438A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
TW201519776A (en) | 2013-10-22 | 2015-06-01 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
NZ719759A (en) | 2013-10-22 | 2017-05-26 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
RU2016119553A (en) | 2013-10-22 | 2017-12-04 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | SYNERGETIC PESTICIDAL COMPOSITIONS AND RELATED WAYS |
US9788545B2 (en) | 2013-10-22 | 2017-10-17 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
US9155304B2 (en) | 2013-10-22 | 2015-10-13 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
RU2656391C2 (en) | 2013-10-22 | 2018-06-05 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Pesticide compositions and related methods |
CN108812681B (en) | 2013-10-22 | 2021-02-26 | 美国陶氏益农公司 | Pesticidal compositions and methods related thereto |
RU2658995C2 (en) | 2013-10-22 | 2018-06-26 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Pesticide compositions and related methods |
TW201519777A (en) | 2013-10-22 | 2015-06-01 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
RU2016119560A (en) | 2013-10-22 | 2017-11-28 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | SYNERGETIC PESTICIDE COMPOSITIONS AND WAYS RELATED TO THEM |
AR098090A1 (en) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | SYNERGIC PESTICIATED COMPOSITIONS AND RELATED METHODS |
EP3060045A4 (en) | 2013-10-22 | 2017-04-05 | Dow AgroSciences LLC | Synergistic pesticidal compositions and related methods |
EP3060051A4 (en) | 2013-10-22 | 2017-04-05 | Dow AgroSciences LLC | Synergistic pesticidal compositions and related methods |
RU2016119360A (en) | 2013-10-22 | 2017-11-28 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | SYNERGETIC PESTICIDAL COMPOSITIONS AND RELATED WAYS |
WO2015061155A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
CA2927206A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
CN104072436B (en) * | 2014-07-23 | 2015-10-14 | 张远强 | The tetrazole acetophenone compound of para-orientation, Preparation Method And The Use |
CN104072439B (en) * | 2014-07-23 | 2015-11-04 | 张远强 | The tetrazole acetophenone compound of halogen substiuted, Preparation Method And The Use |
CN104072438B (en) * | 2014-07-23 | 2015-10-14 | 张远强 | Dialkoxy is for tetrazole acetophenone compound, Preparation Method And The Use |
CN104086502B (en) * | 2014-07-23 | 2015-10-14 | 张远强 | Halo tetrazole acetophenone compound, Preparation Method And The Use |
EP3186229A4 (en) | 2014-07-31 | 2018-01-10 | Dow AgroSciences LLC | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
EP3174856A4 (en) | 2014-07-31 | 2018-01-10 | Dow AgroSciences LLC | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
US9249122B1 (en) | 2014-07-31 | 2016-02-02 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
BR112017002735A2 (en) | 2014-08-19 | 2017-12-19 | Dow Agrosciences Llc | Process for the preparation of 3- (3-chloro-1h-pyrazol-1-yl) pyridine |
CA2960985A1 (en) | 2014-09-12 | 2016-03-17 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
TW201706265A (en) | 2015-03-09 | 2017-02-16 | 必治妥美雅史谷比公司 | Lactams as inhibitors of ROCK |
US10233155B2 (en) | 2016-12-29 | 2019-03-19 | Dow Agrosciences Llc | Processes for the preparation of pesticide compounds |
CN110139853B (en) | 2016-12-29 | 2023-06-16 | 美国陶氏益农公司 | Process for the preparation of pesticidal compounds |
CN109651350B (en) * | 2019-01-11 | 2022-05-24 | 贵州大学 | Heterocyclic substituted 1,3,4-oxa (thia) diazoles compound and preparation method and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ326354A (en) * | 1996-01-15 | 1999-05-28 | Janssen Pharmaceutica Nv | 3-(substituted-1-piperazinyl)-6-(substituted-1,2,4-thiadiazol-5 -yl)-pyridazine derivatives and medicaments |
WO2000066578A1 (en) * | 1999-04-30 | 2000-11-09 | Pfizer Products Inc. | Compounds for the treatment of obesity |
AU5251200A (en) * | 1999-06-21 | 2001-01-09 | Mitsubishi Pharma Corporation | Novel imidazole derivatives |
AU2001261189A1 (en) * | 2000-05-03 | 2001-11-12 | Tularik, Inc. | Pyrazole antimicrobial agents |
GB0108102D0 (en) * | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
AU2003226927A1 (en) * | 2002-04-09 | 2003-10-27 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
UA79755C2 (en) * | 2002-04-16 | 2007-07-25 | Bayer Pharmaceuticals Corp | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
US7229987B2 (en) * | 2002-05-13 | 2007-06-12 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
DE10306250A1 (en) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals |
GB0314373D0 (en) * | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
-
2004
- 2004-01-25 DE DE102004003812A patent/DE102004003812A1/en not_active Withdrawn
-
2005
- 2005-01-24 AR ARP050100241A patent/AR047454A1/en unknown
- 2005-01-25 WO PCT/EP2005/000699 patent/WO2005070925A1/en active Application Filing
- 2005-01-25 DE DE502005009723T patent/DE502005009723D1/en active Active
- 2005-01-25 ES ES05701163T patent/ES2346889T3/en active Active
- 2005-01-25 AU AU2005206307A patent/AU2005206307A1/en not_active Abandoned
- 2005-01-25 PT PT05701163T patent/PT1711494E/en unknown
- 2005-01-25 KR KR1020067015036A patent/KR20060127917A/en not_active Application Discontinuation
- 2005-01-25 PE PE2005000096A patent/PE20050768A1/en not_active Application Discontinuation
- 2005-01-25 BR BRPI0507100-3A patent/BRPI0507100A/en not_active IP Right Cessation
- 2005-01-25 CN CNA2005800095532A patent/CN1934105A/en active Pending
- 2005-01-25 TW TW094102153A patent/TW200536850A/en unknown
- 2005-01-25 CA CA002554138A patent/CA2554138A1/en not_active Abandoned
- 2005-01-25 JP JP2006550072A patent/JP2007518770A/en not_active Abandoned
- 2005-01-25 AT AT05701163T patent/ATE470666T1/en not_active IP Right Cessation
- 2005-01-25 EP EP05701163A patent/EP1711494B1/en not_active Not-in-force
- 2005-01-25 DK DK05701163.7T patent/DK1711494T3/en active
-
2006
- 2006-07-17 IL IL176916A patent/IL176916A0/en unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10618056B2 (en) | 2007-09-11 | 2020-04-14 | X-Zell Inc. | Systems and methods for high gradient magnetic separation of biological material |
US9791067B2 (en) | 2014-07-31 | 2017-10-17 | Steffes Corporation | Flare tip valve dampening |
US11226271B2 (en) | 2016-03-07 | 2022-01-18 | X-Zell Biotech Pte Ltd | Systems and methods for identifying rare cells |
Also Published As
Publication number | Publication date |
---|---|
ATE470666T1 (en) | 2010-06-15 |
WO2005070925A1 (en) | 2005-08-04 |
CN1934105A (en) | 2007-03-21 |
TW200536850A (en) | 2005-11-16 |
PE20050768A1 (en) | 2005-11-21 |
JP2007518770A (en) | 2007-07-12 |
AR047454A1 (en) | 2006-01-18 |
IL176916A0 (en) | 2006-12-10 |
KR20060127917A (en) | 2006-12-13 |
EP1711494A1 (en) | 2006-10-18 |
DE502005009723D1 (en) | 2010-07-22 |
DK1711494T3 (en) | 2010-10-11 |
AU2005206307A1 (en) | 2005-08-04 |
DE102004003812A1 (en) | 2005-08-11 |
BRPI0507100A (en) | 2007-06-19 |
EP1711494B1 (en) | 2010-06-09 |
ES2346889T3 (en) | 2010-10-21 |
PT1711494E (en) | 2010-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2554138A1 (en) | Aryl substituted heterocycles, method for production and use thereof as medicaments | |
US7319108B2 (en) | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | |
ES2297758T3 (en) | POLYCLINAL AMINES REPLACED WITH ARILO, PROCEDURE FOR PREPARATION AND USE AS MEDICINES. | |
CA2554233A1 (en) | Substituted n-cyclohexyl imidazolinones having an mch-modulatory effect | |
EP1794159B1 (en) | 7-azaindoles and their use as ppar agonists | |
AU2008314233B2 (en) | Imidazo[1,2-a]pyrimidine derivatives for treating diseases such as diabetes | |
IL198112A (en) | 3-aminoimidazo [1,2-a]pyridine derivatives having an sglt1-and sglt2-inhibiting action for the treatment of type 1 and type 2 diabetes | |
US7241787B2 (en) | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | |
MXPA06008338A (en) | Aryl substituted heterocycles, method for production and use thereof as medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |